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ABSTRACT 
Parkinson’s disease (PD) is a chronic and progressive neurodegenerative disorder 
named by the French neurologist Jean-Martin Charot, after the British physician James 
Parkinson who first described the disease as “Shaking Palsy”.  Pathologically, PD is 
characterized by a progressive loss of dopaminergic neurons in the substantia nigra pars 
compacta (SNpc), a marked reduction of dopamine in the striatum, the presence of ubiquitin 
and α-synuclein positive cytoplasmic inclusions known as Lewy bodies, and depigmentation 
of the locus cereleus.  The prevailing theory regarding processes that are likely to account for 
progressive degeneration of the dopaminergic neurons in the nigrostriatal axis involves on 
mitochondrial dysfunction, oxidative stress, excitotoxicity and neuroinflammation. Of those, 
neuroinflammation and oxidative stress have gained the most focus recently. Research over 
the last decade has provided extensive evidence that the sustained microglial and astroglial 
neuroinflammatory responses cause progressive and delayed dopaminergic 
neurodegeneration. However, the mechanisms by which glial cells activation and subsequent 
inflammation lead to dopaminergic neurodegeneration remain poorly understood. 
Development of effective therapeutic approaches to halt the disease progression of PD is of 
paramount importance. My objective in this Ph.D. thesis work was to characterize important 
signaling molecules activated in neuroinflammation mediated neurodegenerative pathways as 
well as characterze of novel compounds in a pre-clinical mouse model of PD. Protein 
interacting with never in mitosis – A (Pin1) is a peptidyl-prolyl  isomerase, that specifically 
recognizes phosphorylated serine or threonine residues immediately preceding proline 
(pSer/Thr-Pro) in a subset of proteins in which it isomerizes the cis/trans conformation of the 
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peptide bond. High expression levels of Pin1 in terminally differentiated and post mitotic 
neurons suggest that it plays an important role in neurons, except in cell cycle regulation and 
proliferation. Recently, Pin1 overexpression was shown to facilitate formation of -synuclein 
inclusions in a cellular model of -synuclein aggregation. Pin1 was also localized in Lewy 
bodies in PD patients. But the level, activity, and role of Pin1 in the pathogenesis of PD are 
incompletely known. We hypothesized that Pin1 is differentially activated in neuronal and 
glial cells of the nigral dopaminergic system, and that it regulates NF-κB-mediated sustained 
neuroinflammatory processes in cell culture and in an animal model of Parkinson’s disease. 
Herein, we demonstrate for the first time that there is a dopaminergic neuron specific 
upregulation of Pin1 in human postmortem PD brain sections as well as in cell culture and 
animal models. We observed a rapid increase in Pin1 expression in both the 1-methyl-
4phenyl pyridinium (MPP
+
)-treated cell culture and in 1-methyl-4-phenyl-1-2-3-6-
tetrahydroptridine MPTP treated mice. Also, Pin1 acts as an important pro-apoptotic factor in 
the selective degeneration of dopaminergic neurons. Importantly, pharmacological inhibition 
of Pin1 attenuates MPTP-induced Pin1 expression in vitro and in vivo and protects against 
MPTP-induced neurodegeneration in the nigrostriatal axis. We also demonstrate for the first 
time that, microglia and astrocytes express Pin1 and that there is a strong association between 
Pin1 and NF-κB p65 in BV2 microglial cells.  Recent studies demonstrated that the promoter 
regions of proinflammatory molecules contain the DNA binding site for NF-κB. We have 
shown that Pin1 and NF-κB p65 inhibition by Juglone leads to attenuation of glial cells 
activation and subsequent reduction of proinflammatory reactions in cell culture and in an 
animal model of PD. While characterizing the role of Pin1 in the pathogenesis of PD, we also 
tested the efficacy of novel compounds for protection of dopaminergic neurons in a mouse 
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model of PD. We demonstrate that the novel compound diapocynin, a metabolite of 
apocynin, blocks MPTP-induced activation of microglial and astroglial cells, thus inhibiting 
the inflammatory and oxidative stress processes in MPTP-treated mice. Diapocynin also 
protects the nigrostriatum against MPTP toxicity. The final chapter of this work characterizes 
the anti-inflammatory and neuroprotective properties of mito-apocynin, a mitochondria 
targeted compound in the MPTP mouse model of PD. Mitoapocynin prevents the behavioral 
imapariments and dopamine loss caused by MPTP-induced toxicity. We have shown that 
mito-apocynin protects the nigrostriatum by attenuating glial cell mediated 
neuroinflammation and oxidative stress. Collectively, the research described herein 
characterizes the novel and important roles of Pin1 in the neuroinflammation and 
pathophysiology of Parkinson’s disease, as well as establishes the efficacy of novel 
compounds in protection of the nigrostriatum in a pre-clinical mouse model of Parkinson’s 
disease. 
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CHAPTER I 
  
GENERAL INTRODUCTION 
 
Thesis Layout and Organization 
The alternative format was chosen for writing this dissertation as it consists of 
manuscripts that are either under peer review or being prepared for submission. The 
dissertation contains a general introduction, four research papers, a general conclusion that 
discusses the overall findings from all the chapters and acknowledgement. The references for 
each manuscript chapter are listed at the end of that specific section. References pertaining to 
the background and literature review as well as those used in general conclusion section are 
listed at the end of the dissertation. The General Introduction (Chapter I) briefly provides the 
current knowledge on Parkinson’s disease and describes an overview of the research 
objective. The Background and Literature Review I provide background information on 
Parkinson’s disease (PD), pathological features of PD, physiology and chemistry of 
dopamine, genetics of PD and apoptosis in PD, MPTP mouse models of PD and role 
transcription factor NF-κB in neurodegeneration. It also has the current knowledge of 
peptidyl prolyl cis/trans isomerase, Pin1 in cancers and neurodegenerative disorders, and 
provides an overview of the research objectives pertaining to chapters II and III. Background 
and Literature Review II summarize the current evidences implicating a pathogenic role for 
reactive gliosis in dopaminergic neurodegeneration, role of oxidative stress and inflammation 
in PD pathogenesis, and current therapeutic approaches against progressive 
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neurodegeneration in PD. Also, it provides an overview of research objectives pertaining to 
chapter IV and V. 
This dissertation contains the experimental data and results obtained by the author during his 
Ph.D. study under the supervision of his major professor Dr. Anumantha G. Kanthasamy at 
Iowa State University, Department of Biomedical Sciences. 
Introduction 
Parkinson’s disease (PD) is the most common movement associated 
neurodegenerative disorder affecting balance, movement, flexibility and coordination. 
Pathologically it is characterized by the loss of dopaminergic neurons in the substantia nigra 
region of the midbrain and its terminal in the striatum, the presence of cytoplasmic inclusions 
(Lewy bodies) in degenerating dopaminergic neurons in the nigra and activation of glial cells 
(Dauer and Przedborski, 2003). The pathophysiological mechanisms behind nigral 
neurodegeneration in PD are still not clear. Expanding research had shed significant light in 
understanding PD etiology and molecular pathogenesis. In the last two decades, researchers 
focused mainly on mitochondrial dysfunction, oxidative stress, apoptosis and 
neuroinflammation to elucidate the disease mechanisms. Also, numerous studies conducted 
in in vitro and in vivo models of PD suggest the roles played by these mechanisms result in 
irreversible and selective degeneration of dopaminergic neurons (Hunot and Hirsch, 2003; 
Jenner, 2003). Epidemiological studies implicate both environmental factors and genetic 
predisposition as risk factors contributing to PD (Di Monte, 2003).  
Recent reports suggest an important role of neuroinflammation of nigrostriatal degeneration 
in PD patients (Dauer and Przedborski, 2003; Gao et al., 2003). Activation of glial cells 
(microglia and astrocytes) is evident in close proximity to the damaged or dying neurons in 
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substantia nigra. Elevated levels of inflammatory molecules such as nitrite and inducible 
nitric oxide synthase are found in substantia nigra of PD patients (Qureshi et al., 1995; Hunot 
et al., 1996). Additionally, a variety of proinflammatory cytokines such as tumor necrosis 
factor (TNF-α), interleukin -1β (IL-1β), interleukin 6 (IL-6), eicosanoids and other immune 
neurotoxins are found either in CSF or affected brain regions in PD (Mogi et al., 1994; 
Bessler et al., 1999; Nagatsu et al., 2000). A recent report demonstrated nuclear factor-κB 
(NF-κB), a transcription factor that is required for the transcription of proinflammatory 
molecules, is activated in substantia nigra of PD patients and MPTP-treated mice (Ghosh et 
al., 2007). Despite all these findings, the mechanism of glial cell activation and production of 
cytokines in response to neuronal toxicity and what activates the neurons and glial cells to 
promote dopaminergic neuronal degeneration is yet unknown. Reversible phosphorylation on 
Ser/Thr – Pro (S/T-P) motifs regulated by Pro-directed protein kinases and phosphatases is 
an important molecular switch in controlling various cellular processes (Gothel and Marahiel, 
1999). Since the discovery of protein interacting with never in mitosis – A (Pin1), much is 
known about the conformational importance of Pro-directed kinases in cellular signaling 
(Uchida et al., 1999). Pin1 is unique among the peptidyl-prolyl  isomerases in that they 
specifically recognize phosphorylated serine or threonine residues immediately preceding 
proline (pSer/Thr-Pro) in a subset of proteins and isomerizes the cis/trans conformation of 
peptide bond (Joseph et al., 2003; Lu, 2004). Recently Ryo et al., 2006 reported that Pin1 
overexpression facilitates formation of -synuclein inclusions in a cellular model of -
synuclein aggregation and Pin1 also localizes in Lewy bodies in PD patients. Previous 
reports indicate the role of Pin1 in controlling several transcription factors that mediate 
induction of iNOS (Gothel and Marahiel, 1999; Shen et al., 2005). But its level, activity and 
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role in the inflammatory responses in the pathogenesis of PD are completely unknown. The 
present study characterizes the novel molecule Pin1 in cell culture animal models of PD as 
well as investigates the pathological roles of Pin1 in oxidative stress and inflammation 
mediated dopaminergic neurodegeneration of PD. In addition, this study also investigates the 
efficacy of novel compounds in protecting nigrostrital axis in MPTP mouse model of PD.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
Background and Literature Review I 
 This review section will provide background information on Parkinson’s disease 
(PD), pathological features of PD, physiology and chemistry of dopamine, genetics of PD, 
apoptosis in PD, MPTP mouse models of PD, and role of transcription factor NF-κB in 
neurodegeneration. Also discussesed is the current knowledge of peptidyl prolyl cis/trans 
isomerase, Pin1 in cancers and neurodegenerative disorders. 
Parkinson’s disease 
 Parkinson’s disease (PD) is a progressive neurodegenerative disorder that affects 
more than 1million individuals over the age of 60 within the United States (Jankovic and 
Stacy, 2007). According to recent article, the number of new cases increased by about 50,000 
annually (Dauer and Przedborski, 2003). Although PD is an age-related disorder affecting 
nearly 3% of people over 60 years and 4-5% people over 85 years of age, nearly 10% of PD 
cases are under 40 years of age (Mizuno et al., 2001). Epidemiological studies suggest that 
sporadic PD cases (90%) are predominant with late onset whereas, remaining 10% cases are 
characterized by early onset and these cases mainly occur in familial clusters (Mizuno et al., 
2001; Tanner, 2003).  The familial or early onset PD had been linked with mutations in 
several genes such as parkin, ubiquitin C-terminal hydrolase L1, α-synuclein, leucine rich 
repeat kinase 2(LRRK2), PINK-1 or DJ1 (Gwinn-Hardy, 2002; Tang et al., 2006; Weng et 
al., 2007; Bonifati et al., 2008). The cause of sporadic PD or non-familial PD are yet 
unknown, but several reports suggest environmental toxins, genetic factors, mitochondrial 
dysfunction, apoptosis, oxidative stress and neuroinflammation could be the possible factors 
behind the PD neurodegeneration (Schapira, 1994; Ben-Shachar et al., 1995; Hoehn and 
Yahr, 1998; McGeer et al., 2001). Among the environmental toxins, infectious agents, 
6 
 
pesticides, herbicides and heavy metals have been implicated in the pathogenesis and 
progression of the disease (Mizuno et al., 2001). Recent investigations now stressed on 
inflammation and oxidative stress to be the central players in the pathogenesis of PD.  
Clinical features of Parkinson’s disease 
 PD has been considered as a motor disease and the motor symptoms include tremor at 
rest, bradykinesia, rigidity, loss of postural balance. Among these symptoms tremor, 
bradykinesia and rigidity are the early symptoms, whereas abnormalities in postural balance 
appear late. Besides these cardinal features certain other motor symptoms have also been 
reported in PD like difficulties in getting up from the chair and turning in bed, a shuffling 
gait, micrographia (small or cramped handwriting), decreased arm swing, difficulty in cutting 
food and feeding, reduced hygiene, and a general drag in the activities of daily living 
(Jankovic, 2008). Cognitive impairment, depression and dementia have also been reported in 
PD patients and appearance of these symptoms is dependent on factors like age,  the presence 
of Lewy bodies, co-occurrence of AD,  level of progression of the disease, and gender 
(Bunting-Perry, 2006; Welge-Lussen et al., 2009). Additionally, PD patients have 
dramatically greater chances of developing dementia when compared to age matched 
controls (Aarsland et al., 2001; Farlow and Cummings, 2008). 
 Along with cardinal features and cognitive deficits, there is an increasing awareness 
of the non-motor aspects of PD such as insomnia (Double et al., 2003), sleeping disorders, 
anxiety, psychosis and mania, alcohol or other substances abuse, and sexual disorders  
(Schneider et al., 2008; Park and Stacy, 2009, Simuni, 2009 #38). Additionally, olfactory 
deficits have also been observed in PD patients very frequently irrespective of 
disease
 
severity and duration (Double et al., 2003).  
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Pathological features of Parkinson’s disease 
 Primary pathological feature of PD is the loss of dopaminergic neurons in the 
substantia nigra (SN) region of the midbrain and its terminal in the striatum (Dauer and 
Przedborski, 2003). This loss of dopaminergic neurons causes most of the motor symptoms 
of PD. Surprisingly, the dopaminergic neurons of the adjacent ventral tegmental area (VTA) 
are relatively spared of degeneration. But, neuropathology of PD revealed that the 
neurodegeneration not only involves the dopaminergic neurons in SN, but also reaches to the 
dorsal motor nuclei of the hypoglossus and vagus nerves, dorsal part of raphe nucleus as well 
as the anterior olfactory nucleus and olfactory bulb, before it extends to the mesencephalic 
areas which include SN (Braak et al., 2003). Beside dopaminergic neurodegeneration, 
degeneration of serotonergic neurons in raphe nuclei and norepinephrinergic neurons in the 
locus coeruleus also occur (Braak et al., 2003). In the following section, we will briefly 
discuss an overview of the major dopaminergic systems in the brain, the basal ganglia and its 
functional anatomy, and some of the clinical aspects of PD pathology. 
Major dopaminergic systems of the brain 
In the brain, different dopaminergic pathways ascend from the following major nuclei 
– the mesencephalon (midbrain); the substantia nigra pars compacta (SNpc), the ventral 
tegmentum area (VTA) and the hypothalamus (Van den Heuvel and Pasterkamp, 2008). 
These nuclei are the major source of four major dopaminergic pathways such as the 
nigrostriatal pathway, mesolimbic pathway, mesocortical pathway and the tuberoinfundibular 
pathway. The nigrostriatal pathway is the largest among them, comprising of 70% of total 
central nervous system (CNS) dopaminergic neurons which synthesizes nearly 80% of brain 
dopamine (Van den Heuvel and Pasterkamp, 2008). This pathway starts from the SNpc of 
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ventral midbrain and projects to the dorsal striatum, ventral striatum and cerebral cortex. The 
dopaminergic neurons in the SNpc are very densely packed (hence the term pars compacta) 
and they contain neuromelanin, a dark pigment (hence the term nigra). These pigmented 
dopaminergic neurons mainly degenerate in PD. The seratonergic inputs from the medial and 
dorsal raphae nuclei and noradrenergic input from the locus coeruleus comes to the SNpc 
which in turn sends dopaminergic efferents to other brain regions (Rommelfanger et al., 
2007). As the nigrostriatal pathway is connected to the dorsal sensorimotor striatum, it 
controls with motor function. The mesolimbic pathway ascends from the VTA region and 
projects not only to ventral striatum and nucleus accumbens, but also to other brain regions 
such as hippocampus and amygdale. The mesolimbic pathway plays an important role in 
emotion, motivation and addiction. The mesocortical pathways ascend from the VTA region 
and projects to cerebral cortex and it plays an important role in complex cognition (Bjorklund 
and Dunnett, 2007; Van den Heuvel and Pasterkamp, 2008). The tuberoinfundibular pathway 
arises in the hypothalamus and ends in the pituitary, where it inhibits prolactin secretion 
(Bjorklund and Dunnett, 2007). 
Dopamine neurochemistry 
Dopamine (DA) - the neurotransmitter produced by the dopaminergic neurons in the 
SNpc is similar to other catecholamines – noradrenaline (NAd) and adrenaline (Ad). The 
precursor amino acid of all these neurotransmitter is tyrosine. Tyrosine is converted to 3, 4-
dihyroxy-L-phenylalanine (L-DOPA) by tyrosine hydroxylase (TH), the rate limiting enzyme 
in the biosynthesis of dopamine. In the next step, L-DOPA is decarboxylated to DA by 
aromatic L-amino acid decarboxylase/dopamine decarboxylase (DDC). Dopamine can be 
synthesized both in and outside the brain due to DDC’s presence in both the central nervous 
9 
 
system (CNS) and its periphery. But, DA cannot cross the blood brain barrier (BBB) and 
therefore has to be synthesized from L-DOPA inside the brain. In the noradrenergic neurons, 
DA is further converted to noradrenaline by dopamine -hydroxylase (DBH). DA after 
synthesized get released in to the synaptic junction through dopaminergic neuron terminals 
but it can be inactivated by reuptake into the pre-synaptic neurons by specialized membrane 
monoamine transporters, including the DA transporter (DAT) and noradrenaline transporter – 
the vesicular monoamine transporters (VMAT) and concentrated into synaptic vesicles. 
Intracellularly, dopamine is degraded by monoamine oxidase enzyme to 
dihydroxyphenylacetic acid (DOPAC) which is further degraded to homovanili acid (HVA) 
by catechol-o-methyl transferase (COMT). Both these catabolic products are also quantified 
in studies pertaining to neuroprotection in PD because the biological levels of these 
metabolites is also an indicator of the neurprotection by the neuroprotective compounds in 
question (Kandel and Squire, 2000). 
 
Figure 1. Dopamine biosynthesis pathway. Source: (Hare and Loer, 2004) 
Neuroanatomy of basal ganglia 
The basal ganglia is a critical part of extrapyramidal motor system consisting of 
striatum, external (GPe) and internal (GPi) pallidal segments, subthalamic nucleus and 
substantia nigra (comprising of pars compacta – SNpc and pars reticularis – SNpr). The 
striatum is made up of two regions – caudate nucleus/putamen (neostriatum) and ventral 
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striatum. Substantia nigra of ventral midbrain has cell bodies in the SNpc and axons in the 
Striatum region. The neostriatum and nucleus accumbens send their output directly into the 
output nuclei – the globus pallidus internal segment (GPi) and SNpr or indirectly with 
intermediate stops in globus pallidus external segment (GPe) and sub-thalamic nucleus 
(STN). In turn, the GPi and SNpr send their output back to cerebral cortex via the thalamus. 
The pathways consist of two subtypes. The first one ‘direct pathway’, consists of 
monosynaptic connections with GPi and the SNpr. The other one is called the indirect 
pathway (GABAergic neurons – Enkephalin) and it is made of polysynaptic connections 
traversing the GPe segment and connecting with the GPi/SNpr via the subthalamic nucleus 
(STN). The direct pathway is mediated by excitatory D1 receptors and in this pathway 
medium spiny neurons project from striatum and directly inhibit the output nuclei GPi and 
SNpr. The medium spiny neurons inhibit these output nuclei because the output of the GPi 
and SNpr to the thalamus is inhibitory, which ultimately leads to a less inhibitory effect on 
the cerebral cortex, via the thalamus. The indirect pathway is mediated by inhibitory D2 
receptors and in this pathway medium spiny neurons send an inhibitory GABAergic 
projection towards the GPe. Because of this inhibitory effect, the medium spiny neurons 
were inhibited and the GPe becomes free and can normally project its output to its target 
nuclei. The STN receives inhibitory GABAergic input from GPe as well as inhibitory signal 
directly to the SNpr. The STN also sends excitory input to the SNpr and GPi, which becomes 
inhibited by the GPe. Consequently, the cerebral cortex also sends a direct excitatory 
influence on the STN. Therefore, indirect pathway excites the output nuclei, which in turn 
leads to an inhibition of the thalamic/cortical output. Collectively, the indirect and the direct 
pathways have a contradictory effect. The direct pathway facilitates motor or cognitive 
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programs from cortical areas, whereas the indirect pathway inhibits these programs (Albin et 
al., 1989).  
 
Figure 2. Direct and Indirect pathways. A. The supplementary motor area (SMA) is 
activated through the 'direct' pathway as follows. (1) Corticostriate fibers from the 
sensorimotor cortex activate GABAergic neurons in striatum having D1 receptors tonically 
facilitated by nigrostriatal inputs. (2) The activated striatal neurons inhibit medial pallidal 
(GPM) neurons (3) with consequent disinhibition of ventral lateral nucleus (VLN) 
thalamocortical neurons (4) and activation of SMA (5), which both modifies ongoing 
corticostriate activity and initiates impulse trains along corticospinal (CST) and 
corticoreticular (CRST) fibers.  
B. (1) Corticostriate neurons from the sensorimotor cortex strongly activate GABAergic 
neurons (2) in the striatum that synapse on others (3) in the lateral pallidal segment (GPL). 
The double effect is disinhibition of the subthalamic nucleus (STN). STN discharges 
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strongly (4) on to the GABAergic neurons of the medial pallidal segment (GPM); these in 
turn discharge strongly (5) into the ventral lateral nucleus (VLN) of thalamus, resulting in 
reduced output along thalamocortical fibers (6) traveling to the supplementary motor area 
(SMA). Inputs (7) from SMA to corticospinal and corticoreticular fibers (CST, CRST) 
become progressively weaker, with pathetic consequences for initiation and execution of 
movements. (Modified from “Clinical Neuroanatomy and Neuroscience- Fifth Edition” by 
MJ Turlough FitzGerald, Gregory Gruener, Estomih Mtui)  
MPTP mouse model of Parkinson’s disaease 
 The use of animal models to gain insight into human diseases and the potential 
treatment is extremely valuable. As opposed to isolated cell culture (in vitro) models, the use 
of a living animal as a model system is more reliable and productive for studying 
multifactorial diseases like PD. PD is a uniquely human disorder and the eytiology of PD is 
not known completely. There are no animal models which can mimic the exact features of 
PD in human. However, some of the pathological symptoms can be reproduced using 
different toxins such as methamphetamine, 6-hydroxydopamine, rotenone, paraquat and 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in animal models (Langston and 
Ballard, 1983; Chiba et al., 1984; Heikkila et al., 1984; Finnegan et al., 1987; Betarbet et al., 
2000; Deumens et al., 2002; McCormack et al., 2002). Since the discovery of MPTP in the 
early 1980s, its ability to degenerate nigrostriatum dopaminergic neurons after systemic 
administration in a number of different species, led to its recognition as a potent Parkinsonian 
neurotoxins (Langston and Ballard, 1983 ; Schneider et al., 1987).  
Conversion of MPTP to MPP+, the neurotoxic substance 
In non-human primates, MPTP administration develops clinical features very similar 
to human PD (Schneider et al., 1988; Schneider, 1989). MPTP is a protoxin, highly lipophilic 
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molecule which can easily cross the blood brain barrier within minutes after its systemic 
administration (Markey et al., 1984). Once in the brain, it is converted to 1-methyl-4-phenyl-
2,3-dihydropyridinium (MPDP
+
) via monoamine oxidase b (MAO-B) in astroglial cells and 
serotonergic cells (Chiba et al., 1984; Kitahama et al., 1991). However, MPDP
+
 is an 
unstable molecule which immediately converted to 1-methyl-4-phenylpyridinium (MPP
+
), 
the actual neurotoxin (Chiba et al., 1985; Peterson et al., 1985). MPP
+
 then released from 
glial cells and enters to dopaminergic neurons via dopaminergic transporter (DAT). MPP
+
 is 
far less lipophilic than MPTP and is unable to cross the blood-brain barrier (Bezard et al., 
1999). Once inside the neuron, MPP
+
 is passively transported to mitochondrial matrix 
(Ramsay and Singer, 1986). Intramitochondrial MPP
+
 inhibits oxidative phosphorylation by 
imparing ADP stimulated oxygen consumption and the multi-subunit enzyme Complex I 
(NADH-ubiquinone oxidoreductase).  
 
Figure 3. Conversion of MPTP to MPP
+
 (Tipton et al., 2001) 
Report have also shown that MPP
+
 binds to Complex I and blocks the terminal step of 
electron transport transfer from the highest potential iron-sulfur cluster of Complex I, 
resulting in impaired synthesis of ATP (Ramsay et al., 1987). Additionally, Complex I 
inhibition by MPP
+
 also results in an increased production of reactive oxygen species (ROS). 
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Using MPTP mice model of PD, researchers also demonstrated oxygen-dependent formation 
of ROS. Both impaired synthesis of ATP and production of ROS lead to stimulation of 
apoptotic pathways which ultimately lead to dopaminergic neurodegeneration.  
Different MPTP dosing schedule 
            Among various and commonly used neurotoxins, MPTP is the most popular one as, 
use of MPTP is very simple, systematic admistration produces PD like symptoms, it can 
mimic the clinical PD features in rodents and primates more closely than any other 
neurotoxins. Depending on doses and time of administration, MPTP mouse model of PD is of 
three types-acute, sub-acute and chronic. In acute regimen, 4 doses of MPTP (ranges from 
15mg/kg to 20mg/kg) at 2 h interval are administered via intraperitoneally (i.p.), sub-acute 
MPTP paradigm consists of 3-5 doses of MPTP (ranges from 20mg/kg/dose to 
30mg/kg/dose) via i.p. with single dose per day and in chronic model of MPTP, mice receive 
3 doses of MPTP (ranges from 20mg/kg to 30 mg/kg) per week for 5 weeks via i.p. along 
with probenecid (sub-cutaneous) treatment. While all these paradigms rely on same initial 
mechanism of neurotoxicity, the modes of cell death are different in each model. Following 
acute administration of MPTP, death of DA neurons occurs primarily via non-apoptotic or 
necrotic pathways (Jackson-Lewis et al., 1995; Przedborski and Vila, 2003), whereas, in sub-
acute and chronic treatment, neurons appear to die via apoptosis (Tatton and Kish, 1997). In 
both theses models, the loss of dopamine takes place almost immediately after treatment, 
while the neuronal degeneration occurs in a slower rate. One big shortcoming of MPTP 
mouse model is lack of progressiveness in dopaminergic neurodegeneration. Following 
MPTP treatment, death of DA neurons starts within 12h after the last injection and is 
completed by 4-5 days post-treatment (Jackson-Lewis et al., 1995), where as in PD, slow 
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progressive dopaminergic neurodegeneration occurs. Besides loss of dopaminergic neurons 
in nigrostraitum, the neuropathology of PD is also characterized by the presence of 
cytoplasmic inclusion known as lewy bodies in surviving neurons (Shults, 2006). However, 
chronic MPTP mouse model and mice administered with MPTP via osmotic pumps do show 
lewy bodies (Fornai et al., 
2005; Jin et al., 2005).  
But, in acute or sub-acute 
MPTP intoxicated mice, 
lewy bodies could never 
be seen. Different factors 
such as age, weight, strain 
and gender backgrounds have been reported to influence reproducibility and the extent of 
MPTP-induced damages in mice (Giovanni et al., 1991; Hamre et al., 1999; Staal and 
Sonsalla, 2000). Moreover, different strains of mice and even within a given strain obtained 
from different vendors can exhibit different sensitivity to MPTP (Heikkila et al., 1989). 
However, these different sensitivities have been reported to be transmissible as an autosomal 
dominant trait (Hamre et al., 1999). The most severe neurotoxicity of MPTP was observed in 
the C57BL/6 mice strain in comparison to the other mice strains as the clearing of MPTP and 
MPP
+
 was less rapid in the brains of the C57BL mice when compared to other mice strains 
(Schwarting et al., 1999; Sedelis et al., 2000). Consistency in the reproducibility of MPTP-
induced neurotoxicity is best observed in the mice in 8-12 weeks of age weighing about 28g 
body weight, indicating that it is important to investigate on the mice falling under these 
physiological condition  for MPTP studies. MPTP mice model also reproduce the behavioral 
Figure 4. TH-positive dopaminergic neurons in monkey brain 
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deficits associated with PD. Muscle rigidity, tremor, gait and postural imbalances are the 
most common symptoms in PD patients (Meredith, 1958; Hattori and Kubo, 2007). However, 
based on the MPTP dosing regimens, behavioral data are often widely differed in mice 
(Chiueh et al., 1984).  
Genetics of PD 
Although the rare early-onset PD accounts for approximately 5 to 10% of the total PD 
cases, significant advances in understanding the mechanisms of disease pathogenesis have 
been made in the past two decades with the identification of distinct gene loci at which 
pathogenic mutations are associated with parkinsonism. Several genetic mutations have been 
described in the rare familial early onset PD. The most prevalent genes conclusively 
associated with PD are α-synuclein, leucine-rich repeat kinase (LRRK2), PTEN induced 
putative kinase (PINK1), Parkin and DJ-1(PARK7) (Litvan et al., 2007; Cookson and van der 
Brug, 2008). Briefly, in this section, the mutation, pathology and symptoms associated with 
a-synuclin have been discussed.    
Alpha-synuclein is a small presynaptic protein in the CNS (140kDa) encoded by the 
α-synuclein gene SNCA. It is characterized by the presence of repetitive and imperfect 
repeats of KTKEGV amino acids distributed throughout the amino terminal and C terminal 
halves (Maroteaux et al., 1988). Exact physiological function of α-synuclein is not known, 
though, it is suggested that -synuclein significantly interacts with tubulin and may have a 
potential microtubule – associated protein like function. -synuclein may also function as a 
molecular chaperone protein, because, its N-terminal sequence (1-61) possess about 40% 
homology with the 14-3-3 proteins, which are well understood chaperone proteins. 
Additionally, it has been demonstrated α-synuclein interacts with cholesterol and 
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sphingomyelin containing vesicles and that interaction leads to its stabilization (Kamp and 
Beyer, 2006). Two mutations in -synuclein – A30P and A53T were identified in familial 
PD in a German family and a Greek-Italian family, respectively. For last few years, mice 
over-expressing A30P and A53T mutants serve as important genetic models of PD.  In the 
PD brain, α-synuclein is detected in lewy bodies in neurons of the brain stem and cortex and 
aggregates of α-synuclein are a major protein component of these structures (Lee, 2003). 
Previous reports demonstrated the mutation of α-synuclein that leads to develop b-sheets rich 
structure and polymerize into oligomers (Lee, 2003) and this oligomeric α-synuclein may be 
toxic to the dopaminergic neurons (Conway et al., 2000). This toxicity could also be 
attributed to the auto-oxidation of dopamine on protofibrillar α-synuclein aggregation 
(Conway et al., 2001). Also, these oligomers are highly resistant to prolonged boiling, high 
SDS concentrations and treatment with urea (Perrin et al., 2001). These oligomeric fibrils 
which accumulate within the cell bodies and neurites as Lewy bodies and Lewy neuritis, also 
cause damage to ER, mitochondria and other organelles. Overexpression of -synuclein in 
dopaminergic cells treated with dieldrin (a pesticide) resulted in susceptibility of the 
dopaminergic neurons to apoptosis, suggesting possible role of -synuclein in the idiopathic 
PD (Sun et al., 2005). In contrast, over-expression of human wild-type (WT) -synuclein 
resulted in attenuation of dopaminergic neuronal apoptosis (Kaul et al., 2005a). Recently, we 
have shown that human WT -synuclein interacts with pro-apoptotic proteins - PKC and 
attenuates dopaminergic apoptosis and -synuclein negatively regulates PKC in 
dopaminergic neurons by reducing p300 Histone acetyl transferase (HAT) activity (Jin et al., 
2011). Aging is another factor that may contribute to the α-synuclein toxicity in the age 
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related accumulation of oxidative and nitrative α-synuclein aggregation (Lee and 
Trojanowski, 2006). Additionally, amyloid b peptide (Ab) which is responsible for 
aggregation in Alzheimer’s disease, promotes α-synuclein aggregation. It has been recently 
demonstrated that α-synuclein is directly transmitted from neuron overexpressing the protein 
to adjacent healthy embryonic stem cells in culture or in transgenic animals (Desplats et al., 
2009). Additionally, misfolded α-synuclein aggregates mimic to the pathogenic prion protein 
conformer (PrP
sc
) which could lead to aggregation of native protein (Ferreon et al., 2009). 
Lentivirus mediated overexpression of -synuclein led to neurotoxicity with preferential loss 
of dopaminergic neurons (Cooper et al., 2006).  From the existing findings, it is not clear if 
-synuclein plays a pro-survival or an anti-survival role in dopaminergic neurons. Extensive 
investigations are required to give a better picture of -synuclein’s roles in PD pathology. 
Apoptosis in PD 
Rapidly growing evidence iindicates that mitochondrial dysfunction leads to 
consequent loss of energy production (ATP), oxidative stress and associated apoptosis. 
Recent observations have found changes in the mitochondrial respiratory chain complex I in 
the necropsy samples of PD patients and in rotenone, paraquat or MPTP induced PD models 
that trigger the dopaminergic degeneration (Greenamyre et al., 1999; Greenamyre et al., 
2001; Ayala et al., 2007).  
Among the protein complexes that make up the electron transport chain, 
Mitochondrial complex I is one of them. It resides in the inner membrane of the 
mitochondria. Inhibition of complex I results in an interruption in the flow of electrons along 
the electron transport chain, which leads to inappropriate synthesis of ATP. Consequently, 
resultant energy deficiency as well as oxidative stress and apoptosis pathways become gets 
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activated and causes neurodegeneration (Knott et al., 2008). Inhibition of Complex I leads to 
the leaking of electrons from the electron transport chain and results in partial reduction of 
oxygen to superoxide which further damages and impairs the mitochondrial function and 
makes the cell vulnerable to the activation of apoptotic pathways (Casetta et al., 2005; Zhou 
et al., 2008). Apoptosis is a predominant mechanism which is morphologically characterized 
by cell shrinkage, cytoplasmic blebbing and involution. Apoptosis event is also involved in 
breaking up of cells into smaller apoptotic bodies that are removed by phagocytosis without 
the involvement of inflammatory responses. Although, it is not completely known whether 
the pattern of dopaminergic neurodegeneration follows apoptosis or necrosis, apoptosis is 
believed to be a dominant mechanism of cell death during PD (Anglade et al., 1997; Tatton et 
al., 2003). Growing evidence from necropsy investigations of PD patients also suggests 
apoptosis could be a primary form of cell death during PD. But as apoptotic pathways are 
very long process, it occurs over several years and subsequently, the dying cells are cleared 
rapidly. Examination of post-mortem brain tissues of PD patients provides the most 
information on apoptosis as a predominant mechanism of dopaminergic neuronal cell loss. 
Several reports have demonstrated that the dying neurons express Bcl-2 family of pro- and 
anti-apoptotic proteins and caspases, and these results suggest that apoptotic mechanisms are 
the predominant pathways in the dying neurons (Mogi et al., 1996; Tortosa et al., 1997). 
Also, apoptotic mechanisms are initiated in the MPTP and other neurotoxins models of PD 
depending on the dosing regimen of those toxins. For example, sub-acute and chronic low-
dose of MPTP triggers the apoptotic cell death pathways. A recent study has demonstrated 
that the Bax ablated mice are resistant in the MPTP mouse model of PD (Vila et al., 2001). 
Similarly, over-expression of anti-apoptotic Bcl-2 is also protective in a MPTP model (Cao et 
20 
 
al., 2006). The tumor suppressor protein p53 regulates Bax protein expression and that p53 
activity and expression are upregulated in the MPTP-treated mice (Trimmer et al., 1996).  
Similarly, p53 null mice are also resistance to MPTP-induced dopaminergic 
neurodegeneration (Duan et al., 2002). Additionally, MAPKs and JNK ablated mice are also 
resistant to MPTP toxicity (Saporito et al., 1999; Saporito et al., 2000).   
Permeabilization of the mitochondrial outer membrane (MOMP) by the pro-apoptotic 
members of the Bcl-2 family of proteins initiates the intrinsic pathway of apoptosis, resulting 
in the release of apopotogenic factors from the innermembrane space into the cytoplasm. 
Cytochrome c is one of these factors which binds to APAF-1 and causes a conformational 
change to APAF-1 which leads to its oligomerization and recruitment of caspase-9 to form a 
complex called apoptosome. Consequently, caspase-9 is activated and in turn activates and 
cleaves the executioner caspase-3 and caspase-7. Activated executioner caspases further 
activates the apoptotic cascade by cleaving key substrates to produce the biochemical and 
cellular events that are typically associated with apoptosis (Lin et al., 2010; Kiechle et al., 
2002). Recently, we have discovered that PKC-d, one of the key substrates of caspase-3 
activated in MPTP and other toxin related models in PD (Zhang et al., 2007a). Previously we 
have shown that PKC is proteolytically cleaved by active caspase-3 to generate a 
constitutively active catalytic fragment of PKC which mediates further downstream 
apoptotic signaling in dopaminergic neurons (Kitazawa et al., 2003; Kaul et al., 2005b; 
Afeseh Ngwa et al., 2009). 
Pin1 
 Protein phosphorylation is one of the most important regulatory mechanism in both 
prokaryotic and eukaryotic organisms (Stock et al., 1989; Barford and Neel, 1998). 
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Regulatory phosphorylation generally occurs on serine, threonine or tyrosine residues in 
eukaryotic proteins and histidine, arginine and lysine in prokaryotes. Reversible 
phosphorylation on Ser/Thr – Pro (S/T-P) motifs regulated by Pro-directed protein kinases 
and phosphatases is an important molecular switch in controlling various cellular processes 
(Gothel and Marahiel, 1999; Lu, 2000; Jager et al., 2006). Proline-directed kinases, such as 
cyclin-dependent protein kinases, extracellular signal-regulated kinases, stress-activated 
protein kinases/c-Jun-N-terminal kinases, p38 MAP kinases, glycogen synthase kinase – 3, 
Polo-like kinases and some of the Ser/Thr phosphatases, phosphorylate or dephosphorylate 
such motifs to regulate cellular signaling (Sudol et al., 2001; Shaw, 2007). Recent studies 
demonstrated that Ser/Thr-Prophosphorylated proteins undergo post-phosphorylation 
conformational modifications by the phosphorylation-specific peptidyl-prolyl cis/trans 
isomerase (PPIase) (Lu et al., 2007; Lu and Zhou, 2007). Since the discovery of protein 
interacting with never in mitosis – A (Pin1), a lot has been learned with respect to the 
conformational importance of the Pro-directed kinases in cellular signaling (Uchida et al., 
1999; Fujimori et al., 2001). Pin1 is a peptidyl-prolyl  isomerases but it is unique among 
PPIase, in that, it specifically recognizes phosphorylated serine or threonine residues 
immediately preceding proline (pSer/Thr-Pro) in a subset of proteins, and isomerizes the 
cis/trans conformation of the peptide bond (Joseph et al., 2003; Lu, 2004). 
Structure of Pin1 
Pin1 is an 18kDa protein and it has a two domain structure that comprised of N-
terminal WW domain (named after two invariant Trp residues) and C-terminal PPIase 
domain. The WW domain binds to specific pSer/Thr-Pro motif and PPIase domain 
isomerizes specific pSer/Thr-Pro motifs to regulate protein functions by controlling their 
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conformation (Lu et al., 1999; Zhou et al., 2000). The two domains are joined together by a 
flexble linker. Molecular modeling study finds the high homology of Pin1 across human, rat 
and mouse. Various nuclear magnetic resonance (NMR) analyses revealed that Pin1 
dynamically binds to its substrates 
and regulates their conformation 
(Jacobs et al., 2003; Pastorino et 
al., 2006; Namanja et al., 2007). 
Still, it is not clear why Pin1 binds 
only to specific pSer/Thr-Pro 
residues in certain proteins. 
However, different articles 
speculated that the sequence that 
is important for the Pin1 binding 
specificity is located on the WW domain at an intrinsically flexible loop and the flexibility of 
this loop changes upon ligand binding, suggesting the importance of sequence specific 
dynamics for Pin1 substrate (Namanja et al., 2007).  
Regulation of Pin1 function 
 Pin1 function is tightly controlled at multiple levels under various physiological 
conditions. Substrate availability controls the subcellular localization and function of Pin1 
due to presence of Ser/Thr-Pro motifs (Lu et al., 2002). Transcription factor E2F controls the 
expression of Pin1in response to growth factors (Ryo et al., 2002). Tumor suppressor breast 
cancer-1, early onset (BRCA-1) is one of the most prominent gene that suppresses the 
expression of Pin1 (MacLachlan and El-Deiry, 2000). Pin1 is also regulated by various post-
Figure 5. Schematic diagram of structure of Human 
Pin1. This schematic diagram was obtained from the 
freely accessible Macromolecular Structure Database at  
http://www.ebi.ac.uk/msd-
srv/msdlite/atlas/visualization/1pin.html  
(Authors: J. P. Noel, R. Ranganathan R and T. Hunter). 
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translational modifications. Phosphorylation of Pin1 is regulated in a cell cycle dependent 
manner which includes phosphorylation on Ser 16 in the WW domain, resulting in blocking 
of Pin1 interaction with its substrates (Lu et al., 2002). Additionally, Polo-like kinase-
1(PLK1) also phopsphorylates Pin1 on Ser65, resulting in increased stability of Pin1 by 
reducing its ubiquitination (Eckerdt et al., 2005). Moreover, Pin1 enzymatic activity is 
blocked by oxidative modifications that occur in the early stages of Alzheimer’s disease 
(Sultana et al., 2006).  
Role of Pin1 in controlling biological activities 
Pin1 interacts with and regulates the stability of its phosphor-substrates, at the post-
phosphorylation levels, thereby controlling their biological processes.  Numerous studies 
have shown the Pin1 catalyzed conformational regulation has a profound impact on the 
regulation of cell cycle proteins, growth, stress responses, immune responses, germ cell 
development, neuronal differentiation and survival (Atchison and Means, 2004; Braithwaite 
et al., 2006). Deregulation of Pin1 signaling is implicated in a growing number of 
pathological conditions such as Alzheimer’s disease (AD) (Akiyama et al., 2005; Maruszak 
et al., 2009), asthma (Esnault et al., 2008), frontotemporal dementia (Thorpe et al., 2004), 
Parkinsonism linked to chromosome 17 (FTDP-17) (Yotsumoto et al., 2009), Pick disease 
(Ramakrishnan et al., 2003), progressive supranuclear palsy (PSP), corticobasal degeneration 
(CBD) (Lee et al., 2001) and cancer (Li et al., 2006). 
Pin1 in controlling the stability of cell cycle proteins in cancers 
 In many human cancers, Pin1 protein is overexpressed and this overexpression is 
associated with poor clinical outcome. Pin1 can promote oncogenesis by upregulating the 
expression of oncoproteins and disrupting cell cycle progression. Pin1 regulates the 
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expression of cyclinD1by controlling the Ras signaling, resulting in inhibition of β-catenin 
and the tumor suppressor APC (Ryo et al., 2002). Occurrence of overexpressed  cyclinD has 
been found in about half of breast cancer patients (Bartkova et al., 1996). In cell culture 
studies, Pin1 regulates the stability and subcellular localization of β-catenin.Its increased 
expression also correlates with upregulated Pin1 expression in breast tumors (Ryo et al., 
2001). Pin1 also binds and isomerizes the phosphorylated Ser246-Pro motif in β-catenin and 
thus inhibits the interaction of β-catenin with APC, which plays role in exporting nuclear β-
catenin into the cytoplasm for degradation. Pin1 further binds to cyclin D1 at the 
phosphorylated Thr-286-Pro motif and catalyses its isomerization which results in 
stabilization and accumulation of cyclin D1 in the nucleus (Liou et al., 2002). After Pro-
directed phosphorylation by JNK, the activity of c-Jun is also controlled by Pin1. Pin1 
increases the protein stability of c-Jun by inhibiting c-Jun polyubiquitination (Wulf et al., 
2002). Pin1 also positively correlates the expression of the anti-apoptotic protein, myeloid 
cell leukemia (MCL-1) whose elevated expression leads to poor survival rate of breast cancer 
patients (Ding et al., 2008). Additionally, Pin1 is identified as the novel regulator of 
extracellular signal-regulated kinase (ERK) (Ding et al., 2008). In addition to stabilizing and 
activating oncoproteins, Pin1 can also inactivate and destabilizes a huge number of tumor 
supressors and cell growth inhibitors. Pin1 specifically isomerizes the cis/trans conformation 
of phosphorylated Thr58-Pro of c-Myc, which in turn enhances the dephosphorylation 
activity of protein phosphatase 2A (PP2A) on Ser62. Similar to c-Myc, misregulation of 
cyclin E function also causes cell cycle defects and onset of oncogenesis (Yeh and Means, 
2007). Pin1 facilitates Cyclin E protein degradation during cell cycle progression, whereas, 
the absence of Pin1 results in an accumulation of cyclin E at the G1/S phase of the cell cycle 
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(Yeh and Means, 2007). Pin1 also regulates a variety of oncoproteins associated with 
transcription by increasing β-catenin and nuclear factor kappa b (NF-κB) stability, and 
decreasing the stability of c-Myv, cyclin E and RAR. Additionally, Pin1 also controls other 
transcription-associated proteins such as steroid receptor coactivator-3 (SRC-3) that is 
overexpressed in breast and ovarian cancers (Yi et al., 2005). Pin1 regulates transforming 
growth factor-beta (TGF-β) signaling which is essential in regulating proliferation, 
differentiation, migration and apoptosis (Siegel and Massague, 2003). Additionally, it has 
been found that Pin1 binds to phosphorylated Ser670 of GRK2 (G protein-coupled receptor 
kinase 2, plays role in cancer formation) and triggers GRK2 degradation (Nigg, 2001).  
Pin1 in neuronal function and apoptosis 
 Pin1 is expressed in most neurons at high levels (Ryo et al., 2001; Wulf et al., 2001). 
Also, Pin1 expression is induced during differentiation process of neurons (Hamdane et al., 
2006). Pin1 regulates several neuronal proteins that are important for neuronal function and 
survival including tau, amyloid precursor protein (APP), and myeloid cell leukemia sequence 
(MCL-1) (Zhou et al., 2000; Pastorino et al., 2006; Li et al., 2007). High expression levels of 
Pin1 in terminally differentiated and post mitotic neurons suggest that it plays several 
important roles in neurons except cell cycle regulation and proliferation (Becker and Bonni, 
2006). Pin1 interacts with Ser65 phosphorylated BIMEL and thereby stabilizes BIMEl, 
resulting in neuronal apoptosis (Becker and Bonni, 2007). All survival and death signaling 
pathways in neurons converge at the mitochondria where they integrated mainly by the Bcl2 
family of proteins. The proapoptotic ‘BH3 only’ subfamily is the only members critical for 
the activation of mitochondria mediated cell death as they are upstream molecules of the 
apoptotic pathway. JNK signaling is believed as one of the key regulator of BIMEL in 
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neurons (Becker and Bonni, 2007). The selective enrichment of Pin1 at the mitochondrial 
membrane of BIMEL occurs through binding of WW domain of Pin1 to Ser65-
phosphorylated site of BIMEL which contains JNK interacting protein 3(JIP3). Pin1 
associates with JIP3 in neurons in a phosphorylation dependent manner (Becker and Bonni, 
2007). In addition to upregulating BIM gene expression through the activation of c-JUN, 
JNK directly phosphorylates the BIMEL protein at serine 65 which leads to activation of 
apoptotic function of BIMEL in neurons, but suppresses cell death in proliferating non-
neuronal cells, possibly through the proteosomal degradation of phosphorylated BIMEL. In 
addition to that, Pin1 induced apoptotic death in NGF-treated PC12 neuronal cells is blocked 
by expression of dominant negative-Jun (Barone et al., 2008). In contrast, Pin1 knockout 
mice show increased oligodendrocytes apoptosis after spinal cord injury (Li et al., 2007) and 
untreated aged Pin1 (-/-) mice show patterns of neurodegeneration features, suggesting pro-
survival role of Pin1. 
Pin1 and Alzheimers disease 
 Although most human neurons express Pin1, its levels are abnormally low in the 
Alzheimer’s disease (AD) brain. The neuropathological hallmarks of AD include presence of 
neurofibrillary tangles and neurite plaques in the brain. The neurofibrillary tangles consist of 
paired helical filaments composed of hyperphosphorylated microtubule-associated protein 
tau. Similarly, the neuritic plaques appear due to over production or lack of degradation of 
amyloid-b (Ab) peptides derived from APP (Amtul et al., 2002; Mattson and Chan, 2003). 
Pin1 promotes dephosphorylation of the pThr231-Pro motif in tau by the trans-specific 
protein phosphatase PP2A (Lu et al., 1999). Pin1 knockout promotes accumulation of the 
pThr231-Promotif in the tangle-specific conformation (Zhou et al., 2000). So, Pin1 promotes 
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tau dephosphorylation and restore tau function possibly by catalyzing cis to trans 
isomerization. So in absence or reduced activity of Pin1, the cis pThr231-Pro motif 
accumulates, leading to tau hyperphosphorylation, aggregation and tangle formation. In 
addition to that Pin1 also promotes APP processing and Ab production (Amtul et al., 2002). 
Pin1 interacts with pThr668-Pro motif of APP and causes its isomerization. In the mouse, it 
has been reported that the absence of Pin1 promotes amyloidogenic APP processing and 
increases the toxic substance Aβ42 in an age dependent manner (Pastorino et al., 2006). 
Collectively, Pin1 plays pivotal role in protecting against age-dependent neurodegeneration 
in AD and might be a new drug target for treating the disease.        
Pin1 and Parkinson’s disease 
 Pin1’s level, activity and function in the pathogenesis of PD are completely unknown. 
Recently, Ryo et al., 2006 reported that Pin1 accumulates in lewy bodies (which is a 
cytoplasmic inclusions containing α-synuclein), and promotes the formation of α-synuclein 
inclusions by protecting α-synuclein from degradation in kidney cells (Ryo et al., 2006). But, 
α-synuclein degradation is not directly linked to Pin1 PPIase activity, suggesting that Pin1 
and α-synuclein do not have direct interaction. However, Pin1 binds sunphilin-1, an alpha-
synuclein regulatory protein at pSer211-Pro and Ser215-Pro motifs and enhances its 
interaction with α-synuclein, facilitating the formation of α-synuclein inclusions (Ryo et al., 
2006). 
Pin1 and immune responses  
 The fundamental effect of Pin1 on protein conformation accounts for its diverse role 
in cell cycle progression, proliferation and transcription. Pin1 also increases the activity of 
nuclear factor kappa beta (NF-κB), a transcription factor that plays a crucial role in 
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inflammation. Pin1 also inhibits degradation of β-cateninand NF-κB  p65, increasing their 
levels (Monje et al., 2005). All these transcription factors are associated with induction of 
inflammatory gene products. In response to cytokine signals, Pin1 binds to and isomerizes 
the phosphorylated p65 subunit of NF-κB  and prevents NF-κB from binding to IkB 
(inhibitor of NF-κB), resulting in increased NF-κB activity (Ryo et al., 2003). Pin1 has been 
reported to inhibit ubiquitin mediated proteolysis of p65 by SOCS1 (suppressor of cytokine 
signaling-1) (Ryo et al., 2003). Additionally, Pin1-deficient mice and cells are resistant to 
NF-κB mediated cytokine upregulation. Pin1 has also been shown to activate the 
transcription factor activating protein-1 (AP1) (Monje et al., 2005). Inducible nitric oxide 
synthase (iNOS) is one of the inflammatory genes activated by NF-κB  and AP-1 (Xie et al., 
1993; Du et al., 2006). Pin1 may also contribute to the onset of allergic asthma2 and 
microbial infection (Shen et al., 2005; Saitoh et al., 2006). In addition to that, Pin1 interacts 
with phosphorylated IRF3 and promotes its polyubiquitination and proteasome-dependent 
degradation thus facilitates innate immunity against viral infection (Saitoh et al., 2006). 
Pin1’s roles during apoptosis are varied. While inhibition of Pin1 led to apoptosis in vascular 
smooth muscle cells and Pin1 was required for pro-survival signaling in eosinophils (Shen et 
al., 2009), Pin1’s pro-apoptotic function has been demonstrated during downregulation 
inhibitor of apoptosis protein-survivin in neuroblastoma cells (Dourlen et al., 2007) and 
promoting tumor cell death by dissociating tumor suppressor p53 from apoptosis inhibitor 
iASPP (Mantovani et al., 2007). In the nervous system, Pin1 has been shown to regulate 
oligodendrocyte apoptosis after spinal injury by binding and stabilizing Mcl-1 after JNK3 
activation (Li et al., 2006) and also induce death of developing neurons during JNK 
signaling.        
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Table 1. List of selected Pin1 substrates 
Substrate 
name 
Pin1 binding 
motif 
Role of Pin1 Pathways/disease 
involved 
References 
Synphilin-1 Ser211, 
Ser215 
Promotes lewy body 
formation; stabilizes α-
synuclein 
Parkinson’s disease (Ryo et al., 
2006) 
c-Fos C-terminal Regulates stability and 
transcriptional activities 
 (Monje et al., 
2005) 
c-Jun Ser63, Ser73 Regulates transcriptional 
activities 
Breast cancer (Wulf et al., 
2001) 
β-Catenin Ser246 Regulates stabilization, 
localization and activation 
Cell proliferation; 
Cancers 
(Ryo et al., 
2001) 
Cyclin D1 Thr286 Regulates stabilization, 
localization and activation 
Cell proliferation; 
Cancers 
(Liou et al., 
2002) 
NF-κB /p65 Thr254 Neuclear translocation and 
stabilization 
NF-κB  activation; 
Cytokine release 
(Ryo et al., 
2003) 
Akt Thr92, Thr450 Regulates stability Oncogenin pathways (Liao et al., 
2009) 
P53 Ser33, 
Thr181, 
Ser315 
Stabilization and promoter 
binding activities 
DNA damage; 
Genotoxic stress 
(Wulf et al., 
2002; Cohen et 
al., 2008) 
Bcl-2 Not known yet Increases the bioactivity, 
prevents, 
dephosphorylation 
Apoptotic pathways (Basu et al., 
2002) 
BIMEL Ser65 Stabilization and apoptosis Neuronal apoptosis (Becker and 
Bonni, 2006) 
SMRT Ser1241, 
Thr1445 
Destabilization Lumphoma; 
Leukemia; Prostate 
cancer 
(Stanya et al., 
2008) 
Oct4 Ser12 Modulates stability and 
transcriptional activity 
Stem cell 
pluripotency 
(Nishi et al., 
2011) 
PPAR-γ Ser84 Prevents 
polyubiquitination 
Atherosclerosis (Fujimoto et al., 
2010) 
c-Myc Thr58 Degradation Tumorigenesis (Yeh et al., 
2004) 
Cyclin E Ser384 Regulation of cellular 
levels 
Cell cycle; 
Tumorigenesis 
(Yeh et al., 
2006) 
Tau Thr231 Regulate protein stability 
and dephosphorylation 
Taupathy; Neuronal 
differentiation; 
Alzheimer’s disease 
(Lu et al., 1999; 
Lim et al., 
2008) 
Pim-1 
kinase 
Not known yet Destabilization of Pim1 Lumphoma; Prostate 
cancer 
(Ma et al., 
2007) 
TGF-β Not known yet Regulates accumulation 
and translation in 
neutrophil 
Chronic asthma (Shen et al., 
2008) 
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Pin1 inhibitors 
Untill now, there are few compounds that have been reported to act as inhibitors of 
Pin1. Among several inhibitors, Juglone is regarded as one of the most potent inhibitor of 
Pin1. Juglone is an aromatic organic naphthoquinone (5-hydroxy-1, 4-naphthalenedione, 
(C10H6O3), naturally occurs in the leaves, roots, and bark of plants in the black walnut. 
Napthoquinone is known to have various physiological activities and also it plays role in 
induction of apoptosis (Kang et al., 2002).  
Juglone irreversibly and specifically inactivates enzymatic activity of E. coli parvulin 
and human Pin1 by modification of thiol groups of cysteine residue in parvulin (Hennig et 
al., 1998). The inhibition of isomerase activity by juglone is 
caused by partial unfolding of the PPIase activity site. Also, 
juglone inhibits numerous parvulins as well as other 
enzymes comprising Cys residues in their catalytic domains. 
Juglone plays role in various cellular events such as 
induction of DNA damage (Wang et al., 2001a) and cell death (Paulsen and Ljungman, 
2005). Recently, Esnault et al., 2007 (Esnault et al., 2008) showed that Juglone prevented 
acute and chronic rejection of MHC mismatched, orthotopic rat lung transplants by reducing 
the expression of IFN-γ and CXCL-10 mRNA stability, accumulation and protein expression 
after cell activation. Juglone also attenuates rheumatoid arthritis development and COX-2 
expression in human primary culture RA chrondrocytes and CII treated DBA/1J mice (Jeong 
et al., 2009). Additionally, recent reports suggested anti-inflammatory, anti-viral and anti-
Figure 6. Structure of Juglone 
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fungal properties of Juglone (Omar et al., 2000). Juglone at a dose of 5.7M in vitro blocked 
Pin1’s and E. coli parvulin isomerase activity completely and these doses of Juglone had no 
effect on other PPIases (Hennig et al., 1998). Besides juglone there are some other synthetic 
inhibitor of Pin1 such as PiB (diethyl-1,3,6,8-tetrahydro-1,3,6,8-tetraoxobenzo 
phenanthroline-2,7-diacetate) and PiJ (diethyl-1,3,8,10-tetrahydro-1,3,8,10-tetraoxoanthra 
diisoquinoline-2, 9-diacetate).  The structures of PiB and PiJ have double-ring structures like 
juglone, but otherwise their overall structures are completely different from the juglone. 
Recently, a novel Pin1 inhibitor, dipenramethylene thiuram monosulfide (DTM) has been 
identified (Tatara et al., 2009). DTM is soluble in DMSO, and is a competitive inhibitor of 
Pin1. Molecular modeling studies showed that DTM binds to the active site of PPIase 
domain of Pin1. In mouse embryo fibroblasts (MEF) lysate, DTM inhibited Pin1 PPIase 
activity but not FKBP or cyclophilin PPIases (Tatara et al., 2009). Additionally, several 
peptide mimetics have also been reported to inhibit Pin1 (Zhang et al., 2007b). Molecular 
Pin1short interfering RNA (Pin1 siRNA) and dominant negative constructs of Pin1 also 
specifically inhibit the levels and activity of Pin1 respectively in situ.  
NF-κB  
The nuclear factor kappa B (NF-κB) is a key mediator of inducible transcription in 
the immune system. It consists of five related transcription factors that regulate inducible 
gene expression in various physiological processes. It was first identified in mature B and 
plasma cells by Sen and Baltimore (Sen and Baltimore, 1986). The mammalian NF-κB 
family consists of p65 (Rel A), RelB, c-Rel, 105/p50 (NF-κB1) and p100/p52 (NF-κB2) that 
associate with each other to form distinct transcriptionally active homo and heterodimer 
32 
 
complexes. They all share a conserved 300-amino acid-long amino-terminal REL homology 
domain (RHD) (Ghosh et al., 1998) and are regulated by eight IκB family members. 
 The amino terminal part of the RHD mediates specific DNA binding to NF-κB consensus 
sequences present in regulatory elements of NF-κB target genes (5’-GGGPuNNPyPyCC-3’), 
whereas the carboxy-
terminal part of the RHD 
is mainly responsible for 
dimerization and 
interaction with IκBs 
(Ghosh et al., 1995; Chen 
et al., 1998).  
Role of NF-κB in 
neurodegenerative 
disorders  
 The nuclear factor 
kappa B or NF-κB refers 
to the Rel family of 
transcription factors 
consisting of five family 
members: p65/RelA, ReB, 
c-Rel, p50/p105 (NF-κB 
1), and p52/p100 (NF-κB 
2). The subunits exist in unstimulated cells as homo or heterodimers bound to inhibitor kappa 
Figure 7. Activation pathway of NF-κB 
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B (IkB) family proteins. NF-κB  was discovered in 1986 as the proinflammatory factor that 
responds to LPS signaling (Sen and Baltimore, 1986). Initially, NF-κB has been considered 
as an immunologic transcription factor. However, more recently, NF-κB  activity has been 
implicated in diverse disease pathogenesis and biologic processes (Verma, 2004). NF-κB 
proteins are characterized by the presence of a conserved 300 amino acid Rel homology 
domain (RHD) that is located at the N terminus of the protein and is responsible for 
dimerization, interaction with IkB and binding to DNA. Additionally, there are two 
subgroups of the NF-κB family, three of the subunits, p65, relB and c-rel, contain 
transcription activation domain (TAD) at the c-terminus. The p50 and p52 subfamily 
members are proteolytically cleaved from larger proteins p105 and p100, respectively, and do 
not contain TADs. Instead they act as transcriptional suppressor. The p65/p50 heterodimer, 
the prototypical NF-κB  dimer leads to the transcription of various genes, whereas the 
p50/p50 homodimer, which also binds to the NF-κB  consensus sequence with a higher 
affinity than p65/p50, inhibits transcription (Adib-Conquy et al., 2000). NF-κB is activated 
through two different pathways: the canonical/activated and non-canonical pathways. The 
canonical pathway is generally induced by TNF-α , IL-1, TLR or LPS and uses a large 
variety of signaling adaptors to engage IKK activity. The non-canonical pathway depends on 
NIK (NF-κB -inducing kinase) induced activation of IKKa. The inhibitor kappa B kinase or 
IKK complex, which phosphorylates IκB following its activation, consists of two 
homologous catalytic kinase subunits, IKK-a and IKK-b, and the regulatory subunit IKKy or 
NEMO (NF-κB essential modifier) (May et al., 2000). Various molecules upstream to IKK 
are involved in the NF-κB signaling pathways. LPS activated TLR4 binds to MyD88 and 
IRAK, which then signal through TRAF6, leading to the activation of IKK. Other signaling 
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proteins include MyD88, RIP, NIK and TRAF (Hayden and Ghosh, 2004). IKK-g interacts 
with the upstream molecules, which results in the oligomerization of IKK-g. IKK-g then 
induces phosphorylation or possible autophosphorylation of the IKKa or b subunits. The 
catalytic subunits then release from IKK-g and phosphorylate IkB at Ser32 and Ser36. After 
phosphorylation, IkBa is poly-ubiquitinated at Lys22 and degraded by the 26S proteosome. 
This degradation mechanism leads to the loss of nuclear export signal provided by the IKB 
and activates the nuclear localization (NLS) signals on the NF-κB subunits. NF-κB  then 
migrates to the nucleus where it binds to the promoter region of its target molecules and 
facilitates gene expression of pro-inflammatory, cell growth and other regulated genes (Tak 
and Firestein, 2001; Hayden et al., 2006; Hayden and Ghosh, 2008).  
IkB protein family comprises three functional groups: the typical IκB proteins IκBα, 
IκBβ and IκB€, which are present in the cytoplasm of unstimulated cells and undergo 
stimulus-induced degradation and resynthesis. IκBα is a prototypical member of IκB family 
of proteins. As in other organ systems, functional NF-κB complexes are present in essentially 
all cell types in the nervous system, including neurons, astrocytes, microglia, and 
oligodendrocytes (O'Neill and Kaltschmidt, 1997). The most common subunits expressed are 
p50, p65, and IκBα. Receptor-linked signal transduction pathways that ultimately result in 
NF-κB activation, such as those activated by TNF-α and Fas ligand, have also been 
documented in neurons and glial cells (Bruce et al., 1996). Additional neuron-specific signals 
that activate NF-κB include nerve growth factor (NGF) (Carter et al., 1996) and the secreted 
form of β-amyloid precursor protein (βAPP) that is involved in Alzheimer’s disease (Mattson 
and Chan, 2003). As in other organs, NF-κB influences the expression of a complex array of 
genes in the nervous system and, in general, the genes serve important functions in cellular 
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responses to injury and in neuronal plasticity. Genes encoding of several different injury-
responsive cytokines are induced by NF-κB in glia and neurons. These include TNF-α and 
IL-6, which are produced in particularly high amounts by microglia and astrocytes; βAPP, an 
injury-responsive cytokine/neurotrophic factor; the calcium-binding protein calbindin-D28k, 
which may play roles in modulating calcium-mediated neuronal signaling and cell death; 
inhibitor-of-apoptosis proteins (IAPs), which can protect neurons against apoptosis in 
experimental models of stroke and seizures; manganese superoxide dismutase (Mn-SOD), a 
mitochondrial antioxidant enzyme that has been shown to be neuroprotective; and Bcl-2, the 
prototypical member of the Bcl-2 family of antiapoptotic proteins. Additional genes induced 
by NF-κB in glial cells include the cell adhesion molecule intercellular adhesion molecule-1, 
the inducible form of nitric oxide synthase (iNOS), and glial fibrillary acidic protein (GFAP). 
Presence of consensus DNA binding sites for NF-κB in promoter regions of most 
proinflammatory molecules, and inhibition of induction of their expression upon inhibition of 
NF-κB activation, suggest that activation of NF-κB is important for the induction of 
proinflammatory molecules (Ghosh, 1999). NF-κB is activated by pro-inflammatory 
cytokines, induced cell proliferation and anti-apoptotic gene expression, and it also enhances 
angiogenesis via vascular endothelial growth factor expression (Aggarwal et al., 2004; 
Greten and Karin, 2004). Activation of NF-κB has been reported in various chronic 
inflammatory diseases including asthma, rheumatoid arthiritis and EAE model of multiple 
sclerosis (Dasgupta et al., 2004). Postmortem analysis of human PD brain provide evidence 
of the activation of NF-κB in dopaminergic neurons of human PD patients (Hunot et al., 
1997). Recently, Ghosh et al., 2007 demonstrated that NF-κB is required for the transcription 
of most of the proinflammatory molecules and it is activated in the SNpc of PD patients and 
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MPTP-intoxicated mice. Selective inhibition of NF-κB in mice by NBD (NEMO binding 
domain) peptides protected dopaminergic neurons from MPTP toxicity (Ghosh et al., 2007).  
Furthermore, other neurotoxins such as rotenone and 6-hydroxydopamine (6-OHDA) used in 
experimental models of PD, stimulate NF-κB (Blum et al., 2001; Wang et al., 2002; Ghribi et 
al., 2003). Based on these findings, it is plausible that the activation of NF-κB may be 
essential for neurotoxin-induced degeneration in nigral neurons.  
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Background and Literature Review II 
In this section, the activation of the glial cells in PD and MPTP mouse model of PD, 
glial cells mediated inflammation and oxidative stress, different neuroprotective strategies to 
cure PD and mitochondria targeted neuroprotective compounds in mouse model of PD are 
reviewd. 
Pathophysiology of PD 
 Despite intense research, the cause of dopaminergic neurodegeneration in PD is not 
known completely. Among different cellular and molecular changes that are believed to be 
involved in the progressive degeneration of dopaminergic neurons, neuroinflammatory 
mechanism is one of them (Dauer and Przedborski, 2003). Neuroinflammation mechanism 
comprises microglial and astroglial activation, proinflammatory cytokines and molecules and 
oxidative stress. It is now well documented that microglial activation leads to loss of DA 
neurons in PD patients. Levels of nitrite (NO2), a metabolite of NO and inducible nitric oxide 
synthase (iNOS) are higher in the central nervous system (CNS) of human PD cases and in 
animal models of PD (Mogi et al., 1994). Consistent with this finding, iNOS knockout 
animals were resistant to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) -induced 
dopaminergic neuronal loss in the substantia nigra (Przedborski and Vila, 2003). One of the 
major sources of reactive oxygen species (ROS) in neurodegeneration is NADPH oxidase, a 
multimeric enzyme that generates both O
2-
 and H2O2 (Qureshi et al., 1995). In addition to that 
levels of proinflammatory cytokines (TNF-α, IL-1β, IFN-γ, IL-6), chemokines and 
prostaglandins levels are also elevated in PD brains (McGeer et al., 1988; Nagatsu et al., 
2000). Recent reports suggest that NF-κB, a transcription factor that is required for 
transcription of proinflammatory molecules is also activated in the substantia nigra of PD 
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patients and MPTP-treated mice (Ghosh et al., 2007)  Additionally, Nurr1, a nuclear orphan 
receptor suppresses glial activation by docking to NF-ĸB-p65 on target inflammatory gene 
promoters and protects against dopaminergic neurodegeneration in substantia nigra. 
Microglia and its activation 
 Microglia constitutes about 10% of all glial cells and they are distributed all over the 
brain with maximum population in substantia nigra. Microglia was first identified by Del Rio 
Hortega in 1919 as mesodermal 
cells entering the brain in late 
embryonic phase (Hortega, 
1919). Under normal condition, 
microglia displays a ramified 
morphology and is referred as 
resting microglia. In resting 
condition, microglia play a homeostatic role in the CNS respond to environmental stresses 
and immunological challenges by scavenging excess neurotoxins and removing dying cells 
and cellular debris (Carson et al., 2007; Tansey et al., 2008). It has been shown that early 
microglial activation within 24h of inflammatory stimulus exposure, leads to elevated 
microglial immunoglobulin reactivity, upregulation of cell adhesion molecule such as 
CD11b, CD18 and intracellular adhesion molecule (ICAM-1) (Orr et al., 2002). Furthermore, 
upon activation, the morphology of microglial cell changes. The cell body becomes enlarged, 
amoeboid shape with thickened processes (Kloss et al., 1999). In the activated state, 
microglia constitutively expresses MHC-II molecule, b2 integrin CD11a, CD11b, CD11c 
(Marlin and Springer, 1987; Greenwood et al., 2003). Stimuli that can trigger microglial 
Figure 8. Expression of CD11b-positive microglia in SN of 
Human brain 
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activation include pathogenically modified CNS protein, antigens from infectious agents 
(such as gram-negative bacterial cell wall component liposaccharide (LPS)), prion proteins, 
α-synuclein, ATP, cAMP, and interleukin (IL)-1β, IL-6, and IL-10 (Hanisch, 2002; 
Nakamura et al., 2002). In addition to these, aging and repeated exposure to envioronmental 
toxins (including pesticides and particulate matter) may contribute to the increased 
permeability to the blood brain barrier which facilitates entry of peripheral immune cells into 
the brain, resulting in microgliosis. At the molecular level, microglial activation may be 
triggered by protein aggregation and formation of inclusions arising from mutation, 
disruption of ubiquitin-proteasome system, bacterial or viral infections or traumatic brain 
injury (Zhang et al., 2005; Austin et al., 2006; Kim et al., 2006).  
Astrocytes - pro-inflammatory or anti-inflammatory 
The function of astrocytes 
is not clear in 
inflammatory reactions. 
After injury, astrocytes 
migrate to the site of injury 
and develop a hypertrophic 
morphology with increased cell bodies and thickened processes and are known as reactive 
astrocytes. Astrocytes do not attack any microglia, instead astrocytes produce factors that are 
important in the inflammatory reactions, seen in SN in PD brains (Miklossy et al., 2006). 
Recent studies have demonstrated activated astroglial cells in human PD brain and in the 
MPTP mouse model of PD (Ghosh et al., 2007; Ghosh et al., 2009). Many ICAM-1 positive 
Figure 9. Expression of GFAP-positive astrocytes in SN of 
Human brain 
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astrocytes are also present in the SN in PD and this may attract reactive microglia to the area 
since such microglia carry counter receptor LFA-1 (Miklossy et al., 2006). Α-synuclein has 
been shown to activate microglia and astrocytes to produce IL-6 and ICAM-1 (Klegeris et al., 
2007). Astrocytes on the other hand, secrete many neurotrophic factors for dopaminergic 
neurons including glial cell derived neurotrophic factor (GDNF), brain derived neurotropic 
factor (BDNF) and mesencephalic astrocytes-derived factor (MANF) (Lin et al., 1993; 
Petrova et al., 2003; Chen et al., 2006; Saavedra et al., 2006). Astrocytes in the SN also 
upregulate protease-activated receptor-1 (PAR-1) in PD and this has a protective effect by 
increasing the activity of glutathione peroxidase (Ishida et al., 2006). Recently, it has been 
shown that astrocytes express NF-E2-related factors (Nrf2), which binds to the antioxidant 
response element to induce antioxidant enzymes (Jakel et al., 2007). Moreover, 
overexpression of Nrf2 in astrocytes is reported to protect against 6-OHDA damage in mice 
(Jakel et al., 2007). Based on all this evidence, it is very difficult to conclude whether 
astrocytes are pro-inflammatory or anti-inflammatory. 
Glial activation in MPTP mouse model of PD 
 A glial activation including microglia and astrocytes has been widely described in 
several animal models of PD. Herein, glial activation in MPTP mouse model of PD is 
discussed. In mice and monkeys, MPTP-induced activation of microglia has been reported by 
several research groups (Hurley et al., 2003; McGeer et al., 2003; Barcia et al., 2004). 
However, the method of MPTP injection (dosing regimen) plays important role in the 
activation of microglia. In acute MPTP model of PD, robust activation of microglail cells 
have been observed whereas, in sub-acute MPTP model, comparatively less microglial 
activation occured (Barcia et al., 2004; Furuya et al., 2004; Ghosh et al., 2009). Microglial 
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activation is also seen after osmotic infusion of complex-I inhibitors in rats (Sherer et al., 
2003; Champy et al., 2004). Moreover, the direct role of the microglial activation in the 
events leading to neuronal degeneration is supported by animal studies showing that 
microglial activation precedes neuronal degeneration (Liberatore et al., 1999).  
 
Figure 10. Cellular events in substantia nigra after MPTP administration (Hirsch et al., 
2009). 
An astroglial reaction has been reported in the substantia nigra and striatum of the 
mice exposed to MPTP (Czlonkowska et al., 2001; Breidert et al., 2002). Astroglial reaction 
in acute MPTP model generally starts from 24h after the last dose of MPTP injection and at 
48h after MPTP (Breidert et al., 2002). In terms of cell proliferation, the astroglial and 
microglial reactions also differ. Newborn microglial cells have been demonstrated by BrdU 
labeling in mice and monkeys exposed to MPTP, whereas, no such staining was observed for 
GFAP positive astroglial cells (Brochard et al., 2009). Microgliosis is involved with an 
increased amount of microglial cells and morpholpogical change of microglial cells, whereas 
astrogliosis is involved with increased expression and morphological changes of the 
astrocytes, but no increase in cell number.  
Neuroinflammatory mechanism 
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The involvement of inflammation in PD was first reported by McGeer et al., 1988, 
where they observed the upregulation of major histocompatibility complex (MHC) in PD 
patients (McGeer et al., 1988). Similarly, increased levels of b2-microglobulins in the 
striatum of PD patients were reported (Mogi et al., 1995). Subsequently, a wide range of 
other proinflammatory molecules has been implicated in the process (Arai et al., 2004). 
Activated microglial cells and reactive astrocytes are the major modulators of inflammatory 
reaction in the brain. After activation of the glial cells, they are capable of producing toxicity 
through the production and release of oxygen- and nitrogen-derived products in a process 
known as respiratory or oxidative bursts. This process of toxicity is based on the regulated 
induction of NADPH (nicotinamide adenine dinucleotide phosphate) oxidase, iNOS 
(inducible nitric oxide synthase) and MPO (myeloperoxidase). NADPH oxidase is the source 
of superoxide, whereas, iNOS produces nitric oxide (NO) and MPO regulates production of 
hypochlorous acid (HOCl).  
Table 2. Evidence of Neuroinflammation in PD brain 
Human/ Model 
systems 
Evidences References 
Human PD brain Higher no. of activated microglia (HLA-DP, 
HLA-DQ, HLA-DR and ferritin) in SN 
(McGeer et al., 1988) 
MPTP model Microglia activation in close proximity to 
dopaminergic neurons. Sustained microglial 
activation 1 year after MPTP injection 
(Gao et al., 2003; Barcia et 
al., 2004) 
Human PD brain Astrogliosis evidenced by increased GFAP and 
glutathione peroxidase immunostaining 
(Damier et al., 1993) 
MPTP model Astroglial activation starts 24 h after MPTP 
treatment 
(Breidert et al., 2002) 
HumanPD brain Increased levels of proinflammatory cytokines 
(IL-1β, TNF-α, IFN-γ, CD23) in the CSF and 
striatum  
(Mogi et al., 1994; Hunot et 
al., 1999) 
MPTP model Upregulation of iNOS in SN; iNOS knock out 
mice protective against MPTP toxicity 
(Wu et al., 2002) 
Human PD brain Increased levels of iNOS and COX-2 in SN and 
striatum 
(Hunot et al., 1996) 
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NADPH oxidase 
NADPH oxidase (also known as PHOX) is a membrane-bound enzyme, which leads 
to the production of O2
-
 from oxygen in the microglial cells leading to damage to the 
dopaminergic neurons (Gao et al., 2003; Wu et al., 2005a). NADPH oxidase is a multimeric 
enzyme composed of plasma membrane bound gp91phox and p22phox subunits and 
cytosolic p40phox, p47phox and p67phox subunits. Upon activation, the cytosolic subunits 
undergo phosphorylation and translocate to the membrane, where together with small G 
proteins they associate with the membrane bound subunits. The assembled and active 
enzyme complex then catalyzes the transfer of a single electron from NADPH to molecular 
oxygen to release superoxide. In normal conditions, NADPH oxidase remains inactive in 
resting microglial cells, but is activated when the microglia becomes activated (Babior, 
2000). By the stimulation of multiple proinflammatory stimulus, including environmental 
stimuli such as LPS, MPTP, nanoparticles, diesel exhaust particles, rotenone, paraquat and 
endogenous proteins such as α-synuclein, β-amyloid, microglia generates reactive oxygen 
species (ROS) (Block and Hong, 2005). In mice lacking a functional NADPH oxidase 
because of the deletion of gene for gp91phox subunit, significant protection against MPTP-
induced loss of nigral DA neurons and degeneration of striatal dopaminergic fibers is 
observed (Wu et al., 2003; Zhang et al., 2004). LPS-mediated loss of nigral DA neurons in 
vivo and in vitro is significantly less in NADPH oxidase-deficient mice compared to NADPH 
oxidase (+/+) mice (Qin et al., 2004). 
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Figure 11. Activation of NADPH complex 
 Nitric oxide (NO) is another potential source of oxidative stress and inflammation. 
NO is produced by nitric oxide synthase (NOS) by converting of L-arginine to L-citrulline 
utilizing NADPH oxidase and O2 as cofactors (Duval et al., 1996; Day et al., 1999). There 
are 3 isoforms of NOS: neuronal NOS (nNOS), inducible NOS (iNOS) and endothelial NOS 
(eNOS), out of which inducible nNOS is expressed in several neuronal subtypes except 
dopaminergic neurons. In contrast to nNOS, iNOS is not normally expressed in the brain; 
however, in the pathological condition iNOS can be induced. Under many conditions, 
activated glial cells produce iNOS which leads to increased production of NO. CD23 
mediated increase in iNOS has been reported in the SN of patients with PD (Hunot et al., 
1996). MPTP administration to mice also produces glial cells mediated increase in iNOS 
expression and NO production (Liberatore et al., 1999). Consequently, mice laking iNOS 
gene is less sensitive to MPTP-induced loss of SN DA neurons (Itzhak et al., 1998). MPTP-
induced striatal dopamine depletion is however not affected in iNOS null mice, nor was 
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MPTP induced microglial activation (Liberatore et al., 1999; Dehmer et al., 2000). Although 
poorly reactive, NO and O2
-
 free radicals can combine together to form the highly reactive 
nitrogen species peroxynitrite (ONOO
-
), which can cause oxidative damage to various 
proteins such as tyrosine hydroxylase (TH) and α-synuclein (Ara et al., 1998; Przedborski 
and Vila, 2001). Iron content in SN is increased in PD patients and in animal models of the 
disease (Hirsch, 2006). Through a superoxide-driven Fenton’s reaction between hydrogen 
peroxide and the free ferrous iron catalyst, a substantial amount of highly reactive hydroxyl 
radicals (OH) might be produced. Reactive astrocytes produce myeloperoxidase (MPO) 
which oxidizes non-reactive nitrites (NO2
-
), the end product of free radical NO to reactive 
NO2
-  
free radicals which in turn also contribute to protein nitrosylation (van der Vliet et al., 
1997). MPO, on other hand also implicated in production of non-radical oxidant 
hypochlorous (HOCl), which can damage macromolecules  directly (Hampton et al., 1998). 
Altogether, an inflammatory, oxidative environment can be produced by activated glial cells 
in SN region.  
Proinflammatory cytokines  
Along with reactive oxygen species (ROS) and reactive nitrogen species (RNS), 
activated glial cells also produce proinflammatory molecules and cytokines and together 
form the basis of many neuroinflammatory responses (Noack et al., 1999; Heo et al., 2001). 
Increased proinflammatory cytokines such as IL-1β, IL-6, TNF-α and interferon g (IFN-γ ) 
are observed in the post-mortem brain as well as in cerebrospinal fluid and nigrostriatum of 
deceased PD  patients (Mogi et al., 1994; Blum-Degen et al., 1995; Muller et al., 1998). In 
humans, the death signaling receptor TNF-α receptor-1 (TNF-R)-1, but not TNF-R2 has been 
found to be expressed in dopaminergic neurons in the SN and activation of TNF-R1 is toxic 
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to neurons (Mogi et al., 2000; Fontaine et al., 2002). Animal studies support an involvement 
of these proinflammatory cytokines in PD. A double knockout mice lacking both TNF 
receptors exhibit protection against MPTP toxicity (Sriram et al., 2002). Results from in vivo 
experiments suggest that IL-1β is toxic to neurons (Martin et al., 2002). Additionally, IL-6 
knockout mice exposed to methamphetamine, show reduced neurodegeneration in SN 
(Ladenheim et al., 2000). 
Neuroprotective strategies  
As discussed previously in this thesis, PD is a multifactorial disease with oxidative 
stress, mitochondrial dysfunction and inflammation play key roles in dopaminergic 
neurodegeneration in nigrostriatum. For last few years, there have been increased efforts to 
search for neuroprotective agents that will protect the irreversible loss of neurons. In this 
part, the current evidence for prevention or slowing of the development of PD by the 
neuroprotective agents will be summarized.  
Anti-inflammatory agents    
 As the evidence of detrimental role of inflammation in the pathogenesis of PD 
accumulate, a pool of anti-inflammatory agents is now under investigation. Data generated 
from non-steroidal anti-inflammatory drugs, microglial inhibitors and anti-inflammatory 
cytokines in cellular and animal studies have supported the notion that control of 
neuroinflammation and oxidative stress is a valuable strategy to retard or prevent 
dopaminergic neurodegeneration in the progression of PD. 
Non-steroidal anti-inflammatory agents (NSAIDS)   
 Non-steroidal anti-inflammatory drugs such as aspirin, ibuprofen and indomethacin 
inhibit COX activity to block the production of proinflammatory lipid mediators, 
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prostaglandins. It has also been reported that NSAIDS lowers the risk of PD in 
epidemiological studies (Chen et al., 2003; Ton et al., 2006; Gao et al., 2011) and protects 
against neuronal death by scavenging reactive oxygen species (ROS) in neuronal cells (Grilli 
et al., 1996) inactivating the proinflammatory transcription factor NF-κB  (Kopp and Ghosh, 
1994) and activating the peroxisome proliferator-activated receptor-g (PPARg), a mediator of 
anti-inflammatory activities in microglia (Bernardo et al., 2005). Pretreatment of NSAIDS is 
neuroprotective in MPTP and 6-OHDA models of PD and in in vitro (Esposito et al., 2007). 
Some reports suggest that ibuprofen reduces the risk of PD, but another NSAIDS, 
acetaminophen fails to attenuate the disease progression (Chen et al., 2005; Gao et al., 2011). 
A case-controlled study also demonstrates that NSAIDS and aspirin show no association with 
altering the risk of PD (Becker et al., 2011). In contrast, some studies also report that aspirin 
triggers increased risk of PD (Bower et al., 2006; Hernan et al., 2006). In contrast, other 
studies report that aspirin scavenges ROS and is neuroprotective (Di Matteo et al., 2006; 
Maharaj et al., 2006). In conclusion, NSAIDS could be valuable with a decreased risk of 
developing PD, but their efficacy in halting the disease progression is questionable.  
Minocycline  
 Minocycline is a semi-synthetic second-generation lipophilic, tetracycline that crosses 
the blood brain barrier and exerts anti-inflammatory and antioxidant effects (Ryan et al., 
2001; Faust et al., 2009). Minocycline inhibits the microglial activation and p38MAPK 
cascade which reduces release of proinflammatory cytokines and NO, thereby protecting 
neuronal death (Du et al., 2001; Tikka and Koistinaho, 2001; Wu et al., 2002). It also blocks 
the release of cytochrome c from mitochondria and expression of caspase-1 and caspase-3 
(Chen et al., 2000; Zhu et al., 2002). In animal models of PD, minocycline treatment has 
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shown to be effective in MPTP-, 6-OHDA-, LPS-induced dopaminergic neurodegeneration 
(Du et al., 2001; He et al., 2001; Quintero et al., 2006).  
Table 3. Anti-inflammatory agents in PD models 
Neuroprotective 
agents 
Model systems Results References 
Aspirin & 
Ibuprofen 
MPTP mouse; 
Human PD 
clinical trial  
Restored neurotransmitter levels 
and protected dopaminergic 
neurons; lowered the risk of PD 
(Chen et al., 2003; 
Chen et al., 2005) 
Minocycline 
 
MPTP mouse; 
Human clinical 
trial 
Prevented MPTP-induced 
neurotransmitter loss in striatum 
and protected dopaminergic 
neurons; effective in slowing down 
the progressive nature of PD 
(Tikka and 
Koistinaho, 2001; 
Wu et al., 2002; 
NINDS, 2006) 
Rasagiline MPTP and 6-
OHDA mice 
model; Human PD 
clinical trial 
Restored neurotransmitter levels 
and protected dopaminergic 
neurons; reduced long term 
progression of PD 
(Heikkila et al., 
1984; Hauser et al., 
2009) 
Estrogen Human clinical 
traial 
Reduced the symptoms in PD 
patients 
(Shulman, 2007) 
Nicotine LPS and 6-OHDA 
mice models; 
Human clinical 
trial 
Protected nigral dopaminergic 
neurons; restored striatal dopamine 
levels; lowered the risk of 
developing PD  
(Johnston, 1976; 
Costa et al., 2001a)} 
Melatonin MPTP and 6-
OHDA mice 
model; human 
clinical trial 
Protected nigral dopaminergic 
neuronal loss; improved duration 
of sleep and reduced sleep 
disturbances 
(Ferger et al., 1998; 
Costa et al., 2001b) 
Phenyl butyrate MPTP and 6-
OHDA model; No 
clinical trial yet 
Protected dopaminergic neurons in 
SN; reduced impairment in motor 
and ognitive function in mice 
(Gardian et al., 
2004; Zhou et al., 
2011) 
Statins MPTP and 6-
OHDA model; No 
clinical trial yet 
Protected dopaminergic neurons in 
SN; restored striatal dopamine; 
protected behavioral activities  
(Ghosh et al., 2009; 
Ritz et al., 2010) 
NBD peptide MPTP model; No 
clinical trial yet 
Protected dopaminergic neurons in 
SN; restored striatal dopamine; 
protected behavioral activities 
(Ghosh et al., 2007) 
Caffeine MPTP and 6-
OHDA models of 
PD; human 
clinical trial 
Restored dopamine levels; 
decreased motor dysfunction; 
decreased risk of PD   
(Costa et al., 2010; 
Kachroo et al., 2010) 
GDNF MPTP and 6-
OHDA rodents 
and primates PD 
Restored dopamine levels (Wu et al., 2005b) 
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However, other studies have demonstrated that it exacerbates the MPTP-induced behavioral 
imparities, striatal terminal loss and damage to DA neurons in vivo and in vitro (Yang et al., 
2003; Diguet et al., 2004). However, recent results from a Phase II clinical trial shows 
effectivenes of minocycline in slowing down the disease progression, without any adverse 
events in PD patients. Thus it suggests that minocycline should be considered for Phase III 
clinical trial (2008). 
Rasagiline  
Rasagiline (N-propargyl-1 (R)-aminoindam) is a highly selective and irreversible 
potent MAO-B inhibitor that attenuates MPTP and 6-OHDA-induced dopaminergic neuronal 
loss in vivo (Rabey et al., 2000; Youdim et al., 2001). Chronic administration of Rasagiline 
improves motor abnormalities and dopaminergic neuron survival in mice (Blandini et al., 
2004). Rasagiline also increases the expression of different neurotrophins such as BDNF, 
GDNF and NGF (Maurer et al., 2003). By inhibiting caspase-3 and PARP-1 activation and 
translocation of GAPDH, Rasagiline suppresses the mitochondrial apoptosis (Akao et al., 
2002; Weinreb et al., 2004). It also increases the expression of anti-apoptotic protein Bcl-2 
through the PKC pathway (Akao et al., 2002). In humans Rasagiline successfully reduced the 
long term progression and symptoms of PD (Hauser et al., 2009; Olanow et al., 2009). 
Recently, in phase III clinical study, Rasagiline delayed the need for antiparkinsonian drugs 
and patients had lower scores on the PD symptoms rating scale (Rascol et al., 2011).  
Pioglitazone and rosiglitazone  
 Pioglitazone and rosiglitazone are the agonists of the nuclear hormone receptor 
PPARg and currently approved for the treatment of type II diabetes. In the CNS, by 
inihibiting oxidative stress, inflammation and apoptosis, they exhibit neuroprotective effects 
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in models of neurodegenerative disorders (Chaturvedi and Beal, 2008). Recent study has 
demonstrated that by attenuating MAO-B, pioglitazone prevents MPTP-induced activation of 
nigral microglial cells and protects dopaminergic neurons in mice (Dehmer et al., 2004; 
Quinn et al., 2008). Recently, the neuroprotective effects of rosiglitazone have been shown in 
the MPTP model of PD (Schintu et al., 2009).  
Caffeine and nicotine   
 Recent epidemiological studies support neuroprotective role of drinking caffeinated 
beverages (Ross et al., 2000; Saaksjarvi et al., 2008), although one study showed no 
protection (Xu et al., 2006). Chronic administration of caffeine protects against paraquat and 
maneb-induced neurotoxicity in mice (Kachroo et al., 2010). Additionally, in MPTP-treated 
mice, caffeine protects behavioral imparities and striatal dopaminergic terminals (Chen et al., 
2001). Nicotine is comparable to caffeine with regards to lowering the risk of developing PD 
(Simon et al., 2009). In a recently published paper on Chinese population, there is a 
significant reduced rate of PD in individuals who drank coffee and smoked cigarettes (Tan et 
al., 2003). Additionally, in humans, acute nicotine treatment can improve impaired 
behavioral symptoms in PD patients (Holmes et al., 2011). Currently, nicotine is in phase II 
clinical trial focusing on optimizing dosage and increasing sample size.  
Others 
In addition to the above mentioned agents, there are several compounds that are also 
successful in different neurotoxins based animal models and clinical trials. Uric acid (UA), a 
natural antioxidant reduces the risk of PD in a dose dependent manner (de Lau et al., 2005). 
Vitamin E (a-tocopherol), lipid soluble anti-oxidant, has been shown to reduce oxidative 
stress caused by iron accumulation in the brain (Lan and Jiang, 1997), whereas, co-treatment 
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of vitamin E and vitamin C shows a decrease in PD progression in early stages of PD (Fahn, 
1992). The role of vitamin D in PD is controversial. Some studies suggest its neuroprotective 
properties in 6-OHDA and cell culture models, where as in one case-controlled human study 
they found an increased risk of PD with high consumption of vitamin D (Anderson et al., 
1999; Wang et al., 2001b). Additionally, various molecules including glial cell line-derived 
neurotrophic factor, neurturin, BDNF, TGF-β, and basic FGF showed some protective effects 
in animal models of PD (Flanders et al., 1998; Kordower et al., 2000). However, clinical 
application of those molecules has been limited because of difficulties in delivery and side 
effects. These peptides do not readily diffuse across the BBB or ventricular lining and have 
limited or unstable bioavailability and some toxicity (Kordower et al., 1999). However, 
Ghosh et al, (2007) have shown that NBD peptide, a selective NF-κB inhibitor and which has 
Antennapedia homeodomain that crosses the blood brain barrier of mice and reduces nigral 
activation of NF-κB, suppresses nigral expression of proinflammatory molecules and 
attenuates nigrostriatal degeneration in MPTP-intoxicated mice (Ghosh et al., 2007). Besides 
that, cholesterol lowering drug statins also protects the dopaminergic neurons in MPTP 
mouse model of PD and currently statin is in clinical trial II (Ghosh et al., 2009).  
Mitochondrial approached for dopaminergic neuroprotection  
 Robust evidence of mitochondrial dysfunction from post-mortem brain tissue, cell 
culture and animal models of PD and genetic analysis of human suggests that mitochondrial 
dysfunction plays an important role in pathogenesis of PD. Mitochondrial dysfunction due to 
oxidative stress, mitochondrial DNA deletions, altered mitochondrial morphology, and 
interaction of pathogenic proteins with mitochondria results in dopaminergic 
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neurodegeneration. So, therapeutic approaches targeting mitochondrial dysfunction and 
related oxidative stress are of greater importance in curing PD. 
Mitochondrial dysfunction   
 Various evidence suggests a role of mitochondrial dysfunction in the pathogenesis of 
PD (Beal, 2005; Lin and Beal, 2006). Mutations in the mitochondrial DNA (mt DNA) play a 
role in dopaminergic neuron demise. In addition, high levels of somatic mtDNA point 
mutations in elderly PD patients have also been reported (Simon et al., 2004). However, the 
most promising evidence of mitochondrial dysfunction in PD has been reported from the 
MPTP, a parkinsonian toxicant which causes parkinsonian syndromes in humans, rodents 
and primates by inhibiting the mitochondrial complex-I of the electron transport chain 
(Sandy et al., 1993). Similar to MPTP, other complex-I inhibitors such as rotenone, maneb, 
paraquat, fenzaquin and trichloroethylene result in loss of nigral dopaminergic neurons in 
mice model of PD, implicating mitochondrial dysfunction in the disease pathogenesis 
(Betarbet et al., 2000; Gash et al., 2008). Additionally, impairment of complex-I activity has 
been reported in substantia nigra, platelets and skeletal muscles of PD patients (Benecke et 
al., 1993; Haas, 2007). Moreover, reduced complex-I activity and an increased susceptibility 
to MPP
+
, the toxic metabolite of MPTP were also observed in mitochondrial DNA from PD 
patients, clearly demonstrating the mtDNA encoded defects in PD (Swerdlow et al., 1996; 
Gu et al., 1998). Recently, another convincing evidence of mitochondrial dysfunction in PD 
has been reported in conditional knockout ‘MitoPark’ mice. Mitopark mice have a disrupted 
mitochondrial tyranscription factor A (Tfam) gene in dopaminergic neurons (Ekstrand et al., 
2007). These mice demonstrate reduced mtDNA expression, attenuated expression of 
respiratory chain function in dopaminergic neurons in nigra along with behavioral imparities 
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and striatal dopamine depletion, mimicking progressive PD phenotypes starting from 
18weeks of age (Ekstrand et al., 2007). Reduction of mitochondrial mass and size in the 
dopaminergic neurons as compared to non-dopaminergic neurons of mouse SN have been 
reported, suggesting important role of mitochondrial dysfunction in selective imparities in 
dopaminergic neurons in substantia nigra (Liang et al., 2007). Pathogenic mutations in 
several genes including α-synuclein, LRRK2, parkin, DJ-1 and PINK-1 also play important 
role in mitochondrial dysfunction in PD patients (Dauer and Przedborski, 2003; Thomas et 
al., 2007).  Impairment of mitochondrial function in MPTP mouse model of PD has been 
reported in α-synuclein overexpressed cells and transgenic mice (Hsu et al., 2000; Song et 
al., 2004). Based on all these evidences, it could be inferred that intervening one of these 
processes could alleviate harmful effects of mitochondrial dysfunction. Numerous 
bioenergetics agent that improve mitochondrial function including creatine, CoQ10 are in 
clinical trial for PD. Recently Ghosh et al, (2010) have demonstrated that mitochondria 
targeted antioxidant Mito-Q10,  which is a chemical modification of Co-Q could protect the 
dopaminergic neurons from MPTP-induced toxicity in mice (Ghosh et al., 2010).  
Creatine 
 Creatine is a nitrogenous guanidine compound that forms high energy phosphate 
bonds and occurs naturally in vertebrates and supply energy to muscle and nerve cells. By a 
sodium-dependent creatine transporter, it is naturally taken up into the brain and skeletal 
muscle. It’s physiologically active form is phosphocreatine (PCr), that plays important role in 
maintaining energy balance in the brain. Preclinical studies in various models demonstrate its 
potential role as a neuroprotective agent (Gualano et al., 2010). Creatine has been shown to 
enhance the survival of glutamate-treated neuronal and glial cells by controlling Ras/NF-κB  
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signaling (Juravleva et al., 2005). Recently, neuroprotective role of creatine has been 
demonstrated in MPP+ and 6-OHDA treated dopaminergic neuronal culture, where it 
protects the tyrosine hydroxylase immunoreactive dopaminergic neuron and its fiber (Andres 
et al., 2005). In MPTP mouse model of PD, creatine restores MPTP-induced loss of 
dopamine, protects the dopaminergic neurons dose dependently (Matthews et al., 1999). 
Moreover, creatine in combination with nicoyinamide protects against malonate-induced 
striatal lesions (Malcon et al., 2000). Recent studies also demonstrated that creatine and 
COX-2 inhibitor protects the neurons in G93A transgenic mice model of ALS (Klivenyi et 
al., 1999). Two grams daily creatine administration has been shown to improve behavioral 
difficulties in a clinical trial of 200 subjects who are within 5 years of PD diagnosis (NINDS, 
2006). Although a 2-year placebo-controlled study of 60 subjects study demonstrated no 
improvement in patient PD scores and no effect upon dopamine transporter imaging, 
however, improvement of mood behavior (a nonmotor symptom of PD) was noticed in those 
patients (Bender et al., 2006). Recently, phase III clinical trial has been started by the NIH, 
where creatine is administered with a dose of 10g in a large long term study of PD targeting 
1720 participants with the disease (Bloom, 2007; Couzin, 2007).  
Coenzyme Q10 
 Coenzyme (Co) Q10 is an essential component for electron transport chain (ETC), 
where it accepts electrons from complexes I and II (Yang et al., 2009). It is also a coenzyme 
for complex III and serves as an important powerful antioxidant in the mitochondria that 
prevents oxidativde damage by the free radicals (Geromel et al., 2002). CoQ10 can directly 
scavenge free radicals through interaction with a-tocopherol (Tiano et al., 2007). Along with 
its free radical scavenging activity, it also prevents apoptotic cell death by blocking Bax 
55 
 
binding to mitochondria and by inhibiting the mitochondrial permeability transition 
activation (Naderi et al., 2006). CoQ10 is also a co-factor of mitochondrial uncoupling 
protein (UCP) and by activating UCP, CoQ10 exerts its neuroprotective effects through a 
reduction in mitochondrial free radical generation (Beal, 2004). Mitochondrial UCP 
expression in the SN of primates is increased by CoQ10 (Schulz et al., 1995). 
Neuroprotective properties of CoQ10 have been demonstrated in various in vivo and in vitro 
model of PD. Paraquat and rotenone induced mitochondrial dysfunction and 
neurodegeneration in rat mesencephalic primary neurons are inhibited by CoQ10 (Moon et 
al., 2005). Neuroprotective role of CoQ10 has also been demonstrated in iron-induced 
apoptosis in dopaminergic neurons (Ono et al., 2005). Consequently, pretreatment of 
neuronal cells with CoQ10 maintains mitochondrial membrane potential during oxidative 
stress and reduces the mitochondrial generation of ROS (Somayajulu et al., 2005). In 
different toxin models of PD, neuroprotective role of CoQ10 has also been demonstrated. In 
MPTP mouse model, CoQ10 protects MPTP-induced dopamine depletion and loss of 
dopaminergic neurons in aged mice (Beal MF et al., 1998). Similarly, CoQ10 is also 
successive against MPTP toxicity in chronic MPTP model, which mimics the progressive 
nature of PD (Beal et al., 1998). Oral administration of CoQ10 also produces dose-dependent 
neuroprotective effects against malonate-induced striatal lesion and reduction of ATP (Beal 
et al., 1998). In the cancer chemotherapy combination of two or more drugs are really 
effective, similarly in neuroprotective studies combination therapy can be used. Combination 
of CoQ10 and minocycline in R6/2 transgenic mouse model of Huntington disease (HD) 
resulted in significant attenuation of neuropathological features (Stack et al., 2006). 
Similarly, a combination of creatine and CoQ10 exhibit significant neuroprotective effect in 
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MPTP mouse model of PD (Chaturvedi and Beal, 2008). A double blind, placebo controlled 
phase II study of CoQ10 with 3 different doses such as 300, 600 and 1200mg daily in 80 
early untreated patients for 16 months was conducted recently with 1200mg dose showed 
some statistical improvement in PD rating scale (Shults et al., 2002). In continuation of the 
above mentioned phase II trial, a randomized, double blind, phase II trial of a higher dose 
(2400mg/daily) of CoQ10 was conducted on early untreated PD patients. Although there was 
some trend of improvement of clinical score by CoQ10, unfortunately, scores were not 
statistically significant.  One possible reason could be the lower number of patients (NINDS, 
2007). Recently, a NINDS-funded phase-III, multicenter, randomized, placebo controlled, 
double-blind trial of CoQ10 at doses of 1200 and 2400mg/daily has been initiated on 600 
early, nonmedicated PD patients. Hopefully, some positive outcome will come from this 
clinical trial.  
Mitochondria targeted antioxidants- Mito-Q10 
 Mitochondria targeted antioxidants (MTAs) were shown to be more potent than 
nontargeted parent antioxidants in endothelial cells subjected to oxidant stress (Dhanasekaran 
et al., 2004). Mito-Q10 is a derivative of CoQ10 conjugated to triphenylalkylphosphonium 
ions, which promotes the uptake into mitochondria, where it can counteract mitochondrial 
ROS (Tauskela, 2007).  Recent research has demonstrated that the mitochondrial uptake of 
antioxidants (vitamin E, coenzyme-Q) coupled to a triphenylphosphonium cation (Mito-E, 
Mito-Q10) is facilitated by the large negative membrane potential across the mitochondrial 
inner membrane (Murphy, 1997). As conventional ROS detoxification probes such as 
vitamin E, tempol and ubiquinone do not significantly accumulate within mitochondria. 
Their ability to scavenge mitochondrial reactive oxygen species (ROS) / reactive nitrogen 
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species (RNS) is limited. Previous studies demonstrated the intramitochondrial 
concentrations of MTAs can be 100- to 500-fold higher than the cytosolic levels (Smith et 
al., 1999; Smith et al., 2003). The large negative membrane potential of 150–180 mV across 
the mitochondrial inner membrane potentiates the uptake and distribution of lipophilic 
cations from the intracellular space into the mitochondria (Smith et al., 2003). Similarly, 
substantial decrease in the levels of Co-Q, an antioxidant and critical cofactor in the 
mitochondrial respiratory chain, is reported animal model of PD (Lovenberg et al., 1979; 
Shults et al., 1999). Treating mesencephalic dopaminergic neurons with high level of 
chemically modified, targeted Co-Q, such as Mito-Q10, therefore, seems a logical 
neuroprotective strategy. We recently demonstrate the efficacy of Mito-Q10 in 
neuroprotection both in cell culture and in pre-clinical animal model of PD (Ghosh et al., 
2010). Mito-Q10 protects the MPP+ induced loss of neurons and neurites in a cell culture 
model of PD. Mito-Q10 at a dose of 4 mg/ kg/ day protects the MPTP-induced loss of 
dopaminergic neurons and terminals in nigrostritum and restores MPTP-induced loss of 
dopamine and its metabolites (Ghosh et al., 2010). Along with that, it also significantly 
improves MPTP-induced loss of behavioral activities (Ghosh et al., 2010). The ability of 
Mito-Q10 to function as an antioxidant is related to the redox reaction between the oxidized 
and the reduced forms of Mito-Q10 and ROS/RNS. MTAs exert their antioxidant mechanism 
of action via several pathways. Mito-Q10, a redox mixture of quinone and hydroquinone, 
undergoes reduction in the mitochondrial matrix to form the quinol form (reduced form), 
which is presumably the active form of the drug. The quinol form is oxidized back to 
quinone by ROS/RNS including lipid peroxyl radical, hydroxyl radical, superoxide, and 
peroxynitrite (James et al., 2005). Known mitochondria targeted Mito-quinol reacts slowly 
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with superoxide, Mitoquinone reacts rapidly with superoxide. Mito-Q10 mainly reacts as 
Mito-quinol with lipid peroxidation intermediates (James et al., 2005; Murphy and Smith, 
2007).  
Table 4. Mitochondria targeted Neuroprotective agents in animal and human clinical trials 
Mitochondria 
targeted 
compound 
Characteristics Model 
systems 
Results References 
Creatine Mitochondrial 
stabilizer; ATP 
synthesis 
enhancer 
MPTP mouse 
model; Human 
clinical trial 
Protected against MPTP-
induced dopamine 
depletion; delayed 
progression of PD by 50%; 
currently in phase III trial 
(Matthews et 
al., 1999; 
NINDS, 2006) 
Coenzyme 
Q10 
Antioxidant and 
mitochondrial 
enhancer 
MPTP mouse 
model; Human 
clinical trial 
Protected nigrostriatal 
dopaminergic neurons; 
prevented dopamine 
depletion in striatum; 
delayed progression of PD 
in patients with no adverse 
effects; neuroprotection in 
PD patients 
(Shults et al., 
1999; Shults et 
al., 2002; 
NINDS, 2007) 
Creatine + 
CoQ10 
 MPTP chronic 
model; No 
Human 
clinical trial 
yet 
Combination more effective 
in chronic model- showing 
neuroprotection 
(Yang et al., 
2009) 
Mitoquinone Derivative of 
CoQ10; 
Mitochondria 
targeted 
antioxidant 
MPTP mouse 
model; human 
clinical trial 
Showed dopaminergic 
neuroprotection in SN; 
restored striatal dopamine; 
protected behavioral 
activities; Phase II clinical 
trial demonstrated it didn’t 
alter disease progression 
(Ghosh et al., 
2010; Snow et 
al., 2010) 
Nicotinamide Precursor of 
NADH, a 
substrate for 
complex-I 
MPTP mouse 
model of PDl 
No clinical 
trial yet 
Prevented 
neurodegeneration in mice 
(Schulz et al., 
1995) 
PGC-1α Involve in 
mitochondrial 
biogenesis 
MPTP mouse 
model of PD; 
No clinical 
trial yet 
PGC-1α null mice 
susceptible to MPTP 
toxicity; Promising 
therapeutic target  
(McGill and 
Beal, 2006; St-
Pierre et al., 
2006) 
In brain, manganese superoxide dismutase (MnSOD) is a predominant anti-oxidant enzyme, 
but in neurological distress conditions cellular antioxidant systems including MnSOD are 
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severely affected (Schwartz, 1996). The key issue in MTA-mediated antioxidant therapy is 
whether MTA exerts its protective action at mitochondria, the target point. Mito-Q10 at a 
dose of 40 - 80 mg/ kg when administered via oral gavage prevents liver damage in hepatitis 
C patients (Gane et al., 2010). Currently, phase II clinical trial of Mito-Q10 treatment for PD 
in New Zealand is initiated (Snow et al., 2010). 
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ACTIVATION OF NOVEL PRO-APOPTOTIC PROTEIN PIN1 (PEPTIDYL-
PROLYL CIS/TRANS ISOMERASE) – RELEVANCE TO THE PATHOGENSIS OF 
PARKINSON’S DISEASE 
A manuscript to be submitted to The Journal of Neuroscience   
 
Anamitra Ghosh
1
, Hariharan Saminathan
1
, Arthi Kanthasamy
1
, Vellareddy 
Anantharam
1
, Ajay Rana
2
, Anumantha G. Kanthasamy
1 
 
1 
Department of Biomedical Sciences, Iowa Center for Advanced Neurotoxicology, 
Iowa State University, Ames, IA 50011, USA; 
2 
Department of  
Pharmacology, Loyola University, Chicago, IL 60141 
 
 
Abstract 
Parkinson’s disease (PD) is the second most common neurodegenerative disease 
characterized by a slow and progressive degeneration of dopaminergic neurons in substantia 
nigra (SN). Pathophysiological mechanisms underlying the progressive degenerative process 
in PD is still unclear. Pin1, a peptidyl prolyl isomerase, plays important pathophysiological 
roles in cancers and Alzheimer’s disease, whereas the role of Pin1 in dopaminergic 
neurodegeneration in PD is yet unknown.  We sought to systematically characterize the role 
of Pin1 in PD model. Exposure of MN9D cells to MPP
+
 induced a stochastic increase in Pin1 
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mRNA and protein levels. Additionally, siRNA mediated knockdown of Pin1 almost 
completely prevented MPP
+
-induced caspase-3 activation and DNA fragmentation, 
confirming that Pin1 play a proapoptotic role in dopaminergic neuronal cells.   Paradoxically, 
Juglone, the pharmacological inhibitor of Pin1, attenuated MPP
+
-induced Pin1 upregulation. 
Juglone also attenuated MPP
+
-induced cell death and caspase-3 activation. We also examined 
the changes to Pin1 expression in a MPTP-induced C57BL/6 mouse model of PD and we 
found MPTP injection resulted in an increased expression of Pin1 both in the SN and 
striatum of mice. Also, Pin1 co-localized with tyrosine hydroxylase in the dopaminergic 
neurons in SN of human PD patients and MPTP treated mice. Furthermore, Juglone inhibited 
MPTP-induced Pin1 expression in the nigrostriatum. Additionally, Juglone improved motor 
function, normalized striatal neurotransmitters and protected dopaminergic neurons in MPTP 
treated mice, suggesting that Juglone is capable of neuroprotection in the MPTP mouse 
model. Collectively, our findings demonstrate for the first time that Pin1 is upregulated and 
has neurodegenerative roles in cell culture and animal models of PD. Also, Pin1 inhibitor 
Juglone could be an effective neuroprotective agent in management of PD. 
Introduction 
Parkinson’s disease (PD) is the most common neurodegenerative movement disorder 
affecting 1% of population over 65 years of age (Lees et al., 2009). It is chronic and 
progressive in nature and characterized predominantly by resting tremors, muscular rigidity, 
bradykinesia and postural instability along with several non-motor symptoms (Savitt et al., 
2006). Pathologically it is characterized by gliosis, progressive loss of dopaminergic neurons 
and their terminals in nigrostriatal axis, and appearance of cytoplasmic inclusions known as 
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Lewy bodies in surviving neurons of substantia nigra (SN) (Dunnett and Bjorklund, 1999; 
Dauer and Przedborski, 2003; Ghosh et al., 2009).  
Reversible phosphorylation on Ser/Thr – Pro (S/T-P) motifs regulated by Pro-directed 
protein kinases and phosphatases is an important molecular switch in controlling various 
cellular processes (Gothel and Marahiel, 1999; Lu, 2000; Jager et al., 2006).  Proline directed 
kinases such as cyclin-dependent protein kinases, extracellular signal-regulated kinases, 
stress-activated protein kinases/c-Jun-N-terminal kinases, p38 MAP kinases, glycogen 
synthase kinase – 3, Polo-like kinases and some of the Ser/Thr phosphatases phosphorylate 
or dephosphorylate such motifs to regulate cellular signaling (Sudol et al., 2001; Shaw, 
2007). Since the discovery of protein interacting with never in mitosis – A (Pin1), a lot has 
been known in the conformational importance of the Pro-directed kinases in cellular 
signaling (Uchida et al., 1999).   Pin1 is unique among the peptidyl-prolyl  isomerases, in 
that, they specifically recognize phosphorylated serine or threonine residues immediately 
preceding proline (pSer/Thr-Pro) in a subset of proteins and isomerizes the cis/trans 
conformation of the peptide bond (Joseph et al., 2003; Lu, 2004). Numerous studies have 
shown that Pin1 catalyzed conformational regulation have a profound impact in the 
regulation of cell growth, stress responses, immune responses, germ cell development, 
neuronal differentiation and survival  (Atchison and Means, 2004; Braithwaite et al., 2006).  
Deregulation of Pin1 signaling is implicated in a growing number of pathological conditions 
such as Alzheimer’s disease (AD) (Akiyama et al., 2005; Maruszak et al., 2009), asthma 
(Esnault et al., 2008; Shen et al., 2008), frontotemporal dementia (Thorpe et al., 2004), 
Parkinsonism linked to chromosome 17 (FTDP-17) (Yotsumoto et al., 2009), Pick disease 
(Ramakrishnan et al., 2003), progressive supranuclear palsy (PSP), corticobasal degeneration 
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(CBD) (Hutton et al., 2001; Lee et al., 2001) and cancer (Li et al., 2006). High expression 
levels of Pin1 in terminally differentiated and post mitotic neurons suggest that it plays 
important roles in neurons except cell cycle regulation and proliferation (Lu et al., 1999; 
Becker and Bonni, 2006). In neurodegeneration, Pin1 interacts with mitochondrial – BH3-
only protein BIMEL and activates c-JUN to regulate a neuron-specific activation of 
mitochondrial apoptotic machinery (Becker and Bonni, 2007). Additionally, mitochondrial 
respiratory chain function, oxidative stress and calcium handling capacities cause selective 
degeneration of dopaminergic neurons in PD (Kanthasamy et al.; Vila et al., 2001).   
Recently Ryo et al., reported that Pin1 overexpression facilitates formation of -synuclein 
inclusions in a cellular model of -synuclein aggregation and Pin1 also localizes in Lewy 
bodies in PD patients (Ryo et al., 2006). But Pin1’s level, activity and function in the 
pathogenesis of PD are completely unknown.  
Herein, we report for the first time to our knowledge that, there is a dopaminergic 
neuron specific upregulation of Pin1 in a MPTP model of PD. We have shown that 
expression of Pin1 increases in MPP
+
-treated cell culture model and MPTP treated mice. 
Also, Pin1 functions as an important pro-apoptotic factor in selective degeneration of 
dopaminergic neurons. Furthermore, Pin1 inhibitor Juglone attenuates MPTP induced Pin1 
expression in vitro and in vivo. We also demonstrate that Juglone protects against MPTP 
induced neurodegeneration in nigrostriatal axis. Collectively, our results indicate that Pin1 
could be a possible therapeutic target in the management of PD.   
Materials and Methods 
Chemicals and biological reagents. 1-Methyl-4-phenyltetrahydropteridine (MPP
+
 iodide) 
and MPTP-HCl were purchased from Sigma (St. Louis, MO, USA). Pin1 inhibitor Juglone 
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was purchased from Calbiochem. Caspase substrate (Ac-DEVD-AFC) was obtained from 
Bachem Biosciences (King of Prussia, PA). Bradford protein assay reagent was purchased 
from Bio-Rad Laboratories (Hercules, CA).  Neurobasal medium, B27 supplement, fetal 
bovine serum, L-glutamine, penicillin and streptomycin was purchased from Invitrogen 
(Carlsbad, CA).  
Cell culture. MN9D dopaminergic cell line originated upon fusion of rostral mesencephalic 
neurons from embryonic C57BL/BJ (embryonic day 14 mice) with N18TG2 neuroblastoma 
cells (Choi et al., 1991). MN9D cells were grown in a high-glucose (4500 mg/L) Dulbecco’s 
Modified Eagle’s Medium (DMEM, Sigma-Aldrich, St. Louis, MO) containing 10% Tet-
approved fetal bovine serum (Invitrogen, Carlsbad, CA), 3.7 g L
-1
 NaHCO3 and 4mM l-
glutamine in a 5% CO2 atmosphere at 37°C.  
Treatment paradigm. MPP
+
 (300M) was added to the cells for the duration of the 
experiment. The cells were detached from the flask using a rubber policeman and centrifuged 
at 200 x g for 5 min, washed with ice-cold PBS twice and homogenized with Radio-
immunoprecipitation Assay (RIPA) buffer. Cell lysates, collected by spinning down the cell 
fragments at 20,000 x g for 45 min at 4°C, were used to determine changes to Pin1 
expression. 
siRNA transfection. MN9D cells were plated in 6-well tissue culture plates at 70-75% 
confluency. Transfections were performed using Lipofectamine
TM
 2000 (Invitrogen, 
Carlsbad, CA) according to manufacturer’s instructions. Four to six hours after transfection, 
the media was replaced with fresh growth media. The following day, cells were treated with 
MPP
+
 or vehicle and processed for further experiments. 
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qRT-PCR. After treatment, total RNA were extracted from the MN9D cells or the mice 
brain SN using Absolutely RNA Miniprep Kit (Agilent Technologies, Santa Clara, CA) 
following the manufacturer’s protocol. Total RNA was treated with DNase I to remove DNA 
contamination and then reversibly transcribed into first-strand cDNA using the SuperScript 
III first-strand synthesis system (Invitrogen, Carlsbad, CA) as described in the kit 
instructions. SYBR-green Quantitative PCR was performed with validated primers of Pin1 
and control -actin primers (Qiagen, Valencia, CA) using either FastStart Universal SYBR 
green master (Rox) (Roche Applied Science, Indianapolis, IN) for the MN9D cells or RT
2
 
SYBR
®
 Green qPCR Master Mix (SABiosciences, Fredrick, MD) for the mice tissue. 
Sytox cell death assay.  The MN9D cells were incubated with 300M MPP+ for upto 24 h in 
the presence or absence of 1M Juglone and cell death was determined by the cell 
impermeable Sytox green (Molecular Probes, Eugene, OR). Sytox green intercalates with the 
DNA in the membrane compromised cells to produce a green fluorescence that is 
quantifiable at excitation 485 nm and emission 538 nm using the fluorescence microplate 
system (Synergy 4, Biotek, Winooski, VT) and also allows to be viewed under fluorescence 
microscope. Fluorescence and phase contrast were taken after exposure to MPP
+
 with a 
NIKON TE2000 microscope, and pictures were captured with a SPOT digital camera. 
Caspase-3 activity assay. Caspase-3 activity was determined as previously described 
(Kitazawa et al., 2004; Anantharam et al., 2007). After the MPP
+  
treatment, cells were lysed, 
centrifuged and the resulting supernatants were incubated with 50M Ac-DEVD-AMC (a 
caspase-3 substrate) at 37°C for 1 h and caspase activity was measured by fluorescence plate 
reader (Synergy 4, Biotek, Winooski, VT) with excitation at 380 nm and emission at 460 nm. 
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DNA fragmentation assay. DNA fragmentation was measured using a Cell Death Detection 
ELISA Plus Assay Kit as described previously (Song et al., 2010; Afeseh Ngwa et al., 2009). 
After MPP
+
 treatment, cells were centrifuged and washed with PBS once. DNA 
fragmentation was measured in the cell lysates according to the manufacturer’s protocol. The 
absorbance of the ELISA reaction was measured at 490 and 405 nm using a microplate 
reader (SpectraMAX 190, Molecular Devices Corp., Sunnyvale, CA). 
High-Affinity [
3
H] Dopamine Uptake Assay. Cells in each well were washed twice with 1 
ml of Krebs-Ringer buffer (16 mM NaH2PO4, 16 mM Na2HPO4, 119 mM NaCl, 4.7 mM 
KCl, 1.8 mM CaCl2, 1.2 mM MgSO4, 1.3 mM EDTA, and 5.6 mM glucose; pH 7.4). The 
cells were then incubated with 25 nM [
3
H]dopamine in Krebs-Ringer buffer (0.4 ml/well) for 
20 min at 37°C. Nonspecific uptake of dopaminergic was determined in parallel wells 
incubated with tritiated dopamine and 10 μM mazindol, an inhibitor of neuronal dopamine 
uptake. Briefly, the cells were washed three times with ice-cold Krebs-Ringer buffer (1 
ml/well) and lysed with 1 N NaOH (0.5 ml/well). After washing the lysates were mixed with 
5 ml of scintillation fluid (Scintiverse BD), radioactivity was determined with a liquid 
scintillation counter (Tri-Carb 1600 TR; Packard, Meriden, CT). The specific dopaminergic 
uptake was calculated by subtracting the amount of radioactivity observed in the presence of 
mazindol from that observed in the absence of mazindol. 
Animals and MPTP treatment. Eight- to 12-week-old male C57BL/6 mice weighing 24 to 
28 g were housed in standard conditions: constant temperature (22 ± 1°C), humidity (relative, 
30%), and a 12-h light/dark cycle. Mice were allowed free access to food and water. Use of 
the animals and protocol procedures were approved and supervised by the Committee on 
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Animal Care at Iowa State University (Ames, IA, USA). Mice received either a single high 
dose of MPTP-HCl (30mg/kg free base) or four injections of MPTP-HCl (15mg/kg of free 
base; Sigma-Aldrich) in 1XPBS at 2 h intervals via i.p. The control mice received only 
1XPBS.  
Juglone treatment in mice. Juglone was dissolved in 10% ethanol and was administered to 
mice via intraperitoneal injection. Based on other reports, (Esnault et al., 2007; Jeong et al., 
2009) we injected 10mg/kg dose of Juglone intraperitoneally. However, we observed nearly 
40% mortality rate of mice. Hence, we chose a lower dose (3mg/kg) of Juglone and we never 
noticed any death or other behavioral imparities in mice.  The first dose of Juglone (3mg/kg) 
was administered 24 h before 1
st
 dose of MPTP injection, the second dose of Juglone was 
administered 3 h before the 1
st
 dose of MPTP injection and the third dose of Juglone was 
administered 3 h after the last dose of MPTP injection. For neuroprotection studies, mice 
were treated for additional 6 days of Juglone treatment with a single dose each day.    
Immunoblotting. Cells were collected after exposure to MPP
+
, resuspended in RIPA buffer 
and brain tissues after MPTP treatment were resuspended in modified RIPA buffer, both 
containing protease and phosphatases inhibitor cocktail. Cell suspensions were sonicated 
after resuspension, while tissues were homogenized, sonicated and then centrifuged at 14000 
x g for 1 hr at 4°C. Lysates were separated on 8-12% SDS – polyacrylamide gel 
electrophoresis (PAGE). After the separation, proteins were transferred to a nitrocellulose 
membrane, and nonspecific binding sites were blocked by treating with Odyssey
®
 blocking 
buffer (LiCor, Lincoln, NE). Pin1 (1:2000; mouse monoclonal; R&D Systems, Minneapolis, 
MN), TH (1:1500, mouse monoclonal; Millipore, Billerica, MA), -Actin (1:5000; mouse 
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monoclonal; Sigma, St. Louis, MO) were used to blot the membranes. Secondary IR-680-
conjugated anti-mouse (1:10000, donkey anti-mouse; Molecular Probes, Carlsbad, CA) was 
used for antibody detection with the Odyssey IR imaging system (LiCor, Lincoln, NE).  
Mesencephalic Primary Neuron Cultures and Treatment. Primary mesencephalic and 
striatal neuronal cultures were prepared from the ventral mesencephalon of gestational 14- to 
15-day-old mice embryos as described previously (Zhang et al., 2007). Briefly, 
mesencephalic and striatal tissues from E14 to 15 mouse embryos were dissected and 
maintained in ice-cold calcium-free Hanks’ balanced salt solution and then dissociated in 
Hanks’ balanced salt solution containing trypsin-0.25% EDTA for 20 min at 37°C. The 
dissociated cells were then plated at equal density of 0.6 million cells per well on 12-mm 
coverslips precoated with 0.1 mg/ml poly-D-lysine. Cultures were maintained in neurobasal 
medium fortified with B-27 supplement, 500 mM L-glutamine, 100 IU/ml penicillin, and 100 
g/ml streptomycin (Invitrogen, Carlsbad, CA). The cells were maintained in a humidified 
CO2 incubator (5% CO2 and 37°C) for 24 h. Half of the culture medium was replaced every 2 
days. Approximately 6- to7-day-old cultures were used for experiments. Primary 
mesencephalic and striatal dopaminergic neuronal cells were exposed to 10 µM MPP
+
 in the 
presence or absence of Juglone (1 µM) for 24 h.  
Immunocytochemistry. The primary mesencephalic and striatal neurons were fixed with 4% 
paraformaldehyde in phosphate buffered saline (PBS) for 20 minutes and processed for 
immunocytochemical staining. First, nonspecific sites were blocked with 2% bovine serum 
albumin, 0.5 % Triton X-100 and 0.05% Tween-20 in PBS for 45 min at room temperature. 
Cells were then incubated with different primary antibodies such as TH (1:1600, mouse 
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monoclonal; Millipore, Billerica, MA), Pin1 (1:400, goat polyclonal; Santa Cruz  
Biotechnology, Santa Cruz, CA) at 4°C overnight. Appropriate secondary antibodies (Alexa 
Fluor 488 or 594 or 555; Invitrogen) were used followed by incubation with 10µg/ml 
Hoechst 33342 (Invitrogen) for 5 min at room temperature to stain the nucleus. The coverslip 
containing stained cells were washed twice with PBS and mounted on poly-D lysine coated 
slides (Sigma, St Louis). Cells were viewed under a NIKON inverted fluorescence 
microscope (model TE-2000U; NIKON, Tokyo, Japan) and images were captured with a 
SPOT digital camera (Diagnostic Instruments, Inc., Sterling Heights, MI). 
Quantification of TH positive cell counts and neuronal processes. Tyrosine hydroxylase 
positive dopaminergic neurons and neuronal processes in primary neuronal cultures from 
each coverslip were measured using MetaMorph software, version 5.0 (Molecular Devices, 
Sunnyvale, CA) as described previously (Zhang et al., 2007). For measurement of TH cell 
count, pictures were first taken at 20X lens, then thresholded. After that, neurons were 
counted using the Integrated Morphometry Analysis function. For measurement of neuronal 
processes, pictures were taken using 60X oil immersion lens and the lengths of the processes 
were marked by applying the region and length measurement function in the Integrated 
Morphometry Analysis. TH positive neurons and their processes were counted in at least six 
individual cultures for each treatment.  
Diaminobenzidine immunostaining and stereological counting of TH positive neurons. 
Tyrosine hydroxylase and Pin1 diaminobenzidine (DAB) immunostaining were performed in 
striatal and substantia nigral sections as described previously (Ghosh et al., 2009). Briefly, 
seven days after MPTP injection, mice were sacrificed and perfused with 4% 
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paraformaldehyde (PFA) in 1X PBS  and post-fixed with PFA and 30% sucrose. The fixed 
brains were subsequently cut using a cryostat into 30 µm coronal sections in 30% sucrose-
ethylene glycol solutions at -20C. On the day of staining, sections were first washed with 
PBS and incubated with the anti-TH antibody (1:1600, rabbit anti-mouse; Calbiochem, 
Gibbstown, NJ)  or with the anti- Pin1 antibody (1:400, goat anti-mouse; Santa Cruz 
Biotechnology, Santa Cruz, CA) overnight at 4C. Biotinylated anti-rabbit or anti-goat 
secondary antibodies were used for 2 h at room temperature. The sections were then 
incubated with avidin peroxidase (Vectastatin ABC Elite kit, Burlingame, CA) for 45 min at 
room temperature.  Immunolabeling was observed using DAB which yielded a brown 
colored stain. Total numbers of TH- stained neurons in SN were counted stereologically with 
Stereo Investigator software (MicroBrightField, Inc., Williston, VT, USA) , using an optical 
fractionators (Ghosh et al., 2009). 
HPLC analysis of striatal dopamine and its metabolites levels.  The striatal dopamine 
(DA), DOPAC and HVA levels were quantified using a high-performance liquid 
chromatography (HPLC) with electrochemical detection. Samples were prepared and 
quantified as described previously (Ghosh et al.). Briefly, 7 days after MPTP treatment, mice 
were sacrificed and striata were collected and neurotransmitters from striatal tissues were 
extracted in 0.1 M perchloric acid solutions containing 0.05% Na2EDTA and 0.1% Na2S2O5) 
and isoproterenol (as an internal standard). The extracts were filtered in 0.22 µm spin tubes, 
and 20 µl of the sample was loaded for analysis.  Dopamine and its metabolites (DOPAC and 
HVA) were separated isocratically in a C-18 reversed-phase column using a flow rate of 0.6 
ml/min. A HPLC system (ESA Inc., Bedford, MA, USA) with an automatic sampler 
71 
 
equipped with a refrigerated temperature control (model 542; ESA Inc.) was used in these 
experiments. The electrochemical detection system consisted of a Coulochem-I model 5100A 
with an analytical cell (model 5014A) and a guard cell (model 5020) (ESA Inc.). The data 
acquisition and analysis were performed using the EZStart HPLC Software (ESA Inc.).  
Immunohistochemistry. Twenty four hours after MPTP treatment, mice were perfused with 
4% paraformaldehyde and post fixed with PFA and 30% sucrose respectively. Next, 30 µm 
coronal SN free-floating sections were blocked with 2% bovine serum albumin, 0.5 % Triton 
X-100 and 0.05% Tween-20 in PBS for 1 h at room temperature. Sections were incubated 
with different primary antibodies such as anti- Pin1 antibody (1:500; goat polyclonal; Santa 
Cruz Biotechnology, Santa Cruz, CA), anti-NeuN (1:500; mouse monoclonal; Chemicon, 
Temecula, CA), anti-TH (1:1600; mouse monoclonal; Chemicon, Temecula, CA) for 
overnight at 4°C. After washing with PBS, sections were incubated in appropriate secondary 
antibodies (Alexa Fluor 488 or 594 or 555 from Invitrogen) for 2 h. followed by incubation 
with 10µg/ml Hoechst 33342 for 5 min at room temperature to stain the nucleus. Sections 
were viewed under a NIKON inverted fluorescence microscope (model TE-2000U; NIKON, 
Tokyo, Japan); images were captured with a SPOT digital camera (Diagnostic Instruments, 
Inc., Sterling Heights, MI) using MetaMorph software, version 5.0 (Molecular Devices, 
Sunnyvale, CA). 
Behavioral measurements.  We performed open-field experiment for testing the locomotor 
activities (Ghosh et al.; Zhang et al., 2007) and the rotarod experiment  (Ghosh et al.; Gianni 
et al., 2009) to test feet movement of mice after MPTP and Juglone treatments. An automated 
device (AccuScan, model RXYZCM-16, Columbus, OH, USA) was used to measure the 
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spontaneous activity of mice. The activity chamber was 40×40×30.5 cm, made of clear 
Plexiglas and covered with a Plexiglas lid with holes for ventilation.  The Infrared 
monitoring sensors were located every 2.54 cm along the perimeter (16 infrared beams along 
each side) and 2.5 cm above the floor. Two additional sets of 16 sensors were located 8.0 cm 
above the floor on opposite sides. Data were collected and analyzed by a VersaMax Analyzer 
(AccuScan, model CDA-8, Columbus, OH, USA).   Before any treatment, mice were placed 
inside the infrared monitor for 10 min daily for 3 consecutive days to train them. Five days 
after the last MPTP injection, both open-field and rotarod experiments were conducted.  In 
openfield experiment, mice were monitored for horizontal activity, vertical activity, total 
distance travelled (cm), total movement time (s), total rest time (s) and rearing activity over a 
10 min test session. Using Versaplot and Versadat software we analyzed the data among the 
three groups.  In rotarod, feet movement of mice was observed using a constant 20 rpm 
speed.  Mice were given a 5-7 min rest interval to eliminate stress and fatigue.  
Statistical analysis. Data were analyzed with Prism 3.0 software (GraphPad Software, San 
Diego, CA). Bonferroni and Dunett multiple comparison testing were used. Differences with 
P<0.05 were considered significant.  
Results 
MPP
+
 induces activation of Pin1 in MN9D dopaminergic neuronal cells 
Accumulation of Pin1 in the Lewy bodies of PD and promotion of -synuclein 
aggregates during over-expression of Pin1 in a kidney cell line has left a lot of unanswered 
questions about the role of Pin1 during PD (Ryo et al, 2006). To specifically address the role 
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of Pin1 in a PD model, we utilized highly relevant in vitro model - MN9D mouse 
dopaminergic neuronal cells and in vivo model - C57 black mice for our studies. Initially, we 
sought to understand changes to Pin1 message and protein levels upon treatment with 
Parkinsonian toxicant MPP
+
. We treated MN9D dopaminergic cells with 300M MPP+ and 
assayed the cells at different time points. To examine the changes to Pin1 message levels, we 
first performed qRT PCR. As evident from Figure 1 A and B, MPP
+
 induced Pin1 message 
expression in MN9D dopaminergic cells stochastically with a maximal expression at 3 h 
(p<0.001). Next, we examined whether Pin1 mRNA induction translated to changes in Pin1 
protein levels during MPP
+ 
treatment. We examined changes to Pin1 protein levels by 
immunoblotting. Figure 2 A and B, demonstrates that Parkinsonian toxicant MPP
+
 induced 
Pin1 protein expression detectable by immunoblotting in the lysates of MN9D mouse 
dopaminergic cells starting from 6 h with statistically significant differences at 12 h 
(p<0.001). Together, these results demonstrate that Parkinsonian toxicant MPP
+
 induces Pin1 
expression in MN9D dopaminergic cells. 
Juglone rescues MN9D dopaminergic cells from MPP
+
 induced apoptosis 
Neuroinflammation and apoptosis herald the hallmarks of PD pathogenesis. 
Mitochondrial impairment, activation of the mitochondrial apoptotic machinery and the 
caspases are well established events that culminate in the selective degeneration of 
dopaminergic neurons. Accumulation of Pin1 in the Lewy bodies of degenerating 
dopaminergic neurons of PD patients and the reports of Pin1 in the activation of neural-
specific mitochondrial apoptotic machinery necessitates a thorough investigation of the 
function of this protein during PD. To assess whether Pin1 has a pro-apoptotic or an anti-
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apoptotic function, we used the pharmacological inhibitor of Pin1 – Juglone during the 
treatment of MN9D mouse dopaminergic cells with Parkinsonian toxicant MPP
+ 
for 
monitoring changes to apoptotic events. To examine the changes to Pin1 expression in the 
presence of Juglone, we co-treated MN9D dopaminergic cells with MPP
+
 for different time 
points and separated cell lysates on SDS-PAGE and immunoblotted for Pin1. To our 
surprise, we found that MPP
+
 induced Pin1 expression was significantly attenuated in the 
presence of Juglone (Fig. 2 A). We measured cytotoxicity of MN9D cells using a live-cell 
impermeable fluorescent dye – Sytox green during treatment of MPP+ in the presence or 
absence of Pin1 inhibitor – Juglone. Pin1 inhibition protected MN9D dopaminergic cells 
from MPP
+
- induced cytotoxicity (Fig. 2 B and C). Further, we wanted to examine changes 
to MPP
+ 
induced caspase-3 activation during Pin1 inhibition. Juglone significantly attenuated 
MPP
+ 
induced caspase-3 activation in the MN9D dopaminergic cells (Figure 2 D). Together, 
these results suggest that Pin1 could be a pro-apoptotic factor in the MN9D dopaminergic 
neuronal cells during MPP
+
 induced apoptosis.  Pin1 inhibitor Juglone is also an efficient 
inhibitor of its expression. 
Silencing of Pin1 expression ameliorates MPP
+
 induced apoptotic events 
Because Pin1 inhibitor Juglone attenuated apoptotic events in an in vitro model of 
PD, we sought to examine whether Pin1’s pro-apoptotic function is specific by employing 
genetic tools. We knocked down Pin1 expression with a Pin1-specific siRNA and examined 
changes to apoptotic markers – caspase-3 activation and DNA fragmentation. MN9D 
dopaminergic cells were transfected with a Pin1 specific siRNA. Knock-down of Pin1 
expression could be examined only after treatment of MPP
+
. As shown in Figure 3A, we 
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could knock-down MPP
+
 induced Pin1 expression effectively in the Pin1 specific siRNA 
transfected cells. Knock-down of Pin1 by specific siRNA effectively attenuated apoptotic 
events – caspase-3 activation (Figure 3 B) and the terminal event of apoptosis – DNA 
fragmentation (Figure 3 C). Taken together, by employing pharmacological and genetic tools 
to inhibit Pin1, we show for the first time to our knowledge that Pin1 has a pro-apoptotic role 
in PD pathogenesis. 
Juglone inhibits MPP
+
 - induced expression of Pin1 in primary mesencephalic cultures 
Next, we checked for the expression of Pin1 in primary mesencephalic neuronal 
culture and role of Juglone in attenuating the Pin1 expression. Primary mesencephalic and 
striatal cultures were isolated from E15 mouse embryos and were cultured and grown on 
laminin-coated coverslips. The neuronal cultures were treated with 10M MPP+ in the 
presence or absence of 3M Juglone for 24 h and immunocytochemistry was performed for 
Pin1 and tyrosine hydroxylase (TH). As evident from Fig. 4 A and B, MPP
+
 induced 
increased expression of Pin1 both in primary mesencephalic and striatal cultures. However, 
TH
 
+ve dopaminergic neurons in MPP
+
 treatment also expressed Pin1 in cytosol (Fig. 4A). In 
addition to that, we also found TH+ve dopaminergic neurons are expressing Pin1 in primary 
striatal cultures (Fig. 4B). Evidences of presence of dopaminergic neurons in striatum have 
been reported by many investigators in different species (Mura et al., 1995; Jollivet et al., 
2004; Huot et al., 2007). Similar to Presna et al. (2000), we also detected majority of striatal 
TH+ ve neurons are expressing glutamic acid decarboxylase (GAD) (supplementary figure 
1). Additionally, GAD producing neurons which are also producing dopamine are expressing 
Pin1 in MPP
+
 treatment (supplementary Fig.1). However, we could not detect expression of 
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Pin1 in dopaminergic neurons in MPP
+
 and Juglone co-treatment both in primary 
mesencephalic nigral and striatal culture (Fig. 4 A and B). After confirming the role of 
Juglone in attenuating Pin1 expression, we were interested to check if Juglone rescued 
dopaminergic neurons from MPP
+
 induced neurodegeneration. We measured the lengths of 
processes of TH
 
+ve neurons from mesencephalic (Fig. 4 C) and striatal (Fig. 4 D) cultures 
and found that MPP
+
 and Juglone co-treated dopaminergic neuronal processes are 
significantly longer than the processes of neurons treated only with MPP
+
 (Fig. 4 C and 4 D). 
Integrity of dopaminergic neurons is always correlated positively with dopamine reuptake 
capacity and serves as a functional indicator of the healthiness of the neurites (Liu et al., 
2000). Primary mesencephalic cultures were exposed to 5M MPP+ in the presence or 
absence of  3M Juglone for 48 h. MPP+-Juglone co-treated cells were significantly 
protected from MPP
+
-induced loss of [
3
H] dopaminergic reuptake (Fig. 4 E). Taken together, 
these results clearly demonstrate that Juglone has a neuroprotective effect during MPP
+
 
toxicity and also suggest that the dopamine transporters may be intact during Juglone co-
treatment. 
MPTP activates Pin1 expression and activity in the Substantia nigra of mice  
Our earlier findings demonstrate the selective upregulation of Pin1 in the in vitro 
models of PD (Fig. 1). Next, we sought to examine whether MPTP induces Pin1 activation in 
the mice brain. First, we checked for the expression of Pin1 at different time points after a 
single high dose of MPTP (30mg/kg). We observed the highest expression of Pin1 in SN (Fig 
5 A and B) and the STR (Fig. 5 C and D) 6 h after MPTP injection. The magnitude of Pin1 
expression in nigrostriatum decreased 12h after MPTP injection. There was little expression 
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of Pin1 in nigrostriatum of saline treated control mice.  To further confirm that MPTP 
induced Pin1 expression was paralleled with changes to Pin1 activity, we performed Pin1 
assay in mice SN and STR. As expected, we noticed MPTP-induced a significant increase of 
Pin1 activity in SN in consonance with the time point where we observed a maximal 
expression of Pin1 (Fig. 5 E). However, there was no significant difference in Pin1 activity in 
the STR between control and MPTP treated mice.   
Juglone inhibits the expression of Pin1 in vivo in the nigrostriatum of MPTP-intoxicated 
mice  
After observing increased expression of Pin1 with a single high dose of MPTP, we 
were interested to check Pin1 expression level in acute MPTP model. Mice were injected 
with 4 doses of MPTP on a single day spread at 2h intervals and were sacrificed at different 
time points. As evident from Figure 6 A, Western blotting for Pin1 showed maximum 
expression of Pin1 24 h after MPTP injections. The magnitude of Pin1 expression in 
nigrostriatum was decreased 72 h after MPTP injections. Also, there was some elevation of 
Pin1 expression at 12 h after MPTP injections. Densitometry analysis for band intensities 
also reflected that maximum expression of Pin1 occurred 24h after MPTP injections (Fig. 6 
B). When we checked the expression of Pin1 in striatum at different time points after MPTP 
injections, we found increased expression of Pin1 starting from 6h until 72h following MPTP 
injections (Fig. 6 C). Densitometry analysis of bands also confirmed similar pattern of Pin1 
expression (Fig. 6 D). For our further experiments, we chose 24h time point as we observed 
maximal expression of Pin1 at this time point. To examine the changes to Pin1 message 
levels, we performed qRT-PCR in MPTP and MPTP-Juglone co-treated mice (Fig. 6I). Mice 
were administered Juglone (3 mg / kg body wt.) intraperitoneally 24h prior to MPTP 
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administration. As shown by quantitative real time PCR, MPTP administration led to a 
marked increase in Pin1 message expression in mice SN, whereas, Juglone significantly 
attenuated MPTP induced Pin1 message level (Fig. 6 I).  Next, we were interested to check 
whether Pin1 inhibitor Juglone could suppress MPTP induced Pin1 expression in 
nigrostriatum. Twenty four h after MPTP administration the nigrostriatum were observed for 
changes to Pin1 expression by Western blot. As evident from Figure 6 E-H, we observed a 
robust increase in Pin1 expression in both nigra and striatum. However, in MPTP-Juglone 
co-treated mice we found attenuation of Pin1 expression (Fig. 6 E-H). Taken together, these 
results clearly suggest that Juglone inhibits MPTP induced Pin1 expression in vivo. To 
further confirm that MPTP induces Pin1 expression and Juglone attenuates MPTP induced 
Pin1 expression, we performed immunohistochemistry for Pin1 in the mice SN. DAB-
immunostained pictures clearly showed increased expression of Pin1 in substantia nigra pars 
compacta region of ventral midbrain (Fig. 7 A). Interestingly, MPTP and Juglone co-treated 
mice exhibited inhibition of Pin1 protein expression in SN (Fig. 7 A). Next, we speculated on 
the cell type that shows MPTP induced increase in Pin1expression in SN. To address this 
question we did double labeling immunohistochemistry for Pin1 and NeuN (common 
neuronal marker) in the mice SN. We observed that some NeuN positive neurons, but, not 
all, co-expressed Pin1 in the cytosol (yellow color) upon MPTP treatment (Fig. 7 B), 
whereas, there was little or no co-localization of Pin1 and NeuN in saline treated control 
sections.  Besides dopaminergic neurons, other neuronal subtypes and glial cells are also 
present in SN. To further confirm the neuronal specificity of Pin1 upregulation, we did 
double labeling immunohistochemistry of TH (marker for dopaminergic neuron) and Pin1 in 
SN. It is clearly evident from Figure 7 C, that 70-80% of TH positive dopaminergic neurons 
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showed significant expression of Pin1 in cytosol of MPTP treated mice. Enlarged inset 
pictures clearly show colocalization of TH and Pin1 in cytosol (Fig. 7 C). However, MPTP 
treated mice that also received Juglone show very few colocalized neurons of TH and Pin1 in 
SN (Fig. 7 C), which further demonstrates Juglone’s role in attenuating Pin1 expression in 
mice midbrain.   
Pin1 accumulates in dopaminergic neurons of human Parkinson’s disease midbrain 
tissue 
As we found increased expression of Pin1 in TH positive neurons of MPTP treated 
mice midbrain tissues, we were interested to see whether Pin1 is also upregulated in 
dopaminergic neurons of PD brain. We hypothesized that Pin1 may play an important role in 
the pathogenesis of PD. Recent studies also reported increased expression of Pin1 in human 
PD brains (Ryo et al., 2006). We did double labeling of TH and Pin1 in PD brain tissues and 
age matched control brain tissues. We observed increased expression of Pin1 in SN of PD 
brain and it also co-localized in the cytoplasm of TH positive dopaminergic neurons (Fig. 8 
A). However, in SN of control human sections we detected healthy TH positive neurons with 
little or no Pin1 expression (Fig. 8 A and B). Human PD brain contains both pigmented (with 
neuromelanin) and non-pigmented (without neuromelanin) dopaminergic neurons. Previous 
reports suggested massive loss of dopamine producing pigmented neurons occurred only in 
SN of PD brain (Hirsch et al., 1988; Kastner et al., 1992). In our study, we noticed increased 
expression of Pin1 in the cytosol of pigmented dopaminergic neurons in PD brain (Fig. 8 C), 
whereas in non-pigmented cells less expression of Pin1 was observed (Fig. 8 D). To further 
confirm our findings, we checked Pin1 expression levels in SN of human PD brains by 
western blot. We detected robust increase of Pin1 expression in SN of PD patients than that 
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of the age matched control brains (Fig 8 E). Collectively, these results clearly demonstrate 
that Pin1 has some pathophysiological roles in the neurodegeneration of dopaminergic 
neurons in PD.     
Upregulation of Pin1 is specific to the nigrostriatum region 
In our next experiment, we addressed whether the upregulation of Pin1 which plays 
role in pathogenesis of Parkinson’s disease is specific to the nigrostriatum regions of brain. 
Mice received 4 i.p. injections of MPTP at 2h interval in a single day. Twenty-four hours 
after the last injection mice were sacrificed and cortex and hippocampus regions were 
dissected out. We checked the expression of Pin1 in cortex and hippocampus and found no 
change in expression levels of Pin1 with MPTP treatment when compared with saline treated 
control mice (Fig. 9 A, B). These experiments clearly suggest that Pin1 upregulation 
following MPTP treatment is specific to the nigrostriatum region of brain and therefore, 
relevant to the pathogenesis of PD. 
Juglone improves locomotor functions in MPTP-treated mice 
 After elucidating Juglone’s role in attenuating Pin1 expression in MPTP treated mice 
we were interested to check whether Juglone plays any role in attenuating behavioral deficits 
caused by MPTP. Five days after MPTP injections mice were tested for locomotor activities 
which include openfield and rotarod experiments. Representative maps using Versaplot 
software (Accuscan, OH) showed mice movement in openfield experiment for 10min (Fig. 
10 A). As reported previously (Ghosh et al., 2009) we also observed marked decrease of 
horizontal activities (Fig. 10 B), vertical activities (Fig. 10 C), total distance travelled (Fig. 
10 D), total movement time (Fig. 10 E) and rearing activities (Fig. 10 F) in MPTP treated 
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mice. However, MPTP treated mice that also received Juglone showed significant restoration 
of those behavioral parameters to the levels observed in control mice (Fig.10 A-F). In rotarod 
experiment also we observed similar trend.  At 20 rpm rotarod speed, MPTP treated mice 
showed (75%) decrease in time spent on rotarod compared to control mice (Fig. 10 G). 
Interestingly, Juglone treatment significantly restored (50%) rotarod activities in MPTP 
treated mice (Fig. 10 G). Collectively, these results demonstrate that Juglone restored the 
motor function impairments in MPTP treated mice.   
Juglone increases striatal dopamine and its metabolites levels in MPTP treated mice 
 After establishing the role of Juglone in improving motor imparities, we next 
determined whether Juglone protects neurotransmitter levels during MPTP-toxicity. Mice 
were treated with Juglone (3 mg/kg body weight) via i.p. one day before MPTP injection and 
continued for another 8 days. Seven days after MPTP injections mice were sacrificed and 
STR tissue samples were processed for neurotransmitter analysis by HPLC (as mentioned in 
materials and methods). We observed ≈ 84% decrease in dopamine levels (Fig. 11 A), ≈ 90% 
decrease in dihydrophenylacetic acid (DOPAC) levels (Fig. 11 B) and ≈ 90% attenuation in 
homovanillic acid (HVA) levels (Fig. 11 C) in MPTP treated mice. In contrast, treatment of 
MPTP-injected mice with Juglone increased dopamine levels by ≈ 30% in comparison to 
MPTP alone (Fig. 11 A; p < 0.01). Additionally, Juglone increased DOPAC and HVA levels 
by ≈ 33% (Fig. 11 B; p < 0.01) and ≈ 18% (Fig. 11 C; not significant), respectively. These 
results suggest that Pin1 could be pharmacological target for the management of PD.                           
Juglone protects nigrostriatal dopaminergic neurons from MPTP-induced 
neurodegeneration in vivo  
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 As Juglone significantly protected from striatal neurotransmitter loss in MPTP treated 
mice, we next wanted to determine whether Juglone could protect nigrostriatal axis against 
MPTP toxicity. Mice were treated with Juglone (3 mg/kg body weight) 24 h prior to MPTP 
injections and continued for another 8 days following MPTP injections. Seven days after 
MPTP treatment mice were sacrificed and tyrosine hydroxylase (TH) DAB immunostaining 
were performed in SN regions of ventral midbrain (Fig. 12). Similar to a recent article 
(Ghosh et al., 2009), we also observed loss of TH positive neurons in STR (Fig. 12 A) and 
SN (Fig. 12 B) regions of MPTP treated mice. Higher magnified (10X) pictures clearly 
showed MPTP induced loss of TH positive dopaminergic neurons mainly in substantia nigra 
lateralis (SNl), substantia nigra pars compacta (SNc) and substantia nigra ventricularis (SNr) 
regions (Fig. 12 B, lower panel). In contrast, treatment of MPTP-injected mice with Juglone 
showed that Juglone treatment effectively reduced MPTP induced loss of TH positive 
neurons (Fig. 12 B) and their terminals in striatum (Fig. 12 A). Similarly, by western blot 
also, we observed attenuation of TH expression in striatum and SN of MPTP treated mice 
(Fig. 12 C). However, Juglone treatment effectively restored expression of TH in striatum 
and SN of MPTP treated mice nearly to the control level (Fig. 12 C). To further confirm 
these findings we measured optical density of striatum (Fig. 12 D) and stereologically 
counted TH positive neurons in substantia nigra (Fig. 12 E) excluding ventral tegmental area 
(VTA). We found reduction of striatal TH ODs and significant loss of SNpc TH +ve neurons 
in MPTP treated mice. However, in MPTP injected mice that also received Juglone showed 
protection of striatal TH ODs and nigral TH +ve  neurons. Collectively, these data suggest 
that Juglone protects the nigrostriatum against MPTP-toxicity.  
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Discussion 
Here we present novel findings of selective upregulation of Pin1 expression in the 
dopaminergic neurons of human PD patients and its role in neurodegeneration in a mice 
MPTP model of PD. First, we show that Pin1 is preferentially upregulated in the MN9D 
dopaminergic cells and in dopaminergic neurons of nigrostriatum during MPP
+
/MPTP 
treatment. Secondly, by employing pharmacological and genetic tools, we establish that Pin1 
has a pro-apopototic role in the dopaminergic neurons. Thirdly, pharmacological inhibitor of 
Pin1-Juglone attenuates MPP
+
 / MPTP induced Pin1 expression in MN9D cells / 
nigrostriatum. Finally, Juglone also rescues mice from behavioral deficits and dopaminergic 
degeneration in a mice MPTP model of PD.  
Pin1 co-localizes with -synuclein in the Lewy bodies of degenerating neurons of PD 
and overexpression of Pin1 in a kidney cell line led to Lewy body formation as it increased 
the half-life of -synuclein (Ryo et al., 2006). Pin1’s specific enzymatic mechanism targets 
phosphorylated Ser/Thr-Pro sites and switches a kinase/phosphatase inaccessible Ser/Thr-Pro 
sites from cis conformation to trans conformation which uncovers substrates for the Proline – 
directed kinases. Ablation of Pin1 in p53 null mice resulted in accelerated formation of 
lymphomas and thymic hyperplasia (Takahashi et al., 2007). Proline directed 
phosphorylation is significant for the regulation of post-mitotic development of neurons and 
during neurodegeneration (Rudrabhatla and Pant). Growing reports suggest of Pin1’s role in 
several neurodegenerative disorders and the paucity of information on Pin1’s function during 
PD led us to this investigation.  The roles of Pin1 in Alzheimer’s disease (AD) pathogenesis 
is a subject of contradiction, while, several investigators report of downregulation of Pin1 
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during oxidative stress  and its association with tautopathy and neurodegeneration during AD 
(Butterfield et al., 2006; Sultana et al., 2006). On the other hand, inhibition of Pin1 led to 
attenuation of neurofilament-H phosphorylation and its perikaryal accumulation in AD as 
well as Amyotropic Lateral Sclerosis (ALS) models (Kesavapany et al., 2007; Rudrabhatla et 
al., 2009). Pin1
-/- 
mice exhibited a phenotype of an age dependent accumulation of abnormal 
and hyperphosphorylated tau and neurodegeneration suggesting of a neuroprotective role to 
Pin1 in AD models (Lu et al., 1999). With the roles of Pin1 largely unclear during 
neurodegeneration and since Pin1 accumulates in the Lewy body inclusions we sought to 
understand and characterize Pin1 during PD. We first identified that Pin1 is highly expressed 
in the pigmented dopaminergic neurons of PD patients in comparison to age-matched 
controls. Human PD cases are associated with loss of pigmented dopaminergic neurons in SN 
and our findings of elevated Pin1 expression only in pigmented dopaminergic neurons 
suggest a possible role of Pin1 in pathogenesis of PD. Our in vitro findings suggest that 
during treatment of MN9D dopaminergic cells and primary mesencephalic neurons with 
MPP
+
, there is upregulation of Pin1 at the message and protein levels. Additionally, we 
identified upregulation of Pin1 expression in nigrostriatum of C57 black mice upon MPTP 
insult corroborating our in vitro findings. Precedence for upregulation of Pin1 expression in 
diseased state comes from increased message levels in the circulation of lung cancer patients 
(Ai et al., 2009), Lymph node metastasis in oral squamous cell carcinoma (Miyashita et al., 
2003), hepatocellular carcinomas (Pang et al., 2006), colorectal tumors (Kuramochi et al., 
2006). Functionally, heightened levels of Pin1 in cancerous conditions are associated with 
sensitization of tumor cells to oxidative stress-induced apoptosis. During AD, loss of Pin1 
expression is reported to be a mechanism behind neurodegeneration (Akiyama et al., 2005).  
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On the contrary, upregulation of Pin1 expression during MPTP treatment in the 
dopaminergic neurons and enhanced expression of Pin1 in human PD cases in our study 
suggest that the biological/pathological role of Pin1 in PD may be unique.  
We show in this study for the first time that Pin1 may also be a possible therapeutic 
target for PD. Recent studies demonstrated that Pin1 inhibition has anti-cancer effects in 
experimental studies (Dourlen et al., 2007; Gianni et al., 2009). Juglone (5-hydroxy-1,4-
napthalenedione, (C10H6O3) is an aromatic organic napthoquinone, naturally found in the 
leaves, roots and bark of plants in the black walnut and has been widely used as a Pin1 
inhibitor (Esnault et al., 2007; Jeong et al., 2009). Napthoquinone is known to have various 
physiological activities and also it plays role in induction of apoptosis (Kang et al., 2002). 
Juglone irreversibly and specifically inactivates enzymatic activity of E. coli parvulin and 
human Pin1 by modification of thiol groups of cysteine residue in parvulin (Hennig et al., 
1998). Juglone plays role in various cellular events such as induction of DNA damage (Wang 
et al., 2001) and cell death (Paulsen and Ljungman, 2005). Recently, Esnault et al., 2007  
showed that Juglone prevented acute and chronic rejection of MHC mismatched, orthotopic 
rat lung transplants by reducing the expression of IFN-γ and CXCL-10 mRNA stability, 
accumulation and protein expression after cell activation. Juglone also attenuates rheumatoid 
arthritis development and COX-2 expression in human primary culture RA chrondrocytes 
and CII treated DBA/1J mice (Jeong et al., 2009). Additionally, recent reports suggested anti-
inflammatory, anti-viral and anti-fungal properties of Juglone (Omar et al., 2000). Juglone at 
a dose of 5.7M in vitro blocked Pin1’s and E. coli parvulin isomerase activity completely 
and these doses of Juglone had no effect on other PPIases (Hennig et al., 1998). In our study, 
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we found 3M Juglone significantly restored dopamine reuptake in primary mesencephalic 
neurons and also protected mesencephalic and striatal primary neurons and their neurites 
from MPP
+
 toxicity (Fig. 4 E). We did not detect any level of toxicity to the neurons with this 
dose. Additionally, we also demonstrated that Juglone attenuated MPP
+
 induced Pin1 
expression in MN9D cells. A recent report used 5mg/kg dose of Juglone to block type-2 
rheumatoid arthritis in DBA/1J mice (Jeong et al., 2009). In our study we injected multiple 
doses of Juglone (3mg/kg) intraperitoneally to the C57BL/6 mice. Importantly, these doses of 
Juglone were nontoxic. However, 10mg/kg multiple doses of Juglone showed some toxicity 
to the mice, such as paralysis and 40% death. Here we demonstrate that Juglone effectively 
attenuates the MPTP-induced expression of Pin1 expression in nigrostriatum. Furthermore, 
Juglone also restored the behavioral activities and dopamine and its metabolites level in 
striatum of MPTP treated mice. Additionally, Juglone also protected against MPTP induced 
loss of TH positive neurons and terminals in the nigrostriatum. Taken together, the observed 
protective effect of the Pin1 inhibitor Juglone in an MPTP model of PD strongly suggest 
efficacy of Juglone as a neuroprotective agent at a right dose.                   
Oxidative stress, neuroinflammation and apoptotic degeneration are the key events 
underlying PD pathogenesis. The role of Pin1 in the inflammatory responses of PD is not 
known. Previous reports indicated Pin1’s role in controlling several transcription factors that 
mediate induction of iNOS, a key inflammatory molecule involved in the pathogenesis of PD 
(Gothel and Marahiel, 1999; Shen et al., 2005). It has been known that Pin1 binds to the 
phosphorylated Thr254-Pro residue of transcription factor NF-κB p65 and through this 
interaction it helps in stabilizing p65 in nucleus, maintaining activation of NF-κB (Ryo et al., 
87 
 
2003). NF-κB activation is a key inflammatory mediator and (Ghosh et al., 2007)  previously 
reported induction of NF-κB in SN of PD patients and MPTP-treated mice. But it is not 
known whether there is any interaction between Pin1 and NF-κB in PD. Further research in 
this area could elucidate the inflammatory roles of Pin1 in pathogenesis of PD. Pin1’s roles 
during apoptosis is varied. While inhibition of Pin1 led to apoptosis in vascular smooth 
muscle cells and Pin1 was required for pro-survival signaling in eosinophils (Shen et al., 
2009), Pin1’s pro-apoptotic function has been demonstrated during downregulation inhibitor 
of apoptosis protein-survivin in neuroblastoma cells (Dourlen et al., 2007) and promoting 
tumor cell death by dissociating tumor suppressor p53 from apoptosis inhibitor iASPP 
(Mantovani et al., 2007). In nervous system, Pin1 has been shown to regulate 
oligodendrocyte apoptosis after spinal injury by binding and stabilizing Mcl-1 after JNK3 
activation (Li et al., 2007) and also induce death of developing neurons during JNK 
signaling.  Apoptotic signaling of c-Jun N-terminal kinase (JNK) is regulated by Pin1 after 
JNK activation.  Pin1 dissociates from the neuron-specific JNK scaffold protein JIP3, to 
associate with phosphorylated BH3-only BIMEL and activate the mitochondrial apoptotic 
machinery (Barone et al., 2008). Our findings demonstrate that Pin1 inhibitor Juglone 
attenuates Parkinsonian toxicant MPP
+
 induced apoptotic events, which are further 
corroborated with knock-down of Pin1 expression by specific siRNA. Established reports of 
Pin1’s pro-apoptotic function lends strength to our findings of in a PD model.  
In conclusion, we have demonstrated for the first time in our knowledge that Pin1 is 
upregulated in human PD and MPTP mouse model of Parkinson’s disease. We showed that 
MPP
+
 induces Pin1 activation in MN9D dopaminergic cell lines and in mesencephalic 
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primary neuronal cultures. By employing pharmacological and genetic tools to inhibit Pin1, 
we reported for the first time that Pin1 has a pro-apoptotic role in PD pathogenesis. 
Additionally, we also demonstrated increased expression levels of Pin1 in SN of human PD 
brain and MPTP treated mice. By using Pin1 inhibitor Juglone we could effectively attenuate 
MPTP induced Pin1 expression in mice nigrostriatum. Additionally, Juglone improved 
behavioral imparities and protected nigrostriatum in MPTP treated mice. These results 
clearly suggest that Pin1 may serve as a novel pharmacological target for development of 
neuroprotective agent in PD and Pin1 inhibitor Juglone may be used as novel neuroprotective 
agent. 
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Figure 1  
 
Figure 1. MPP
+
 induces Pin1 expression. A, Real-time PCR; MN9D cells were treated with 
300M MPP+ for 24 hrs and assayed for Pin1 mRNA using qRT-PCR. B, Data represent 
results from six individual measurements and are expressed as mean + SEM. C, Pin1 
immunoblot after  MPP
+
 treatment. MN9D cells were treated with 300M MPP+  for 12 h 
and proteins were separated by 15% SDS-PAGE and probed with Pin1 antibody to observe 
for Pin1 (18kDa) bands. D, Quantification of Western blot revealed that the cells have 
undergone an increase in expression of Pin1 when compared to the control cells. Data 
represent mean + SEM from N=3 in three experiments. * P < 0.05, ** P < 0.01 and *** P < 
0.001 indicate significant differences between treatment groups as indicated. 
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Figure 2 
 
Figure 2. Effect of Pin1 inhibitor Juglone on MPP
+
 induced Pin1 expression, 
cytotoxicity and caspase-3 activation in MN9D dopaminergic neuronal cells. MN9D 
cells were treated with 300M MPP+ for 24 hrs in the presence or absence of 1M Juglone. 
A, Immunoblotting for Pin1 B, cytotoxicity of MN9D cells during 300M MPP+ treatment in 
the presence or absence of 1M Juglone. Cytotoxicity was determined by Sytox green 
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nucleic acid stain by measuring the fluorescence at regular intervals, as described in 
Materials and Methods. C, The two panels demonstrate phase contrast images (left) and 
fluorescence micrographs (right) to show the extent of Sytox green staining of cells in the 
field of view. D, caspase-3 assay in the presence or absence of 1M Juglone. Data represent 
mean + SEM. of n = 6 from three separate experiments. ***, p < 0.001 as indicated by one-
way ANOVA analysis using Dunnett’s multiple comparison tests. 
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Figure 3  
 
Figure 3. siRNA mediated knock down of Pin1 attenuates MPP
+
 induced apopotic 
events. MN9D dopaminergic neuronal cells were cultured, transfected with Pin1 specific 
siRNA and exposed to 300M MPP+ for 18 to 24 hours. A. Immunoblotting for Pin1 from 
siRNA transfected MN9D cell lysates. B. Caspase-3 activation in MN9D cells following 
MPP
+ 
treatment. C. DNA fragmentation in MN9D cells following MPP
+
 treatment. Data 
represent mean + SEM of n = 6 from three separate experiments. ***, p < 0.001 as indicated 
by one-way ANOVA analysis using Dunnett’s multiple comparison tests. 
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Figure 4.  
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Figure 4. Juglone inhibits MPP
+
 induced expression of Pin1 in primary neuronal 
culture. Mesencephalic and striatal tissues from E15 mouse embryos were cultured and 
grown on laminin-coated coverslips. The neuronal cultures were treated with 10M MPP+ 
for 24 h in the presence or absence of 3M Juglone. After culture, primary neurons were 
fixed with 4% paraformaldehyde and incubated with anti-TH and anti-Pin1 antibodies and 
viewed under a NIKON TE2000 fluorescence microscope. A. Double labeling of TH and 
Pin1 in primary mesencephalic culture from substantia nigra. B. Double labeling of TH and 
Pin1 in primary culture from striatum. C & D. Mesencephalic and striatal neuronal process 
length were quantified using MetaMorph image analysis software, as mentioned in Materials 
and Methods. E. Dopamine uptake assay from primary striatal culture. Data represent mean + 
SEM of n = 6 from three separate experiments. ***, p < 0.001 vs Control or MPP+ as 
indicated by one-way ANOVA.  
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Figure 5 
Figure 5. Single dose of MPTP administration leads to time dependent increase of Pin1 
expression.  Mice were administered single dose of MPTP (30 mg / kg) via intraperitoneally 
and sacrificed at different time points (ranging from 1.5 h to 24 h). A. Expression of Pin1 in 
mice substantia nigra at different time points after MPTP administration. B. Densitometry 
analysis of Pin1 obtained from A. C. Expression of Pin1 in mice striatum at different time 
points after MPTP administration. D. Densitometry analysis of Pin1 obtained from C.  E. 
Pin1 activity assay in SN 6 h after MPTP treatment. Mean density, Pin1/β-actin is plotted on 
the y-axis. Data represent mean + SEM of n = 3 from three separate experiments. ***, p < 
0.001 vs Control; **, p < 0.01 vs Control; *, p < 0.05 vs Control.    
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Figure 6.   
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Figure 6. Juglone attenuates MPTP induced Pin1 message and expression in mice 
substantia nigra and in striatum. Mice were injected four doses (i.p.) of MPTP (18mg/kg) 
on a single day and sacrificed at different time points. Another group of MPTP treated mice 
also received Juglone intraperitoneally at a dose of 3mg/kg 24 h before MPTP injection.  A. 
Expression of Pin1 in mice substantia nigra at different time points after MPTP 
administration. B. Densitometry analysis of Pin1 obtained from A.  C. Expression of Pin1 in 
mice striatum at different time points after MPTP administration. D. Densitometry analysis 
of Pin1 obtained from C. Twenty four h after MPTP injection, mice were sacrificed and 
checked Pin1 expression by western blot in substantia nigra (E) and in striatum (G). F & H. 
Densitometry analysis of Pin1 obtained from E & G respectively. I. The mRNA expression 
of Pin1 in SN by quantitative real-time PCR. Mean density, Pin1/β-actin is plotted on the y-
axis.  Data represent mean + SEM three separate experiments. ***, p < 0.001 vs control; **, 
p < 0.01 vs Control or MPTP; * p < 0.05 vs Control or MPTP.  
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Figure 7 
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Figure 7.  Juglone attenuates MPTP induced Pin1 expression in mice substantia nigra. 
Mice were treated with Juglone (3mg/kg) 1 day prior MPTP treatment. Twenty four hr after 
last dose of MPTP treatment mice were sacrificed and substantia nigra sections were 
immunolabeled with different antibodies. A. DAB immunostaining of Pin1 in substantia 
nigra. A single enlarged Pin1 positive cell (inset). B. Double labeling of global neuronal 
marker NeuN and Pin1 in substantia nigra. C. Mice substantia nigra tissues were 
immunolabelled for TH (marker of dopaminergic neurons) and Pin1. Higher magnified 
double labeled pictures of TH and Pin1 (Inset). 
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Figure 8.  
 
Figure 8. Increased expression of Pin1 in human Parkinson’s disease (PD) midbrain. A. 
Human midbrain substantia nigra sections of PD patient and age-matched controls were 
immunostained for TH (marker of dopaminergic neurons) and Pin1. B. Enlarged image of 
control section showing decreased co-localization of TH and Pin1 in substantia nigra. C. 
Neuromelanin containing pigmented TH positive neurons are expressing Pin1 in PD brain 
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section. A single, enlarged, pigmented, TH positive dopaminergic neuron shows Pin1 
expression (inset) D. Attenuation of Pin1 expression in non-pigmented TH positive neurons 
in substantia nigra regions PD brain section. A single, enlarged, non-pigmented, TH positive 
dopaminergic neuron with no Pin1 expression (inset). E. Western blot of Pin1 expression in 
midbrain of human PD patients. 
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Figure 9.   
Figure 9. Expression of Pin1 in mice cortex and hippocampus.  Mice were injected four 
doses (i.p.) of MPTP (18mg/kg) on a single day at 2 h interval. Twenty four h after last dose 
of MPTP injection mice were sacrificed and cortex and hippocampus regions were dissected 
out for checking Pin1 expression by Western blot. A. Expression of Pin1 in cortical regions 
of mice brain. B. Expression of Pin1 in hippocampus regions of mice brain. 
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Figure 10 
 
Figure 10. Juglone improves motor function in MPTP injected mice. Mice received 
Juglone (3mg/kg) via i.p. one day prior to MPTP treatment and continued for another 7 days. 
Five days after MPTP treatment mice were tested for motor functions. A. Moving track of 
mice using Versaplot software. B. Horizontal activity, C. Vertical activity, D. Total distance 
travelled (cm), E. Total movement time (s), F. No. of rearing activities and G. Time spent on 
rotarod. Data are means + SEM of nine mice per group. ***, p < 0.001 vs. control; **, p < 
0.01 vs. control; *, p < 0.05 vs. MPTP.  
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Figure 11  
 
Figure 11. Juglone attenuates MPTP induced loss of dopamine and dopamine-derived 
metabolites. Mice were treated with Juglone (3mg/kg) via i.p. one day prior MPTP treatment 
and continued for another 7 days. Seven days after last dose of MPTP treatment mice were 
sacrificed  and A. dopamine, B. DOPAC and C. HVA were measured from striatum by 
HPLC as mentioned in materials and methods. Data are means + SEM of six mice per group. 
***, p < 0.001 vs. control; **, p < 0.01 vs. control; #, p < 0.01 vs. MPTP. 
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Figure 12.   
 
Figure 12. Effects of Juglone on nigrostriatum in MPTP treated mice. Mice were 
administered with Juglone (3mg/kg dose) via i.p. one day prior to MPTP injection and 
continued for 7 days (1day co-treatment with MPTP and 6 days post-treatment after MPTP). 
Mice were sacrificed 7 days after MPTP treatment and TH-DAB immunostaining were 
performed in A. striatum (2X magnification), B. upper panel - substantia nigra (2X 
magnification) and lower panel - substantia nigra (10X magnification) D. Quantification TH-
positive fibers in striatum and E. stereological counts of TH-positive neurons in the 
substantia nigra.   
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Manuscript Supplementary Figures 
Figure 1.  
 
Figure 1. GABAergic neurons also express Pin1 in striatal primary neuronal culture. 
Striatal tissues from E15 mouse embryos were cultured and grown on laminin-coated 
coverslips. The neuronal cultures were treated with 10µM MPP+ for 24h. After culture, 
primary neurons were fixed with 4% paraformaldehyde and incubated with anti-GAD and 
anti-Pin1 antibodies and viewed under a Nikon TE2000 fluorescence microscope. A. Double 
labeling of GAD (marker of GABAergic neurons) and Pin1 in striatal primary neuronal 
culture. B. MPP
+ 
treated striatal neuronal cultures were immunolabelled for TH and GAD.    
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CHAPTER III 
PIN1 MODULATES ACTIVATION OF PROINFLAMMATORY TRANSCRIPTION 
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Abstract: 
Glial activation and neuroinflammation contribute to the progressive degeneration in 
Parkinson’s disease (PD). Nuclear factor kappa beta (NF-κB), an important modulator of 
inflammation gets activated in PD brain and MPTP-treated mice brain and regulates cell 
proliferation, inflammation, and apoptosis. The prolyl isomerase, Pin1 plays important 
pathophysiological roles in cancers and Alzheimer’s disease where it directly binds to the 
NF-κB protein, p65 and regulates NF-κB signaling. We now present evidences that 
interaction of Pin1 and p65 occurs in mouse microglial cells and controls the inflammatory 
processes. We demonstrated that Pin1 and p65 protein levels are enhanced in BV2 and 
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primary microglial cells in response to different stimuli. Paradoxically, Juglone, the 
pharmacological inhibitor of Pin1, attenuated inflammatory stimuli induced Pin1 and p65 
upregulation. By attenuating p65 activation, Juglone also reduced nitrite production and 
cytokine release from microglial cells in response to different stimuli.  In the MPTP mouse 
model of PD, an increased expression of nigral Pin1 in microglial and astroglial cells were 
observed. Furthermore, the Pin1 inhibitor Juglone attenuated p65 dependent expression of 
proinflammatory cytokines and inducible nitric oxide synthase (iNOS) in MPTP-treated 
midbrain, suggesting a proinflammatory role of Pin1. Taken together, these results suggest 
that Pin1 is an important regulator of NF-κB mediated microglial activation and 
neuroinflammatory processes and therapeutic targeting of Pin1 could be used as a therapeutic 
target in the future.  
Introduction: 
Parkinson’s disease (PD) is one of the most common neurodegenerative motor 
disorders and pathologically is characterized by the selective loss of dopaminergic neurons in 
the substantia nigra of ventral mid brain and their terminal in striatum, resulting in loss of 
striatal dopamine and appearance of cytoplasmic inclusions known as Lewy bodies in 
surviving neurons of substantia nigra (SN) (Dunnett and Bjorklund, 1999; Dauer and 
Przedborski, 2003). PD is chronic and progressive in nature and characterized predominantly 
by resting tremors, muscular rigidity, bradykinesia and postural instability along with several 
non-motor symptoms (Savitt et al., 2006). The etiology of PD is not known completely, but 
recent evidences suggest that glial cells mediated inflammation and oxidative stress increased 
the risk of developing PD (Dauer and Przedborski, 2003). Continuous and prolonged 
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microglial and astroglial activation in close proximity of degenerating dopaminergic neurons 
in the substantia nigra (SN) is evident in PD patients and animal models of the disease 
(McGeer et al., 1988; Hirsch and Hunot, 2009). Various in vitro and in vivo animal models 
have demonstrated elevation of the key enzymes involved in the production of reactive 
oxygen species (ROS) or reactive nitrogen species (RNS), such as microglial NADPH 
oxidase and inducible nitric oxide synthase (iNOS) in SN (Gao et al., 2003; Wu et al., 2003). 
In addition to this, a variety of pro-inflammatory cytokines including tumor necrosis factor 
alpha (TNF-α), interleukin (IL) -1beta (β), IL-6, interferon gamma (IFN-γ) and other immune 
cytokines are found either in CSF or affected regions of PD brain (Nagatsu et al., 2000). 
However, the mechanism behind activation of glial cells and its role in the progressive 
dopaminergic neurodegeneration remains elusive. However, microglial NADPH oxidase 
which releases superoxide in the SN could contribute to the oxidative stress mediated 
dopaminergic neurodegeneration (Wu et al., 2002). Also, the activation of NF-κB  in 
microglial and astroglial cells play critical neurotoxic role by mediating proinflammatory 
cytokine levels in the SN (Ghosh et al., 2007).  
Reversible phosphorylation on Ser/Thr – Pro (S/T-P) motifs regulated by Pro-directed 
protein kinases and phosphatases is an important molecular switch in controlling various 
cellular processes (Jager et al., 2006). The protein interacting with never in mitosis – A 
(Pin1) is an 18kDa isomerase enzyme and it binds to and cis/trans isomerizes a specific 
subset of serine-proline or threonine-proline bonds (Ser/Thr-Pro) in its target proteins (Lu et 
al., 2007). Deregulation of Pin1 signaling is implicated in a growing number of pathological 
conditions such as Alzheimer’s disease (AD) (Maruszak et al., 2009), asthma (Esnault et al., 
2008), Pick disease (Ramakrishnan et al., 2003) and different cancers (Ryo et al., 2002; Li et 
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al., 2006; Pang et al., 2006). Pin1 interacts with mitochondrial – BH3-only protein BIMEL 
and activates c-JUN to regulate a neuron-specific activation of mitochondrial apoptotic 
machinery during neurodegeneration (Becker and Bonni, 2007). Recently Ryo et al., reported 
that Pin1 overexpression facilitates formation of -synuclein inclusions in a cellular model of 
-synuclein  aggregation and Pin1 also localizes in Lewy bodies in PD patients (Ryo et al., 
2006).  
Among 50 Pin1 target proteins, NF-κB p65 is one of them (Ryo et al., 2003). 
Promoter regions of proinflammatory molecules like iNOS and proinflammatory cytokines 
(IL-1β, IL-6, TNF-α) contain the DNA binding site for NF-κB (Ghosh and Karin, 2002). 
Furthermore, the inhibition of NF-κB  activation reduces the induction of proinflammatory 
molecules (Ghosh and Karin, 2002). As, Pin1 is a positive regulator for NF-κB controlled 
promoters (Ryo et al., 2003), Pin1 plays an important role in modulating NF-κB regulated 
inflammatory processes. In an unstimulated state, NF-κB protein complex exists in 
cytoplasm bound to an inhibitory family of proteins called IkB. During activation stimuli, 
IkB (IKK) kinase complex gets activated (Ghosh and Karin, 2002). This complex then 
phosphorylates and degrades IkB by the ubiquitin-proteasome pathway. Free NF-κB protein 
complex then translocate to the nucleus, where they active the proinflammatory genes (Karin, 
2006).  
Here, in our study we demonstrated that Pin1 and NF-κB p65 activation are induced 
in BV2 and primary microglal cells in response to different stimuli and Pin1strongly 
associates with p65. Juglone, a pharmacological inhibitor of Pin1, attenuated both Pin1 and 
p65 expression in microglial cells. NF-κB mediated inflammatory processes were also 
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inhibited by Juglone. In addition to that, MPTP-treated mice showed upregulation of Pin1 in 
nigral microglial and astrocytes. Moreover, treatment of MPTP-injected mice with Juglone 
resulted in attenuation of inflammatory reactions.     
Materials and methods: 
Chemicals and biological reagents. 1-Methyl-4-phenyltetrahydropteridine (MPP
+
 iodide) 
and MPTP-HCl were purchased from Sigma (St. Louis, MO, USA). Pin1 inhibitor Juglone 
was purchased from Calbiochem. RPMI, neurobasal medium, B27 supplement, fetal bovine 
serum, L-glutamine, Sytox assay dye, IR-dye tagged secondary antibodies, penicillin, and 
streptomycin and other cell culture reagents were purchased from Invitrogen (Gaithersburg, 
MD). Recombinant murine TNF, LPS (E. coli 0111:B4) and cytosine arabinoside were 
purchased from Sigma-Aldrich (St. Louis, MO).   
Treatment paradigm. MPP
+
 (10M) was added to the cells for the duration of the 
experiment. The cells were detached from the flask using a rubber policeman and centrifuged 
at 200 x g for 5 min, washed with ice-cold PBS twice and homogenized with Radio-
immunoprecipitation Assay (RIPA) buffer. Cell lysates, collected by spinning down the cell 
fragments at 20,000 x g for 45 min at 4°C, were used to determine changes to Pin1 
expression. 
qRT-PCR. After treatment, total RNA were extracted from the mice brain SN using 
Absolutely RNA Miniprep Kit (Agilent Technologies, Santa Clara, CA) following the 
manufacturer’s protocol. Total RNA was treated with DNase I to remove DNA 
contamination and then reversibly transcribed into first-strand cDNA using the SuperScript 
III first-strand synthesis system (Invitrogen, Carlsbad, CA) as described in the kit 
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instructions. SYBR-green Quantitative PCR was performed with validated primers of TNF-α 
, IL-1β, iNOS, IL-6 and control 18S primers (Qiagen, Valencia, CA) using RT2 SYBR®  
Green qPCR Master Mix (SABiosciences, Fredrick, MD) for the mice tissue. 
Sytox cell death assay.  The BV2 cells were incubated with 10ng/ml TNF-α for 18 h in the 
presence or absence of different doses of Juglone and cell death was determined by the cell 
impermeable Sytox green (Molecular Probes, Eugene, OR). Sytox green intercalates with the 
DNA in the membrane compromised cells to produce a green fluorescence that is 
quantifiable at excitation 485 nm and emission 538 nm using the fluorescence microplate 
system (Synergy 4, Biotek, Winooski, VT) and also allows to be viewed under fluorescence 
microscope. 
Microglial nitric oxide detection. Nitric oxide production by BV2 cells was measured 
indirectly by quantification of nitrite in the supernatant using the Griess reagent (Sigma 
Aldrich). BV2 microglial cells were plated in poly-D-lysine coated 96-well plates at 50,000 
cells per well. Cells were treated with either 1µg/ml LPS for 24 h or 10ng/ml TNF-α for 18 h 
in presence or absence of different doses of Juglone and 100 μL of supernatant was collected 
from each well and an equal volume of the Griess reagent was added. The samples were 
incubated on a plate shaker at room temperature for 15 min until a stable color was obtained. 
The absorbance at 540 nm was measured using a Synergy 2 multi-mode microplate reader 
(BioTek Instruments) and the nitrite concentration determined from a sodium nitrite standard 
curve. 
Multiplex cytokine and chemokine Luminex immunoassays. BV2 and primary microglia 
from time pregnant pups from PKCδ wild-type mice were obtained and seeded in poly-D-
lysine coated 96-well plates respectively. The cells were treated for 24 h with 1µg/ml LPS 
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(for BV2) or 100 ng/mL LPS (for p. microglia) in presence or absence of 3µM Juglone. After 
treatment, 50 µL of supernatant from each well was collected and frozen at -80°C. The levels 
of cytokines and chemokines in the supernatants were determined using the Luminex bead-
based immunoassay platform (Vignali, 2000) using pre-validated multiplex kits (Milliplex 
mouse cytokine and chemokine panels – Millipore Corporation) according to the 
manufacturer’s instructions. 
Intracellular reactive oxygen species (iROS) detection. Intracellular reactive oxygen 
species (iROS) were determined using the fluorescent probe 2’,7’-dichlorodi-
hydrofluorescein diacetate (DCFH-DA) (Calbiochem), according to previously published 
reports (Zhang et al., 2005; Qian et al., 2007). Magnetically separated microglia from PKCδ 
wild-type mice were plated at 10
5
 cells per well in 96-well plates and allowed to attach 
overnight. Before treatment, cells were washed in HBSS and incubated with 40 µM DCFH-
DA in HBSS containing 2% FBS for 30 min. Cells were then treated with 100 ng/mL LPS 
for 24h in the presence or absence of 3µM Juglone. The fluorescence intensity was 
determined using a Synergy-2 multi-mode microplate reader at an excitation of 485/20 nm 
and an emission of 530/25 nm. The fluorescence value from the control cultures was 
subtracted as background and the increase in fluorescence with treatments was expressed as 
increased iROS as previously described (Zhang et al., 2005; Qian et al., 2007). 
Animals and MPTP treatment. Eight- to 12-week-old male C57BL/6 mice weighing 24 to 
28 g were housed in standard conditions: constant temperature (22 ± 1°C), humidity (relative, 
30%), and a 12-h light/dark cycle. Mice were allowed free access to food and water. Use of 
the animals and protocol procedures were approved and supervised by the Committee on 
Animal Care at Iowa State University (Ames, IA, USA). Mice received four injections of 
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MPTP-HCl (15mg/kg of free base; Sigma-Aldrich) in 1XPBS at 2 h intervals via i.p. The 
control mice received only 1XPBS.  
Juglone treatment in mice. Juglone was dissolved in 10% ethanol and was administered to 
mice via intraperitoneal injection. Based on other reports, (Esnault et al., 2007b; Jeong et al., 
2009) we injected 10 mg / kg dose of Juglone intraperitoneally. However, we observed 
nearly 40% mortality rate of mice. Hence, we chose a lower dose (3 mg / kg) of Juglone and 
we never noticed any death or other behavioral imparities in mice.  First dose of Juglone (3 
mg / kg) was administered 24 h before 1
st
 dose of MPTP injection, second dose of Juglone 
was administered 3 h before the 1
st
 dose of MPTP injection and third dose of Juglone was 
administered 3 h after the last dose of MPTP injection. Mice were sacrificed 24 h after the 
last dose of MPTP.     
Immunoblotting. After treatment, cells and mice brain tissues were collected and 
resuspended in modified RIPA buffer containing protease and phosphatases inhibitor 
cocktail. Cell suspensions were sonicated after resuspension, while tissues were 
homogenized, sonicated and then centrifuged at 14000 x g for 1 hr at 4°C. Lysates were 
separated on 8-12% SDS – polyacrylamide gel electrophoresis (PAGE). After the separation, 
proteins were transferred to a nitrocellulose membrane, and nonspecific binding sites were 
blocked by treating with Odyssey
®
 blocking buffer (LiCor, Lincoln, NE). Pin1 (1:2000; 
mouse monoclonal; R&D Systems, Minneapolis, MN), p65 (1:500, rabbit polyoclonal; Santa 
Cruz, CA), -Actin (1:5000; mouse monoclonal; Sigma, St. Louis, MO), iNOS (1:350, rabbit 
polyclonal; Santa Cruz, CA) were used to blot the membranes. Secondary IR-680-conjugated 
anti-mouse (1:10000; Molecular Probes, Carlsbad, CA) and IR dye 800 anti-rabbit (1:10000; 
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Rockland) secondary antibodies.were used and scanned in Odyssey IR imaging system 
(LiCor, Lincoln, NE).  
Immunoprecipitation. For immunoprecipitation studies, briefly, cells were lysed in 
immunoprecipitation buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 10 mM 
NaF, 1% Triton X-100, 1 X halt protease inhibitor mixtures), and the resultant lysates were 
incubated on ice for 15 min followed by centrifugation at 16,000 X g for 15 min. The 
supernatant fractions were then precleared with protein A or protein G beads for 30 min at 
4°C followed by centrifugation at 16,000 g at 4°C for 10 min. Five micrograms of the 
indicated antibody along with 50 Xl of 50% of protein A or protein G beads were added to 
the cell lysates and incubated overnight at 4°C on a rotator. The immunoprecipitates were 
collected, washed extensively with cold PBS, and prepared for SDS-PAGE gel by addition of 
2% SDS sample buffer and then boiling for 10 min (Jin et al.). 
Mesencephalic Primary Neuron Cultures and Treatment. Primary mesencephalic and 
striatal neuronal cultures were prepared from the ventral mesencephalon of gestational 14- to 
15-day-old mice embryos as described previously (Zhang et al., 2007). Briefly, 
mesencephalic tissues from E14 to 15 mouse embryos were dissected and maintained in ice-
cold calcium-free Hanks’ balanced salt solution and then dissociated in Hanks’ balanced salt 
solution containing trypsin-0.25% EDTA for 20 min at 37°C. The dissociated cells were then 
plated at equal density of 0.1 million cells per well on 12-mm coverslips precoated with 0.1 
mg/ml poly-D-lysine. Cultures were maintained in neurobasal medium fortified with B-27 
supplement, 500 mM L-glutamine, 100 IU/ml penicillin, and 100 g/ml streptomycin 
(Invitrogen, Carlsbad, CA). The cells were maintained in a humidified CO2 incubator (5% 
CO2 and 37°C) for 24 h. Half of the culture medium was replaced every 2 days. 
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Approximately 6- to7-day-old cultures were used for experiments. Primary mesencephalic 
and striatal dopaminergic neuronal cells were exposed to 10 µM MPP
+
 in the presence or 
absence of Juglone (1 µM) for 24 h.  
Immunocytochemistry. The primary mesencephalic and mixed neuro-glia cultures were 
fixed with 4% paraformaldehyde in phosphate buffered saline (PBS) for 20 minutes and 
processed for immunocytochemical staining as described previously (Ghosh et al., 2010). 
First, nonspecific sites were blocked with 2% bovine serum albumin, 0.5 % Triton X-100 and 
0.05% Tween-20 in PBS for 45 min at room temperature. Cells were then incubated with 
different primary antibodies such as TH (1:1600, mouse monoclonal; Millipore, Billerica, 
MA), IBA-1 (1:1000, goal polyclonal; Chamicon), GFAP (1:1000; mouse monoclonal; 
Chemicon), Pin1 (1:400, goat polyclonal; Santa Cruz) at 4°C overnight. Appropriate 
secondary antibodies (Alexa Fluor 488 or 594 or 555; Invitrogen) were used followed by 
incubation with 10µg/ml Hoechst 33342 (Invitrogen) for 5 min at room temperature to stain 
the nucleus. The coverslip containing stained cells were washed twice with PBS and mounted 
on poly-D lysine coated slides (Sigma, St Louis). Cells were viewed under a NIKON 
inverted fluorescence microscope (model TE-2000U; NIKON, Tokyo, Japan) and images 
were captured with a SPOT digital camera (Diagnostic Instruments, Inc., Sterling Heights, 
MI). 
Immunohistochemistry. Twenty four hr. after MPTP treatment, mice were perfused with 
4% paraformaldehyde and post fixed with PFA and 30% sucrose respectively as described 
previously (Ghosh et al., 2009). Next, 30 µm coronal SN free-floating sections were blocked 
with 2% bovine serum albumin, 0.5 % Triton X-100 and 0.05% Tween-20 in PBS for 1 h at 
room temperature. Sections were incubated with different primary antibodies such as anti- 
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Pin1 (1:500; goat or rabbit polyclonal), anti-IBA-1 (1:750; goat polyclonal), anti-TH 
(1:1600; mouse monoclonal; Chemicon, Temecula, CA), anti-GFAP (1:1000; Chemicon) for 
overnight at 4°C. After washing with PBS, sections were incubated in appropriate secondary 
antibodies (Alexa Fluor 488 or 594 or 555 from Invitrogen) for 2 h. followed by incubation 
with 10µg/ml Hoechst 33342 for 5 min at room temperature to stain the nucleus. Sections 
were viewed under a NIKON inverted fluorescence microscope (model TE-2000U; NIKON, 
Tokyo, Japan); images were captured with a SPOT digital camera (Diagnostic Instruments, 
Inc., Sterling Heights, MI) using MetaMorph software, version 5.0 (Molecular Devices, 
Sunnyvale, CA). 
Statistical analysis. Data were analyzed with Prism 3.0 software (GraphPad Software, San 
Diego, CA). Bonferroni and Dunett multiple comparison testing were used. Differences with 
P  < 0.05 were considered significant.  
Results: 
Pin1 protein expression is enhanced in BV2 cells in response to different stimuli 
Accumulation of Pin1 in the Lewy bodies of PD and promotion of -synuclein 
aggregates during over-expression of Pin1 in a kidney cell line has left a lot of unanswered 
questions about the role of Pin1 during PD (Ryo et al., 2006). Very little has been known 
about the role of Pin1 in inflammatory reactions. As glial activation and sustained nigral 
neuroinflammation are evident in PD patients, we wanted to check the expression of Pin1 in 
BV2 microglial glial cells in the presence or absence of different inflammatory stimuli. BV2 
microglial cells were treated with 1µg/ml LPS for 24h and after treatment cells were 
collected and immunoblotted for checking expression of Pin1. We found increased 
expression of Pin1 in lysates of LPS treated BV2 cells with statistically significant difference 
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compared with the control BV2 cells (p < 0.01) (Fig. 1A-B). Next, we wanted to see whether 
parkinsonian toxicant MPP
+
 could also induce Pin1 expression in BV2 cells. Cells were 
treated with 10µM MPP
+
 for 24h and checked for Pin1 expression. Significant induction of 
Pin1 expression was observed in MPP+ treated BV2 cells compared to control BV2 cells (p < 
0.01) (Fig. 1C-D). Further, TNF-α also induced dose dependent induction of Pin1 protein 
levels in BV2 cells, with highest induction at 10ng/ml dose. (Fig. 1E-F). Together, these 
results demonstrate for the first time that protein levels of Pin1 upregulated in response to 
different stimuli in activated microglial cells. 
Parkinsonian toxicant MPP
+
 induces Pin1 expression in primary neuro-glial mixed 
culture 
After establishing the induction of Pin1 protein expression in activated BV2 cells, we 
studied the subcellular localization of this isomerase in primary mesencephalic mixed neuro-
glia culture. Neuron-glial mix cultures were obtained from day 14 time pregnant C57BL/6 
female mice embryos. The mixed neuro-glial cultures were treated with 10M MPP+ for 24 
h. After treatment, cells were fixed with 4% paraformaldehyde and immunostained either 
with IBA-1(marker of microglia) and Pin1 (Fig. 2A) or GFAP (marker of astrocytes) and 
Pin1 (Fig. 2B). We used Hoechst to stain the nucleus. In unstimulated mixed neuro-glia 
cultre, we observed very little staining of Pin1 in IBA-1 positive microglial cells and GFAP 
positive astrocytes. However, stimulation with MPP
+
 resulted an increased staining of Pin1 in 
the cytosol of microglial and astrocytes (Fig 2A-B). In addition to that we also checked Pin1 
expression in primary astrocytes separated from day 1 old pups. MPP
+
 treatment causes 
robust upregulation of Pin1 protein expression compared to unstimulated control astroglial 
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cells (Fig. 2C-D). Together, these results suggest that Pin1 is a cytosolic protein whose level 
goes up in glial cells in response to MPP
+
.  
Activation of p65 in BV2 cells in response to different inflammatory stimuli 
The promoter region of pro-inflammatory molecules contains the DNA binding site 
for NF-κB and inhibition of NF-κB reduces the induction of proinflammatory molecules 
(Hayden MS et al., 2004). A recent study reported MPP
+
 induced activation of p65 in mouse 
BV2 microglial cells (Ghosh et al., 2007) and we sought to confirm this finding. BV2 
microglial cells were treated with 10µM MPP
+
 for 24h. After treatment, cells were collected 
and immunoblotted for checking Pin1 expression (Fig. 3A). We found increased expression 
of p65 in MPP+ treated cells. Similar with MPP
+
 treatment, cells were also treated with LPS 
(1µg/ml) for 24h and checked for Pin1 expression. LPS treatment resulted in robust increase 
in p65 protein expression in BV2 cells compared to untreated control cells (Fig. 3B). Further, 
TNF-α dose dependently increased p65 expression in BV2 cells, with maximum induction at 
10ng/ml dose. After establishing the maximum induction of p65 with 10ng/ml TNF-α  dose, 
we were interested to see at what time point after TNF-α  treatment, p65 expression goes up 
maximum. BV2 cells were treated with 10ng/ml TNF-α for different time points ranging 
from 6h to 24. We found maximum induction of p65 expression at 18h of TNF-α  treatment, 
with some upregulation at 24h time point. 
Pin1 binds to p65 in BV2 microglial cells 
To determine if a p65-Pin1 interaction occurs within BV2 cell, co-
immunoprecipitation experiments were performed. BV2 cells were treated with either MPP
+ 
(10um) for 24h or 1µg/ml LPS for 24 h or TNF-α (10ng/ml) for 18h. Immunoprecipitation 
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was then carried out using a p65 antibody, followed by immunoblotting for for Pin1 and p65 
(Fig. 4A). Endogeneous p65 and Pin1 show some association in the control lanes 
(unstimulated state), which is enhanced with MPP
+
 or LPS or TNF-α . To demonstrate the 
specificity of this interaction, we did reversed immunoprecipitation (Fig. 4B). Here also, 
some association between Pin1 and p65 could be noticed in control lanes. However, in MPP
+
 
or LPS or TNF treated cells increased association between Pin1 and p65 occurred (Fig. 4B). 
These results clearly say that there is Pin1 and p65 in teraction in mouse microglial BV2 
cells. 
Juglone inhibits Pin1 expression in BV2 cells  
After establishing induction of Pin1 in BV2 cells in response to different stimuli, we 
were interested to see whether pharmacological inhibitor of Pin1 – Juglone could attenuate 
the Pin1 expression in BV2 cells. To optimize the dose of Juglone, we measured cytotoxicity 
of BV2 cells using a live-cell impermeable fluorescent dye – Sytox green during treatment of 
TNF-α in the presence or absence of Pin1 inhibitor – Juglone (Fig 5A-B). As expected, 
10ng/ml TNF-α didn’t cause any toxicity to the BV2 microglial cells. Co-treatment with 
Juglone show some dose dependent cytotoxicity (Fig 5A-B), with significantly high toxicity 
at 10µM (p < 0.01) and 20µM (p < 0.001) doses of Juglone, where as 1µM and 3µM doses 
didn’t had any significant toxicity. Next, BV2 microglial cells were treated with 10µM MPP+ 
for 24h in the presence or absence of 3 different doses of Juglone (1µM, 3µM and 10µM). 
We observed a dose dependent inhibition of MPP
+
 induced Pin1 expression with Juglone 
treatment, with highest inhibition at 3µM dose (Fig. 5C). 3µM Juglone also attenuated LPS 
and TNF-α -induced Pin1 expression in BV2 cells (Fig. 5 D-E). To further cofirm, our 
findings in western blotting, we did immunocytochemistry in primary mesencephalic mixed 
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neuro-glia culture. Neuron-glial mix cultures were obtained from day 14 time pregnant 
C57BL/6 female mice. The mixed neuro-glial cultures were treated with 10M MPP+ in the 
presence or absence of 3µM Juglone for 24 h. After treatment, cells were fixed with 4% 
paraformaldehyde and immunostained either with IBA-1(marker of microglia) and Pin1 or 
GFAP (marker of astrocytes) and Pin1 (Fig. 5F). We used Hoechst to stain the nucleus. As 
expected, MPP
+
 treatment resulted in increased expression of Pin1 in the cytosol of 
microglial and astrocytes. However, 3µM Juglone treatment attenuates MPP
+
 induced 
induction of Pin1 in microglia and astrocytes. 
Juglone inhibits p65 activation in activated BV2 cells 
After establishing an inhibitory role of Juglone in Pin1 expression, we were curious to 
see whether Juglone had any effect on p65 activation. BV2 cells treated with TNF-α  
(10ng/ml) in the presence or absence of Juglone (3µM) for 18h, were immunostainined for 
Pin1 and p65 double labeling. As expected, TNF-α resulted in increased expression of total 
p65 in the nucleus (Fig. 6A). However, Juglone treatment attenuated p65 translocation to the 
nucleus, as very few microglial cells were found with localization of p65 in the nucleus. To 
confirm these immunofluorescence findings, we did western blotting of p65 in BV2 cells. 
Cells were treated with MPP
+
 in the presence or absence of 3µM Juglone for 24h. As 
expected, MPP
+
 treatment resulted in increased expression of p65 expression whereas 1µM 
and 3µM doses of Juglone dose dependently inhibited p65 expression (Fig. 6B-C). Similar to 
that, LPS and TNF-α also caused an increase of p65 expression in BV2 cells. However, 3µM 
Juglone treatment significantly attenuated p65 expression both in LPS and TNF-α treated 
BV2 cells (Fig. 6C-F).  
Juglone attenuates LPS and TNF-α induced nitric oxide production in microglial cells  
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Nitric oxide production and intracellular ROS (iROS) generation are important 
aspects of the microglial activation response and are particularly relevant in PD models 
where deregulation of microglial activation is believed to augment dopaminergic 
neurodegeneration via oxidative stress. We checked if microglial nitric oxide generation is 
attenuated in the presence of Pin1 inhibitor Joulone. Nitric oxide production was measured 
indirectly using Griess assay both in BV2 cells and primary microglia (Fig 7A-C). BV2 cells 
were treated with LPS (300ng/ml) in the presence or absence of Juglone (3µM). LPS 
treatment for 24 h induced a sharp increase in nitrite levels (> 1.5µM) in BV2 cells, while 
Juglone dose dependently attenuated LPS-induced nitrite levels with maximum attenuation at 
3µM dose of Juglone (Fig. 7A). Similar to that, 3 µM Juglone also significantly (p < 0.05), 
inhibited LPS-induced nitrite levels in primary microglial cells from day 1 old pups (Fig. 
7C). TNF-α also induced significant increase in nitrite release compared to untreated BV2 
cells (p < 0.001) (Fig. 7B). However, Juglone treatment dose dependently attenuated TNF-α 
induced nitrite levels in BV2 cells. Next, we wanted to test whether Juglone inhibited iNOS 
expression in BV2 cells. Cells were treated with 10µM MPP
+ 
in presence or absence of 3µM 
Juglone for 24h. Western blot analysis revealed that Juglone attenuated MPP
+
 induced iNOS 
protein expression (P < 0.05) (Fig. 7D). Similarly, Juglone also reduced LPS or TNF-α 
induced iNOS expression in BV2 cells (Fig. 7E-F). Together, these results support that 
inhibition of Pin1 could lead to attenuation of microglial inflammatory reactions.                          
Juglone attenuates miroglial cytokines in response to LPS stimulation 
To further establish the role of Pin1 in regulating the microglial activation response, 
we used BV2 cells and primary microglial cultures from day 1 old pups. BV2 cells were 
treated with 300ng/ml LPS in presence or absence of 3µM Juglone. 24 h after treatment, the 
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levels of various pro-inflammatory cytokines in the supernatant were determined using a 
multiplex bead-based Luminex assay system (Milipore Bioplex). In LPS-treated BV2 cells, 
the levels of IL-6 (p < 0.001), TNF-α (p < 0.001) and IL-1β (p < 0.001) increased several 
folds compared to untreated cells. However, Juglone significantly reduced LPS induced IL-6 
(p < 0.001), TNF-α (p < 0.01) and IL-1β (p < 0.001) release from BV2 cells (Fig. 8A-C). 
Similarly, we also measured cytokine response in primary microglia treated with LPS and 
Juglone. LPS triggered robust increase in IL-6, TNF-α and IL-1β release in primary 
microglia cells, while Juglone significantly attenuated LPS-induced release of 
proinflammatory cytokines (Fig. 7D-F). These further indirectly substantiate a role of Pin1 in 
modulating inflammatory reactions.  
Expression of Pin1 in glial cells of MPTP-treated mouse  
After establishing the possible role of Pin1 in induction of inflammatory reactions in 
vitro, we examined whether the activation of Pin1 was induced in midbrain of MPTP mouse 
model of PD. Mice were treated with 4 doses of MPTP at 18mg/kg/dose via i.p. at 2 h 
interval. 24h after treatment, mice were sacrificed and frozen substantia nigra (SN) sections 
were processed for immunostaining. MPTP treatment led to robust increase in Pin1 
expression (red color) in the SN compared to saline treated control mice (Fig. 9). Double-
label immunofluorescence analysis indicates that Pin1 was principally expressed by 
astrocytes (Fig. 9A) microglia (Fig. 9B). This Pin1 was present in cytoplasm because it did 
not colocalize with DAPI (Fig. 9). 
Activation of p65 in nigrostriatum of MPTP-treated mice and effect of Juglone on 
MPTP-induced inflammation in midbrain 
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A previous report shows selective activation of NF-κB in substantia nigra of MPTP-
treated mouse led to increased inflammatory reactions (Ghosh et al., 2007). We also found 
activation of p65 in BV2 microglial cells and association of p65 and Pin1 in response to 
different stimuli (Fig. 2-4). To validate our results obtained with BV2 cells, we first checked 
protein expression of p65 in nigrostritum of mice. Acute MPTP treatment led to increased 
expression of p65 both in SN and striatum in time dependent manner with highest expression 
at 24h treatment (Fig. 10A-B). Promoter regions of proinflammatory molecules contain the 
DNA binding site for NF-κB  (Hayden and Ghosh, 2004). Because, Pin 1 inhibitor Juglone 
inhibited the activation of p65 in vitro in the microglial cells in response to different stimuli 
(Fig. 6), we examined whether Juglone was able to suppress the expression of various 
proinflammatory molecules and cytokines in the midbrain. As shown by quantitative real-
time PCR (Fig. 10C) experiments, MPTP treatment led to marked increase in mRNA 
expression of TNF-α , IL-1β, IL-6 and iNOS in the ventral midbrain. However, 3mg/kg 
Juglone significantly inhibited MPTP-induced expression of TNF-α (p < 0.05), IL-1β (p < 
0.05) and iNOS (p < 0.05) (Fig 10C). But, expression of IL-6 was not significantly attenuated 
in MPTP treated mice that also received Juglone. Immunofluoroscence analysis of iNOS also 
showed increased expression of nigral iNOS protein expression in MPTP treated mice 
compared to PBS treated control mice and that iNOS protein was expressed by GFAP-
positive astrocytes (Fig. 11A) and IBA-1 positive microglia (Fig. 11B). Inset pictures clearly 
showed colocalized glial cells and iNOS (merged color of yellow from green and red). 
However, Juglone suppressed MPTP-induced iNOS expression in astrocytes and microglial 
cells (Fig. 11A & B), as very few colocalized cells were observed in SN. These results 
clearly demonstrate that inhibition of Pin1 could be anti-inflammatory.                    
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Discussion: 
Activation of microglia and astrocytes have been well documented in post mortem 
PD brains and mouse models of PD. Activated microglia-induced inflammatory reactions can 
be both sustained and progressive (Gao et al., 2003; McGeer et al., 2003), which means 
microglial activation leads to neurodegeneration and neuronal injury, which in turn further 
reactives microglial activation. But, the signaling pathways regulating microglial activation 
remains unclear. A recent study shows that proinflammatory transcription factor NF-κB 
regulates microglial and astroglial proinflammatory responses in the substantia nigra and 
selective inhibition of NF-κB attuneates inflammatory reactions (Ghosh et al., 2007). NF-κB 
regulates proinflammatory genes such as TNF-α , IL-1β, Il-6 and iNOS in animal and human 
studies (Bremner and Heinrich, 2002). In our study, we have shown increased expression of 
Pin1 and p65 and translocation of p65 to nucleus in microglial cells following stimulation 
with MPP
+
 or LPS or TNF-α. We also reported association between Pin1 and p65 following 
MPP
+
 or LPS or TNF-α induction. Earlier, Ryo et al., 2003 demonstrated that Pin1 binds to 
the phosphorylated Thr
254
 -Pro of p65 and subsequently inhibited IkBa binding (Ryo et al., 
2003). Thus, NF-κB activation along with increased Pin1 expression in response to MPP+ or 
LPS or TNF-α treatment is associated with the increased production of proinflammatory 
molecules.     
Our results in this study indentify Pin1 as a novel intracellular protein regulating the 
glial activation both in vitro and in MPTP mouse model of PD. We demonstrated that Pin1 
protein level is induced during microglial activation by distinct mechanisms and stimuli 
including TNF-α, MPP+and LPS. Our results showed increase in nitric oxide production in 
BV2 and primary microglial cells demonstrated that Pin1 can regulate the microglial RNS 
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generation machinery, which plays vital role in dopaminergic neurodegeneration. In addition 
to that, multiplex cytokine assays further demonstrated the involvement of Pin1 controlled 
NF-κB activation in microglial activation response.  
Pin1 is an 18kDa enzyme with two domains. N-terminal amino acids 1-19 comprised 
the WW domain which determines substrate specificity, whereas the C-terminus contains the 
catalytic PPIase (peptidyl-prolyl isomerase) domain (Yeh and Means, 2007). Significant 
higher levels of Pin1 protein is expressed in many human cancers like liver, breast the 
prostate cancers (Wulf et al., 2001; Bao et al., 2004; Pang et al., 2006). Growing reports 
suggest Pin1’s role in several neurodegenerative disorders and the lack of information on 
Pin1’s function during inflammation mediated PD led us to this investigation.  The roles of 
Pin1 in Alzheimer’s disease (AD) pathogenesis is not clear enough, while, several 
investigators reported downregulation of Pin1 during oxidative stress and its association with 
tautopathy and neurodegeneration during AD (Butterfield et al., 2006). Some other 
researchers demonstrated that inhibition of Pin1 led to the attenuation of neurofilament-H 
phosphorylation and its perikaryal accumulation in AD as well as Amyotropic Lateral 
Sclerosis (ALS) models (Kesavapany et al., 2007; Rudrabhatla et al., 2009). Pin1
-/- 
mice 
exhibited a phenotype of an age dependent accumulation of abnormal and 
hyperphosphorylated tau and neurodegeneration suggesting a neuroprotective role of Pin1 in 
AD models (Lu et al., 1999). The role of Pin1 in the inflammatory processes of PD is not 
clear enough. Pin1 controls expression of several transcription factors that mediate induction 
of iNOS, a key inflammatory molecule involved in the pathogenesis of PD (Gothel and 
Marahiel, 1999). While inhibition of Pin1 led to apoptosis in vascular smooth muscle cells 
and Pin1 was required for pro-survival signaling in eosinophils (Shen et al., 2009), Pin1’s 
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pro-apoptotic function has been demonstrated during downregulation inhibitn of apoptosis 
protein-survivin in neuroblastoma cells (Dourlen et al., 2007) and promoting tumor cell death 
by dissociating tumor suppressor p53 from apoptosis inhibitor iASPP (Mantovani et al., 
2007). In the nervous system, Pin1 has been shown to regulate oligodendrocyte apoptosis 
after spinal injury by binding and stabilizing Mcl-1 after JNK3 activation (Li et al., 2007) 
and also induce death of developing neurons during JNK signaling. Since Pin1 role is not 
clear during neurodegeneration and as it accumulates in the Lewy body inclusions we wanted 
to understand role of Pin1 in inflammation processes during PD. We first identified that Pin1 
is highly expressed in the BV2 cells and primary glial cells (both microglia and astrocytes) in 
response to different stimuli.  
There are several microglial activating agents that causes neurotoxicity. These agents 
include LPS, TNF-α and MPP+. LPS is a Gram-negative bacterial endotoxin that causes 
microglial cell activation (Kim et al., 2000). LPS binds to an LPS receptor membrane 
complex on microglial cells and activates nuclear localization of transcription factor nuclear 
factor κB (NF-κB ) and subsequent activation of  genes in proinflammatory pathways (Orr et 
al., 2002). Intranigral injection of LPS causes strong microglial activation and subsequent 
dopaminergic neurodegeneration in both SN and striatum (Herrera et al., 2000). 
Intraperitoneal injection of LPS has been reported to produce an increase in gene expression 
for Toll-like receptor 2, IFN-γ, COX-2, and IL-6 receptor in the CNS in rodents (Vallieres 
and Rivest, 1997). LPS also induces expression of caspase-11 and increased IL-1β level 
(Arai et al., 2004). Similarly, in our experiment, LPS induced nitrile level and iNOS 
expression along with increased mRNA expression of different proinflammatory cytokines in 
microglial cells.  
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MPTP is a lipophilic molecule which crosses the blood–brain barrier (BBB) and 
reaches the brain within minutes. Once in the brain, MPTP is converted to MPP
+
 by 
monoamine oxidase B (MAO-B) in astroglial cells (Markey et al., 1984). The latter is 
believed to be responsible for glial activation and neuronal death (Dauer and Przedborski, 
2003). In our experiment, we also found activated microglial and astroglial cells expressing 
high levels of Pin1 protein following MPTP administration. Previously, marked activation of 
nigral NF-κB  has been reported in postmortem PD brains and in MPTP mouse model of PD 
(Ghosh et al., 2007). We also showed that parkinsonian neurotoxin MPP
+
 was capable of 
activating NF-κB p65 in BV2 microglial cells and post natal mouse microglial cells. 
However, Juglone, a pharmacological inhibitor of Pin1 was capable of attenuating MPP
+
 
induced NF-κB p65 expression in microglial cells. Once NF-κB is activated, in collaboration 
with other proinflammatory transcription factors, NF-κB  drives the transcription of several 
proinflammatory molecules including iNOS, TNF-α , and IL-1β in both microglia and 
astroglia (Liu et al., 2006). As glial cells mediated production of proinflammatory molecules 
and further activation of gliosis are important features of PD pathology, it appears that NF-
κB activation regulates these pathological features either directly or indirectly and that Pin1 
inhibition (by means of pharmacological inhibitor- Juglone) rescues against inflammatory 
reactions via suppression of NF-κB dependent pathological steps.  
In our study, we used Juglone (5-hydroxy-1, 4-napthalenedione, (C10H6O3), a 
pharmacological inhibitor of Pin1 and it is an aromatic organic napthoquinone, naturally 
found in the leaves, roots and bark of plants in the black walnut and has been widely used as 
a Pin1 inhibitor (Esnault et al., 2007b; Jeong et al., 2009). The enzymatic activity of E. coli 
parvulin and human Pin1 is specifically inactivated by Juglone by modification of thiol 
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groups of cysteine residue in parvulin (Hennig et al., 1998). Recent report demonstrated that 
Juglone prevented acute and chronic rejection of MHC mismatched, orthotopic rat lung 
transplants by reducing the expression of IFN-γ and CXCL-10 mRNA stability, accumulation 
and protein expression after cell activation (Esnault et al., 2007a). Juglone also attenuates 
rheumatoid arthritis development in human primary culture RA chrondrocytes and CII 
treated DBA/1J mice (Jeong et al., 2009). Additionally, recent reports suggested anti-
inflammatory, anti-viral and anti-fungal properties of Juglone (Omar et al., 2000). In our 
study, we found 3M Juglone is non-toxic to the microglial cells. Additionally, we found that 
Juglone attenuated LPS or TNF-α or MPP+ induced Pin1 expression in BV2 and primary 
glial cells. Juglone also attenuated LPS induced nitrite and iNOS expression in microglial 
cells. Recent report demonstrated that 5mg/kg dose of Juglone blocked type-2 rheumatoid 
arthritis in DBA/1J mice (Jeong et al., 2009). In our study, we injected multiple doses of 
Juglone (3mg/kg) intraperitoneally to the C57BL/6 mice. Importantly, these doses of Juglone 
were nontoxic. Here we demonstrate that Juglone effectively attenuates the MPTP-induced 
mRNA expression of proinflammatory molecules and cytokines in nigrostriatum. 
Furthermore, Juglone also attenuated MPTP induced iNOS expression in microglial and 
astroglial cells.  
In conclusion, we have demonstrated for the first time in our knowledge that Pin1 and 
p65 are upregulated in BV2 and mouse primary glial cells in response to LPS ot TNF-α  or 
MPP
+
 stimuli. We showed specific interaction between p65 and Pin1 in BV2 microglial cells. 
By employing pharmacological inhibitor of Pin1, we were able to reduce the expression of 
Pin1 and p65. Juglone also attenuated LPS induced nitrite production and subsequent iNOS 
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expression in microglial cells. LPS induced expression of proinflmmatory cytokine was also 
attenuated by Juglone, suggesting Pin1’s possible role in modulating inflammation. 
Additionally, we also demonstrated increased expression levels of Pin1 in nigral microglial 
and astroglial cells of MPTP treated mice. Juglone was also capable of attenuating MPTP 
induced expression of proinflammatory cytokines in mice midbrain. Additionally, Juglone 
attenuated MPTP-induced nigral iNOS expression in vivo. These results clearly suggest that 
Pin1 may serve as a novel pharmacological target for attenuating neuroinflammation in PD 
and Pin1 inhibitor Juglone may be used as novel neuroprotective agent. 
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 Figure 1 
 
Figure 1. Induction of Pin1 expression in response to different stimuli in BV2 cells. 
A.BV2 cells were treated with 1 µg/ml LPS for 24 h. After treatment, cells were collected 
and expression of Pin1was checked by western blotting. B. Bar graph showing means 
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Western blot Pin1/β-actin ratios ± SEM from 2 different experiments. C. BV2 cells were 
treated with 10µM MPP
+
 for 24 h. After treatment, cells were collected and expression of 
Pin1was checked by western blotting from cell lysates. D. Bar graph showing means Western 
blot Pin1/β-actin ratios ± SEM from 2 different experiments. E. BV2 cells were treated with 
3 different doses (10ng/ml, 20ng/ml and 30ng/ml) of TNF-α for 18 h. After treatment, cell 
lysates were made and expression of Pin1was checked by western blotting. F. Bar graph 
showing means Western blot Pin1/β-actin ratios ± SEM from 3 different experiments. a, p < 
0.01 vs control; c, p < 0.01 vs TNF-α (different doses). 
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Figure 2  
 
Figure 2. Parkinsonian toxicant MPP
+
 induces Pin1 expression in primary 
mesencephalic mixed neuro-glial cultures. Mesencephalic tisues from E15 mouse embryos 
were dissected out and grown on laminin-coated coverslips. The mixed neuro-glial cultures 
were treated with 10M MPP+ for 24 h. After treatment, cells were fixed with 4% 
paraformaldehyde. A. Double labeling of Iba-1 and Pin1 in primary mesencephalic mixed 
neuro-glial culture. B. Double labeling of GFAP and Pin1 in primary mesencephalic mixed 
neuro-glial culture. C. Expression of Pin1 in primary astrocytes culture from C57BL/6 
postnatal day 1 (P1) mouse pups.  
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Figure 3  
 
Figure 3. Induction of p65 expression in response to different stimuli in BV2 cells. 
A.BV2 cells were treated with 10µM MPP
+
 for 24h. After treatment cells were collected and 
expression of Pin1 was checked by western blotting . B. BV2 cells were treated with 1 µg/ml 
LPS for 24 h. After treatment, cells were collected and expression of Pin1was checked by 
western blotting. C. BV2 cells were treated with 3 different doses (10ng/ml, 20ng/ml and 
30ng/ml) of TNF-α for 18 h. After treatment, cell lysates were made and expression of 
Pin1was checked by western blotting. D. BV2 cells were treated with 10ng/ml dose of TNF-
α for different time points (6h, 12h, 18h and 24h). 
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Figure 4 
 
Figure 4. Pin1 associates with p65 in BV2 cells. A. BV2 cells were grown in T25 flasks. 
When cell density reached approximately 80%, the cells were treated with either 10µM 
MPP+ for 24h or 1µg/ml LPS for 24h or 10ng/ml TNF-α for 18h. After treatment, cells were 
lysed in modified RIPA buffer and lysates from each sample was then subjected to 
immunoprecipitation (IP) using antibodies specific for Pin1. IP samples were probed with 
antibodies to p65 to demonstrate a specific nteraction between Pin1 and p65. B. BV2 cells 
were grown in T25 flasks. When cell density reached approximately 80%, the cells were 
treated with either 10µM MPP+ for 24h or 1µg/ml LPS for 24h or 10ng/ml TNF-α for 18h. 
After treatment, cells were lysed in modified RIPA buffer and lysates from each sample was 
then subjected to immunoprecipitation (IP) using antibodies specific for p65. IP samples 
were probed with antibodies to Pin1. Results are representative of two separate experiments.  
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Figure 5  
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Figure 5. Pin1 inhibitor Juglone attenuates MPP+ or LPS or TNF-α induced Pin1 
expression  and  cytotoxicity  in BV2 and primary microglial cells.  BV2 cells were 
treated with 10ng/ml TNF-α  for 18 hrs in the presence or absence of different doses (1µM, 
3µM, 10µM and 20µM) of Juglone. A. Cytotoxicity of BV2 cells during 10M MPP+ 
treatment in the presence or absence of above mentioned four different doses of Juglone. 
Cytotoxicity was determined by Sytox green nucleic acid stain by measuring the fluorescence 
at regular intervals, as described in Materials and Methods. B. The two panels demonstrate 
phase contrast images (right) and fluorescence micrographs (left) to show the extent of Sytox 
green staining of cells in the field of view. C. BV2 cells were treated with10M MPP+ for 
24h in the presence or absence of different doses (1µM, 3µM and 10µM) of Juglone. After 
treatment, cell lysates were prepared and immunoblotted for Pin1. D. BV2 cells were treated 
with 1g/ml LPS for 24h in the presence or absence of 3µM Juglone. After treatment, cell 
lysates were prepared and immunoblotted for Pin1. E. BV2 cells were treated with 10ng/ml 
TNF-α  for 18h in the presence or absence of 3µM Juglone. After treatment, cell lysates were 
prepared and immunoblotted for Pin1. F. Primary glial cells from C57BL/6 postnatal day 1 
(P1) mouse pups were immunolabelled for IBA-1(marker of microglia) and Pin1 (upper 
panel) and for GFAP (marker of astrocytes) and Pin1. Data represent the mean ± SEM of 
three different experiments. **, p < 0.01 vs. TNF-α; ***, p < 0.001 vs. TNF-α. 
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Figure 6  
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Figure 6. Juglone inhibits TNF-α or LPS or MPP+ induced activation of p65 in BV2 
cells. A. BV2 cells were treated with 10ng/ml TNF-α in presence or absence of 3µM Juglone. 
18h after treatment, cells were immunostained for Pin1 and p65. B. BV2 cells were treated 
with10M MPP+ for 24h in the presence or absence of different doses (1µM, 3µM and 
10µM) of Juglone. After treatment, cell lysates were prepared and immunoblotted for p65. C. 
Bar graph showing means Western blot p65/β-actin ratios ± SEM from 3 different 
experiments. D. BV2 cells were treated with 1g/ml LPS for 24h in the presence or absence 
of 3µM Juglone. After treatment, cell lysates were prepared and immunoblotted for p65. E. 
Bar graph showing means Western blot p65/β-actin ratios ± SEM from 3 different 
experiments. F. BV2 cells were treated with 10ng/ml TNF-α  for 18h in the presence or 
absence of 3µM Juglone. After treatment, cell lysates were prepared and immunoblotted for 
p65. G. Bar graph showing means Western blot Pin1/β-actin ratios ± SEM from 3 different 
experiments. ***, p < 0.001 vs. control; **, p < 0.01 vs. control; @, p < 0.05 vs. MPP
+
 or 
TNF-α; #, p < 0.01 vs. MPP+; $, p < 0.05 vs LPS. 
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Figure 7  
 
Figure 7. Juglone attenuates generation of nitric oxide in BV2 and primary microglial 
culture. A. BV2 cells were treated with LPS (1µg/ml) in presence or absence of 3 different 
doses (1µM, 3µM and 10µM) of Juglone. After 24 h of treatment nitric oxide production was 
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determined indirectly by quantifying the nitrite levels in the supernatant using the Griess 
reagent and a sodium nitrite standard curve. B. BV2 cells were treated with TNF-α (10ng/ml) 
in presence or absence of 4 different doses (1µM, 3µM, 5µM and 10µM) of Juglone. After 
18 h of treatment nitric oxide production was determined indirectly by quantifying the nitrite 
levels in the supernatant using the Griess reagent and a sodium nitrite standard curve. C. 
Primary microglial cells from C57BL/6 one day old pups were treated with LPS (100ng/ml) 
in presence or absence of 3µM of Juglone. After 12 h of treatment nitric oxide production 
was determined indirectly by quantifying the nitrite levels in the supernatant using the Griess 
reagent and a sodium nitrite standard curve. D. BV2 cells were treated with10M MPP+ for 
24h in the presence or absence of different doses 3µM of Juglone. After treatment, cell 
lysates were prepared and immunoblotted for iNOS. E. Bar graph showing means Western 
blot iNOS/β-actin ratios ± SEM from 3 different experiments. F. BV2 cells were treated with 
1g/ml LPS for 24h in the presence or absence of 3µM Juglone. After treatment, cell lysates 
were prepared and immunoblotted for iNOS. G. Bar graph showing means Western blot 
iNOS/β-actin ratios ± SEM from 3 different experiments. H. BV2 cells were treated with 
10ng/ml TNF-α in presence or absence of 3µM Juglone. 18h after treatment, cells were 
immunoblotted for iNOS. I. Bar graph showing means Western blot iNOS/β-actin ratios ± 
SEM from 3 different experiments. ***, p < 0.001 vs control; **, p < 0.01 vs control; *, p < 
0.05 vs TNF-α or LPS; #, p < 0.01 vs LPS; @, p < 0.001 vs TNF-α 
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Figure 8  
 
Figure 8. Juglone inhibits LPS induced cytokine production in BV2 cells and primary 
microglia culture. BV2 cells were seeded in equal numbers on poly-d-lysine coated plates. 
The cells were treated with LPS (300ng/ml) for 24 h in the presence or absence of 3µM 
Juglone. After treatment, cytokine levels in the supernatant were quantified using the 
luminex immunoassay system. Levels of IL-6 (A), TNF-α (B) and IL-12 (C) in the 
supernatant. Primary microglia culture was initiated from C57BL/6 one day old pupand 
seeded in equal numbers on poly-d-lysine coated plates. The cells were then treated wilth 
LPS (100ng/ml) for 24 h in the presence or absence of 3µM Juglone. After treatment, 
cytokine levels in the supernatant were quantified using the luminex immunoassay system. 
Levels of IL-6 (D), TNF-α (E) and IL-12 (F) in the supernatant. Data represent the mean ± 
SEM of three different experiments.  ***, p < 0.001 vs. control; **, p < 0.01 vs. control; *, p 
< 0.05 vs. LPS. 
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Figure 9 
 
Figure 9. Increased expression of Pin1 in glial cells of MPTP-treated mice. C57BL/6 
mice were treated with 4 doses of MPTP (18mg/kg/dose) at 2 h interval via i.p. and 24 h after 
MPTP treatment mice were sacrificed. A. Double labeling of GFAP and Pin1 in substantia 
nigra (SN) region of brain. A single enlarged GFAP positive asatroglial cells expresses Pin1 
in the cytosol (inset). B. Double labeling of IBA-1 and Pin1 in SN region of brain. A single 
enlarged IBA-1 positive microglial cell expresses Pin1 in the cytosol (inset).  
 
 
 
160 
 
Figure 10   
 
Figure 10. Activation of p65 in nigrostriatum of MPTP-treated mice. Mice were treated 
with 4 doses of MPTP (18mg/kg/dose) at 2 h interval via i.p. and 24 h after MPTP treatment 
mice were sacrificed. A. Western blotting of p65 in substantia nigra. B. Western blotting of 
p65 in striatum. Mice receiving PBS as a control, MPTP (18mg/kg/dose) or MPTP and 
Juglone (3mg/kg/day) were sacrificed 24 h after the last dose of MPTP administration and 
ventral midbrain region was dissected out. C. The mRNA expression of TNF-α , IL-1β, IL-6 
and iNOS was analyzed by quantitative real-time PCR. Data represent the mean ± SEM of 
six mice per group.  **, p < 0.01 vs. control; ***, p < 0.001 vs. control; @, p < 0.05 vs 
MPTP; a < 0.01 vs MPTP. 
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Figure 11  
 
Figure 11. Juglone attenuates MPTP-induced iNOS expression in glial cells. Mice were 
treated with MPTP (18mg/kg/dose) at 2 h interval via i.p. in the presence or absence of 
Juglone (3mg/kg/day). 24 h after the last dose of MPTP injection mice were sacrificed and 
substantia nigra (SN) tissue sections were processed for immunostaining. A. Double labeling 
of GFAP and iNOS in SN. B. Double labeling of IBA-1 and iNOS in SN. Inset pictures 
demonstrated colocalization of GFAP/IBA-1 and iNOS. Images were captured at 20X and 
60X (insets) magnifications. 
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Abstract 
Parkinson’s disease (PD) is a devastating neurodegenerative disorder marked by 
progressive increases in motor deficits affecting several million people worldwide. Recent 
studies suggest that glial cell activation and its inflammatory response may contribute to the 
progressive degeneration of dopaminergic neurons in PD. Currently, there are no 
neuroprotective agents available that can slow down the disease progression. In the present 
study, we evaluated the antioxidant and anti-inflammatory efficacy of diapocynin, an 
oxidative metabolite of a naturally occurring agent apocynin, in a preclinical 1-methyl-
4phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD. First, oral administration of 
diapocynin (300 mg/kg/day) significantly attenuated MPTP-induced microglial and astroglial 
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cell activation in substantia nigra. Second, MPTP induced expression of gp91phox and iNOS 
activation in the substantia nigra were also attenuated by diapocynin. Diapocynin markedly 
inhibited MPTP-induced 3-nitrotyrosine production and 4-hydoxynonenol (diagnostic 
markers of oxidative and nitrative damage) in the substantia nigra. Treatment with 
diapocynin also significantly improved the locomotor activity, restored dopamine and its 
metabolites and protected the dopaminergic neurons in nigrostriatum in this preclinical 
model of PD. Finally, diapocynin administered 3 days after initiation of disease was able to 
restore the neurotransmitter levels. Collectively, these results demonstrate that diapocynin 
exhibits profound anti-inflammatory, antioxidant and neuroprotective effects in a well-
established animal model of PD. These findings have immediate translational relevance for 
treating PD patients. 
Introduction 
Parkinson’s disease (PD) is the most common neurodegenerative movement disorder 
estimated to affect 1% of population over 65 years of age. It is chronic and progressive in 
nature and is characterized predominantly by resting tremors, bradykinesia, muscular rigidity 
and postural instability along with several non-motor symptoms (Vila and Przedborski, 
2004). The pathological hallmarks of PD are the  depletion of striatal dopamine caused by 
degeneration of dopaminergic neurons in the substantia nigra (SN) region of midbrain, 
appearance of cytoplasmic inclusions known as Lewy bodies in surviving neurons of the SN, 
and activation of glial cells (Dauer and Przedborski, 2003; Ghosh et al., 2009).  
 Although the etiologic mechanisms of PD are poorly understood, recent reports 
implicate brain inflammation and oxidative stress in disease pathogenesis (Dauer and 
Przedborski, 2003; Gao et al., 2003a). Microglia and astrocytes are major mediators of 
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neuroinflammation in PD. Several reports demonstrated the activation of microglial cells and 
astroglial cells in close proximity to the damaged or dying dopaminergic neurons in 
substantia nigra (McGeer et al., 1988). The levels of nitrite (NO2), a metabolite of NO. and 
inducible nitric oxide synthase (iNOS) are higher in the central nervous system (CNS) of 
human PD cases and in  animal models of PD (Hunot et al., 1996). Consistent with this 
finding, iNOS knockout animals were  resistant to 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) -induced dopaminergic neuronal loss in the substantia nigra 
(Dehmer et al., 2000). One of the major sources of reactive oxygen species (ROS) in 
neurodegeneration is NADPH oxidase, a multimeric enzyme that generates both O
2-
 and 
H2O2 (Bokoch and Knaus, 2003). Reaction between superoxide (O
2-
) and NO forms a more 
potent species peroxynitrite (ONOO
-
), another key player in dopaminergic neurodegeneration 
in PD. Moreover, 4-hydroxynonenol (4-HNE), an unsaturated aldehyde derived from lipid 
hydroperoxidase is reported to mediate the induction of neuronal apoptosis in the presence of 
oxidative stress (Awasthi et al., 2008). Proinflammatory cytokines (TNF-α, IL-1β, IFN-γ, IL-
6), chemokines and prostaglandins levels are also elevated in PD brains (Nagatsu et al., 
2000). Recent reports suggest that nuclear factor-κB (NF-κB), a transcription factor that is 
required for transcription of proinflammatory molecules is also activated in the substantia 
nigra of PD patients and MPTP-treated mice (Ghosh et al., 2007). Additionally, Nurr1, a 
nuclear orphan receptor suppresses glial activation by docking to NF-κB-p65 on target 
inflammatory gene promoters and protects against dopaminergic neurodegeneration in 
substantia nigra (Saijo et al., 2009). These findings strongly suggest that mitigation of 
neuroinflammation and oxidative stress may be a viable neuroprotective strategy for 
treatment of PD. 
165 
 
 Several inhibitors of NADPH oxidase have previously been tested for their anti-
inflammatory and antioxidant effects in dopaminergic cells (Anantharam et al., 2007). For 
example, apocynin (4-hydroxy-3-methoxyacetophenone), a plant derived antioxidant, has 
been widely used as an NADPH oxidase inhibitor in in vitro and in vivo experimental models 
of PD (Lafeber et al., 1999; Zhang et al., 2005; Anantharam et al., 2007). High 
concentrations of apocynin have been shown to protect against neuronal damage in SODl 
mutant ALS mice model (Lin et al., 2006). However, apocynin failed to protect the 
dopaminergic neurons against rotenone-mediated neurotoxicity in the absence of glial cells 
(Gao et al., 2003a). Other studies have shown mixed results with regard to apocynin 
(Vejrazka et al., 2005). In vivo, apocynin has been shown to form diapocynin, a dimer of 
apocynin, resulting in the inhibition of NADPH oxidase. In the present study, we used 
diapocynin, a dimeric derivative of apocynin and investigated its antioxidant and anti-
inflammatory roles in mouse model of PD. Results show that diapocynin suppresses MPTP 
induced glial activation, attenuates nigral expression of proinflammatory molecules, reduces 
oxidative stress and exhibits significant protection of the nigrostriatal axis after MPTP 
administration. Additionally, diapocynin also slows down the progression of the disease in 
MPTP model. Collectively, these results suggest that additional preclinical development of 
diapocynin may yield an effective neuroprotective and anti-neuroinflammatory drug capable 
of arresting the progression of PD.  
Materials and methods: 
Animals and treatment. Eight-week-old male C57BL/6 mice weighing 24 to 28 g were 
housed in standard conditions: constant temperature (22 ± 1°C), humidity (relative, 30%), 
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and a 12-h light/dark cycle. Use of the animals and protocol procedures were approved and 
supervised by the Committee on Animal Care at Iowa State University (Ames, IA). Mice 
received diapocynin (300mg/kg/day) in 10% ethanol by oral gavage either 1 day before or 
after 3 days of the MPTP insult. For MPTP treatment, mice received 25mg/kg/day MPTP-
HCl in saline intraperitoneally for consecutive 5 days. Control mice received equivolume 
injection of saline. 
HPLC analysis of striatal dopamine and its metabolites levels. Samples were prepared 
and quantified as described previously (Ghosh et al.,2010 ; Zhang et al., 2007). In brief, 7 
days after MPTP injection mice were sacrificed and striata were collected and stored at -80C. 
On the day of analysis, neurotransmitters from striatal tissues were extracted using an 
antioxidant extraction solution (0.1 M perchloric acid containing 0.05% Na2EDTA and 0.1% 
Na2S2O5) and isoproterenol (as internal standard).  DA, DOPAC and HVA were separated 
isocratically by a reversed-phase column with a flow rate of 0.6 ml/min. An HPLC system 
(ESA Inc., Bedford, MA) with an automatic sampler equipped with refrigerated temperature 
control (model 542; ESA Inc.) was used for these experiments. The electrochemical detection 
system consisted of a Coulochem model 5100A with a microanalysis cell (model 5014A) and 
a guard cell (model 5020) (ESA Inc.).  The data acquisition and analysis were performed 
using the EZStart HPLC Software (ESA Inc.).  
HPLC/MS analysis of Diapocynin. Amount of diapocynin from Striatum and substantia 
nigra was quantified using the Agilent 1100 series LCMS binary pump, PDA detector (UV 
diode array detector) and an auto sampler.. On the day of analysis, 20µL sample was passed 
through the 0.2µm filter at the eluent flow rate of 0.25 ml/min.  Negative-ion, atmospheric 
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pressure chemical ionization was used at amplitude 1.5Volts and Manual MS/MS was done.    
The mobile phase used in LC-MS consisted of a gradient elution. Solvent A was 480: 20: 
0.38 water: methanol: ammonium acetate (v/ v/ w) and solvent B was 20: 480: 0.38 water: 
methanol: ammonium acetate (v/ v/ w).  The standards series were taken as 0.3µg, 1.0µg, 
3.0µg, 10 µg, 30 µg.  The actual molecular wt of diapocynin is 329.1 but by breaking the 
molecule in MS/MS it becomes 313.9 g/mol by elimination of one methyl molecule.  The 
retention time for diapocynin peak was 1.9 min.  Data were fit to a straight line by linear 
regression analysis using Quant analysis software. 
Western blotting. Mice were sacrificed 4 days or 7 days after MPTP treatment and 
substantia nigra tissue was dissected out.  Brain lysates containing equal amounts of protein 
were loaded in each lane and separated in a 10 to 15% SDS-polyacrylamidegel 
electrophoresis gel as described previously (Jin et al., 2011 ; Zhang et al., 2007).Proteins 
were transferred to a nitrocellulose membrane and nonspecific binding sites were blocked by 
treating with Licor odyssey blocking buffer. The membranes were then incubated with 
different primary antibodies such as anti-TH (Chemicon), anti-IBA-1 (Abcam), anti-GFAP 
(Chemicon), anti-iNOS (Santa Cruz), anti-gp91phox (Abcam), anti-3NT (Chemicon) and 
anti-4HNE (R&D). Next, membranes were incubated with Alexa Fluor 680 goat anti-mouse 
or Alexa Fluor 680 donkey anti-goat (Invitrogen) or IR dye 800 donkey anti-rabbit 
(Rockland) secondary antibodies. To confirm equal protein loading, blots were reprobed with 
a β-actin antibody (Sigma; 1:10000 dilution). Western blot images were captured with a 
Licor Odyssey machine (Licor, NE). The western blot bands were quantified using NIH 
Image J software.   
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Immunohistochemistry.  One day after last MPTP treatment, mice were perfused with 4% 
paraformaldehyde and post fixed with PFA and 30% sucrose respectively. Next, fixed brains 
were cut into 30µ sections and were incubated with different primary antibodies such as anti-
IBA-1antibody (Abcam), anti-GFAP (Chemicon), anti-iNOS (Santa Cruz), anti-3NT 
(Chemicon), anti-gp91phox (Abcam) and anti-4HNE (R & D) for overnight at 4C.  
Appropriate secondary antibodies (Alexa Fluor 488 or 594 or 555 from Invitrogen) were 
used followed by incubation with 10µg/ml Hoechst 33342 for 5 min at room temperature to 
stain the nucleus.  Sections were viewed under a Nikon inverted fluorescence microscope 
(model TE-2000U; Nikon, Tokyo, Japan); images were captured with a SPOT digital camera 
(Diagnostic Instruments, Inc., Sterlings Heights, MI). 
Fluoro-Jade B and TH double labeling.  On the day of staining, sections were incubated 
with anti-TH antibody (Chemicon) followed by Alexa Fluor 568 donkey anti-mouse 
(Invitrogen) secondary antibody.  Then Fluoro-Jade B staining was done on the same 
sections by modified FJB stain protocol including incubation in 0.06% potassium 
permanganate for 2 min and 0.0002% FJB stain for 5 min.  Sections were viewed under a 
Nikon inverted fluorescence microscope (model TE-2000U; Nikon, Tokyo, Japan); images 
were captured with a SPOT digital camera (Diagnostic Instruments, Inc., Sterlings Heights, 
MI). 
DAB immunostaining and stereological counting.  DAB immunostaining was performed 
in striatal and substantia nigral sections as described previously (Ghosh et al., ; Ghosh et al., 
2009).  In brief,  30 µm sections were incubsated with either anti-TH antibody (Calbiochem, 
rabbit anti-mouse, 1:1800) or anti-IBA-1(Abcam, goat anti-mouse, 1:1000) or anti-GFAP 
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(Chemicon, mouse anti-mouse, 1:1000) antibody for overnight at 4C.  Next, sections were 
incubated in biotinylated anti- rabbit or goat or mouse secondary antibody followed by 
incubation with avidin peroxidase (Vectastatin ABC Elite kit, Vector laboratories)   
Immunolabeling was observed using diaminobenzidine (DAB), which yielded a brown stain.  
Total numbers of TH positive neurons in SN were counted stereologically with Stereo 
Investigator software (MBF Bioscience, Williston, VT, USA), using an optical fractionators 
(Ghosh et al., 2010 ; Ghosh et al., 2007).   
Behavioral measurements.  An automated device (AccuScan, model RXYZCM-16, 
Columbus, OH) was used to measure the spontaneous activity of mice.  The activity chamber 
was 40×40×30.5 cm, made of clear Plexiglas and covered with a Plexiglas lid with holes for 
ventilation.  Data were collected and analyzed by a VersaMax Analyzer (AccuScan, model 
CDA-8, Columbus, OH).  Before any treatment, mice were placed inside the infrared monitor 
for 10 min daily and 5 min daily for 3 consecutive days to train them.  After 5 days of last 
MPTP injection, openfield and rotarod experiments were conducted.  Locomotor activities 
were presented for 10 min test secession.  For rotarod experiment 20 rpm speed was used.  
Mice were given a 5-7 min rest interval to eliminate stress and fatigue.    
Data analysis.  Data analysis was performed using Prism 4.0 software (GraphPad Software 
Inc., San Diego, CA).  Raw data were first analyzed using one-way analysis of variance and 
then Tukey’s post-test was performed to compare all treatment groups.  Differences with p < 
0.05 were considered significant.     
Results 
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Diapocynin inhibits the glial activation in the substantia nigra of MPTP-induced mouse 
model of PD.  
The treatment schedule of mice with diapocynin is shown in Fig. 1A.  We first 
determined whether diapocynin crosses the blood brain barrier.  The LC-MS results show 
substantial accumulation of diapocynin in substantia nigra (SN) and striatum (ST) of brain 
after 13 days of oral gavage treatment of diapocynin (300mg/kg/day) (SI Fig. 7).  Then we 
determined if diapocynin protected against MPTP-induced microglial activation and 
astrogliosis.  MPTP treatment induced increased expression of IBA-1 positive microglial 
cells (Fig. 1B-D) and GFAP positive astrocytes (Fig. 1E-G) in SN of MPTP treated mice.  In 
addition to that, DAB immunostaining of IBA-1 showed increased number of amoeboid 
shaped microglial cells with thick processes, characterization of microgliosis, and DAB 
immunostaining of GFAP showed bigger cell bodies of astroglial cells with increased and 
thick processes, characterization of astrogliosis (Fig. 1B and E).  Next, we investigated 
whether diapocynin could attenuate MPTP-induced glial activation in mice SN.  As shown 
by DAB immunostaining experiment, diapocynin strongly inhibited MPTP induced 
microgliosis, as the IBA-1 positive microglial cells were very few in number, with smaller 
cell bodies and thin processes (Fig. 1B).  Diapocynin significantly decreased MPTP-induced 
increases in GFAP positive astroglial cells in the mouse SN (Fig. 1E).  Western blot analysis 
for IBA-1 and GFAP also shows that diapocynin suppressed nigral IBA-1 (Fig. 1C and D) 
and GFAP (Fig. 1F and G) protein expression in MPTP-treated mice.  These results suggest 
that diapocynin significantly attenuates MPTP-induced increases in glial cell population in 
the mouse SN.  
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Diapocynin inhibits MPTP-induced increases in iNOS expression in mouse SN.   
Previous reports have demonstrated the role of inflammation in the dopaminergic 
neurodegeneration in PD and its animal models (Hunot et al., 1996; Ghosh et al., 2007).  
Inducible nitric oxide synthase (iNOS), an important proinflammatory molecule, is typically 
elevated in disease conditions (Ghosh et al., 2009).  We observed a marked increase in the 
expression of iNOS in SN of MPTP-treated mice versus saline-treated control mice (Fig. 2A 
and B).  However, diapocynin attenuated MPTP induced expression of iNOS protein (Fig. 
2A and B).  Additionally, immunofluorescence analysis for iNOS in the SN sections shows 
that MPTP treatment led to marked increase in nigral iNOS protein expression and that iNOS 
colocalized with GFAP positive astrocytes and IBA-1 positive microglial cells (Fig. 2C and 
D).  However, consistent with their inhibitory effect on the activation of glial cells, 
diapocynin suppressed MPTP induced expression of iNOS (Fig. 2C and D).  These results 
demonstrate that diapocynin effectively suppresses the expression of proinflammatory 
molecule iNOS in vivo in the SN of MPTP treated mice.   
Diapocynin attenuates MPTP-induced activation of microglial NADPH oxidase.   
NADPH oxidase is the major source of reactive oxygen species (ROS) and recent 
findings suggested that NADPH oxidase-induced oxidative stress played a pivotal role in 
nigral dopaminergic neurodegeneration in PD and its animal models (Wu et al., 2003).  The 
western blot analysis showed an increased expression of gp91phox, a membrane bound 
subunit of NADPH oxidase after MPTP injection (Fig 3A-B) compared to weak expression 
in saline treated mice (Fig. 3A-C).  Robust gp91phox immunoreactivity was seen specifically 
in larger cells with thick, shorter ramifications in the SN of MPTP treated mice (Fig. 3C).  
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Double immunolabeling studies confirmed that gp91phox immunoreactivity appeared to 
colocalize with IBA-1 positive microglia (Fig. 3C, middle panel).  In MPTP model of PD, 
gp91phox does not colocalize either with astrocytes or dopaminergic neurons (Wu et al., 
2003).  Diapocynin treatment attenuated MPTP induced gp91phox protein expression in the 
IBA-1 positive microglial cells in the SN (Fig. 3A-C).  These results suggest that diapocynin 
effectively blocks the MPTP-induced microglial NADPH oxidase.  
Diapocynin inhibits formation of peroxynitrite and 4-hydroxynonenol (4-HNE) in the 
nigral dopaminergic neurons of MPTP treated mice.   
3-NT has been widely used as a marker of nitric oxide-dependent oxidative stress 
(Ara et al., 1998).  The western blot analysis demonstrates increased expression of 3-NT 
protein in the SN of MPTP treated mice that were markedly decreased following diapocynin 
treatment (Fig 4A and B).  Further confirmation came from immunolabeling of 3-NT in the 
SN sections.  In the MPTP treated sections, we observed increased expression of 3-NT 
particularly in the SN region of ventral midbrain and that 3-NT colocalized (yellow color) 
with tyrosine hydroxylase (TH) positive dopaminergic neurons (Fig. 4C).  However, 3-NT 
expression was observed in very few TH positive dopaminergic neurons in the MPTP- 
treated mice that also received diapocynin (Fig. 4C).  These results strongly suggest that 
diapocynin inhibits peroxynitrite (ONOO-) formation induced by MPTP in dopaminergic 
neurons in the SN.  Along with peroxynitrite, 4-HNE formation was also increased (Fig. 4D 
and E).  MPTP treatment led to marked increase in protein expression of 4-HNE in the SN.  
However, diapocynin strongly inhibited MPTP induced expression of this unsaturated 
aldehyde in the SN (Fig. 4D and E).  Consistent with these findings, immunofluorescence 
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analysis of the SN sections (Fig. 4F) showed that level of expression of 4-HNE was much 
higher in the MPTP treated SN sections than saline treated control sections and that 4-HNE 
colocalized with TH-positive dopaminergic neurons. However, treatment of MPTP treated 
mice with diapocynin led to the attenuation of 4-HNE in the dopaminergic neurons (Fig. 4F).  
These results suggest that diapocynin mitigates oxidative stress in nigral dopaminergic 
neurons of MPTP-intoxicated mice.   
Diapocynin improves locomotor activities in MPTP-injected mice.   
To assess the effectiveness of diapocynin against motor deficits induced by MPTP, 
we measured the locomotor and open field activities.  We used VersaMax infrared 
computerized activity monitoring system (Accuscan, OH) and a rotarod instrument 
(Accuscan, OH) for measurement of locomotor activities and motor coordination, 
respectively.  Animals were subjected to behavioral measurements 4 days after the last does 
of MPTP treatment (Fig. 1A).  Representative motor activity maps of movement of saline 
treated control, MPTP and MPTP plus diapocynin treated mice are shown in Fig 5A.  As 
observed in the VersaPlot (Fig 5A), we found decreased movement of MPTP treated mice 
and improvement of locomotion in MPTP plus diapocynin treated group.  Subacute MPTP 
treatment resulted in marked decrease in horizontal activity (Fig. 5B), vertical activity (Fig. 
5C), total distance travelled (Fig. 5D), movement time (Fig. 5E), number of stereotypy (Fig. 
5G), number of rearing (Fig. 5H) and rotarod performances at 20 rpm speed (Fig. 5I) 
consistent with our previous observations (20).  Additionally, rest time was increased in the 
MPTP treated mice (Fig. 5F).  Again, diapocynin significantly restored MPTP induced 
locomotor and motor co-ordination impairments (Fig 5B-I).  In addition to that, we found 
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significant restoration of behavioral imparities with diapocynin treatment in a transgenic 
LRRK2 mice model of PD (Data not shown). 
Diapocynin protects against MPTP-induced neurodegeneration.   
Seven days after MPTP treatment, mice were sacrificed and brains were processed for 
tyrosine hydroxylase (TH) immunostaining, western blotting and HPLC neurochemical 
analysis (Fig. 6A-H).  As observed earlier (Ghosh et al., 2010), MPTP treatment led to 
degeneration of TH positive dopaminergic neurons and its terminals in the SN and the 
striatum (ST) (Fig. 6A, 2X magnification).  Higher magnified 10X pictures (Fig. SI 8A) 
clearly demonstrated loss of neurons in substantia nigra pars compacta (SNpc), substantia 
nigra lateralis (SNl) and substantia nigra reticularis (SNr) regions of nigral tract.  
Additionally, stereological counting of TH positive neurons in SN of MPTP treated mice also 
showed > 60% reduction (Fig. 6E).  However, in MPTP treated mice that also received 
diapocynin, nigral TH positive neurons and striatal TH terminals were restored to near 
control levels (Fig. 6A & E and Fig. SI 8A).  Consistent with these findings, western blot of 
TH in nigra and striatum also showed significant decrease of TH protein levels in MPTP 
treated mice (Fig. 6B-D).  However, orally administered diapocynin significantly restored the 
nigral and striatal TH protein levels in MPTP treated mice (Fig. 6B-D).  To further confirm 
that diapocynin protects against MPTP-induced dopaminergic neurodegeneration, we 
performed Fluoro-Jade B (FJB) staining in nigral dopaminergic neurons.  FJB effectively 
stains the degenerating neurons and it is also used as a marker of neuronal damage 
(Kanthasamy et al., 1999).  As anticipated, we detected a decreased number of TH positive 
neurons in the MPTP treated sections.  However, FJB positive cells were increased in the 
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MPTP treated sections, suggesting neurodegeneration in the SN (Fig. SI 8B).  Additionally, 
we also observed some TH positive cells that showed FJB staining, indicating dying 
dopaminergic neurons.  However, MPTP-treated mice that also received diapocynin 
demonstrated fewer FJB positive cells, suggesting survival of neurons. 
Next we determined whether diapocynin protects against biochemical deficits caused 
by MPTP, we quantified levels of dopamine (DA) and its metabolites, dihydroxyphenyl-
acetic acid (DOPAC) and homovanillic acid (HVA) in striata 7 days after MPTP treatment.  
As shown in Fig. 6F, MPTP injection led to a >75% reduction of the striatal DA levels 
compared with the striata of saline injected control mice.  Interestingly, MPTP plus 
diapocynin treated mice showed only <40% decrease of the striatal dopamine levels (Fig. 
6F).  Diapocynin treatment also restored DOPAC and HVA levels significantly in MPTP 
treated mice (Fig. 6G &H).  Next, to address whether diapocynin at a dose of 300mg/kg/day 
is toxic to mice, we treated mice with only diapocynin for 12 days and checked locomotor 
activities and striatal neurotransmitter levels.  Diapocynin did not have any effect on 
behavioral (data not shown) or striatal dopamine content (Fig. 6F-H).  In order to determine 
whether diapocynin interferes with the toxic metabolic conversion of MPTP to MPP
+
 by 
MAO-B, we measured the level of MPP
+
 in striatum 3 h after the final MPTP injection. We 
found that diapocynin had no effect on striatal levels of MPP
+
 (MPTP mice, 1860 ± 569 
ng/g; MPTP plus diapocynin mice, 1775 ± 586 ng/g). Together, these results suggest that 
diapocynin is neuroprotective in MPTP mouse model of PD.  
Post treated diapocynin rescues striatal neurotransmitter depletion in MPTP treated 
mice.   
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Normally after the diagnosis of the disease, patients are treated with drugs.  We also 
speculated whether diapocynin post-treatment could protect against the MPTP-induced 
dopaminergic toxicity.  Mice were treated with MPTP at a dose of 25mg/kg/day for 3 days 
followed by co-treatment of MPTP and diapocynin (300mg/kg/day) for 2 days.  Mice also 
received another 6 doses of diapocynin (300mg/kg/day) and on 7
th
 day mice were sacrificed 
for neurotransmitter analysis.  As evident from Fig. SI 9, we observed significant reduction 
of striatal DA (~75%), DOPAC (~73%) and HVA (~70%) in MPTP treated mice.  However, 
in MPTP treated mice that also received diapocynin 3 days after initiation of the disease, 
showed a reduction of ~52% of DA (Fig. SI 9A), ~50% of DOPAC (Fig. SI 9B) and ~40% of 
HVA (Fig. SI 9C).  Thus diapocynin is capable of slowing down the progression of 
dopaminergic neurodegeneration in the MPTP mouse model of PD.  
Discussion: 
Growing evidence suggests the important role of neuroinflammation and oxidative 
stress in the progressive loss of nigral dopaminergic neurons in PD.  However, no effective 
therapy is available to halt the progression of the disease.  Therefore, synthesizing a novel 
compound with anti-inflammatory and anti-oxidative properties and testing its efficacy in a 
preclinical animal model of PD is essential prior to testing in humans. NADPH oxidase has 
emerged as a major source of oxidative stress in the brain, particularly in neurodegenerative 
disorders such as PD, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), and multiple 
sclerosis (Bedard and Krause, 2007).  Apocynin is an efficient inhibitor of NADPH oxidase 
that generates reactive oxygen species (ROS) during the inflammatory processes 
(Anantharam et al., 2007).  Although the mechanism of inhibition of apocynin is not clear, it 
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is thought to prevent the recruitment of cytosolic NADPH oxidase subunit p47phox to the 
membrane, thereby, inhibiting NADPH oxidase activity.  Apocynin has been shown to 
attenuate superoxide formation and oxidative stress in vivo along with reduction of acute 
inflammation in lung and spinal cord (Impellizzeri et al.,2011 ; Impellizzeri et al., 2010; 
Hougee et al., 2006).  In addition to that, apocynin administered at a dose of 300mg/kg/day 
protects against oxidative damage induced by cerebral ischemia (Wang et al., 2006) and ALS 
(Harraz et al., 2008).  In vitro studies in dopaminergic neuronal cell lines and primary 
cultures also demonstrated protective role of apocynin in 1-methyl-4phenyl-pyridinium ion 
(MPP
+
) or MPTP induced NADPH oxidase mediated apoptotic cell death (Gao et al., 2003b; 
Anantharam et al., 2007).  In contrast to anti-oxidative role of apocynin, pro-oxidative nature 
of apocynin has been shown in non-phagocytic cells, where it increases ROS production 
significantly (Vejrazka et al., 2005).  Apocynin also failed to show any improvement in 
transgenic mouse model of AD (Dumont et al., 2011) or ALS (Trumbull KA et al., 2012). 
Thus, these studies suggest that the development of an improved apocynin related compound 
may yield a better neuroprotective agent for treatment of PD.   
In this study, we chemically synthesized and delineated the functions of diapocynin, a 
metabolite of apocynin with potential anti-oxidative and anti-inflammatory properties.  
Recent studies have shown  conversion of apocynin  to diapocynin (apocynin dimer) in vivo 
which prevents the assembly and activation of NADPH oxidase complex (Johnson et al., 
2002).  Additionally, diapocynin is 13-fold  more lipophilic than apocynin (Luchtefeld et al., 
2008).  Here, we show that diapocynin inhibits MPTP-induced activation and expression of 
both iNOS and gp91phox in activated microglia, suggesting that diapocynin is anti-
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inflammatory.  Diapocynin also attenuates the formation of ONOO- and 4-HNE in 
dopaminergic neurons in response to various stimuli, suggesting its antioxidant properties.  In 
addition, diapocynin also protects against MPTP-induced motor deficits, striatal 
neurotransmitter depletion and nigrostriatal degeneration.  To our knowledge, this is the first 
report showing anti-inflammatory, anti-oxidative stress and neuroprotective role of a novel 
apocynin derivative in MPTP animal model of Parkinson’s disease.   
In the central nervous system, glial activation involving astrocytes, microglial cells, 
lymphocye infiltration, production of proinflammatory mediators, including cytokines, 
chemokines, prostaglandins, reactive mediators such as RNS and ROS are all hallmarks of 
inflammatory reactions.   Active metabolite of MPTP, MPP
+
 is believed  to be responsible 
for glial activation mediated inflammation and neurodegeneration (Dauer and Przedborski, 
2003).  In our study, we also observed marked activation of microglia and astrocytes by 
western blotting and immunohistochemistry after MPTP treatment in substantia nigra and 
diapocynin significantly attenuated MPTP induced microgliosis and astrogliosis (Fig. 1B-G).  
Nuclear factor kappa B (NF-κB), a transcription factor has been shown to be an important 
regulator of the microglial and astroglial proinflammatory reactions in the SN.  The promoter 
regions of proinflammatory molecules including inducible nitric oxide synthase (iNOS) 
contain the  binding sites for NF-ĸB (Ghosh et al., 2007).  Astroglia and microglia in the 
healthy brain do not express iNOS but following toxic, or inflammatory damage, reactive 
astroglia and microglia express iNOS in the brain (Galea et al., 1992).  Nitric oxide (NO) 
generated by iNOS and derived from activated glial cells is believed to contribute to 
neurodegenerative diseases such as AD, PD,  HIV associated dementia, HD and ALS (Galea 
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et al., 1992; Ghosh et al., 2009).  Studies have shown that MPTP treatment produces 
significantly reduced neuronal loss in mice deficient in iNOS compared to their wild type 
counterparts (Liberatore et al., 1999).  In this study we demonstrate that diapocynin, 
pharmacological inhibitor of microglial NADPH oxidase effectively attenuates MPTP-
induced increases in iNOS expression (Fig. 2) suggesting the potential use of diapocynin as 
an anti-inflammatory agent.   
Along with reactive nitrogen species (RNS), reactive oxygen species (ROS) also 
plays a pivotal role in oxidative stress and inflammation in PD.  NADPH oxidase is the major 
ROS producing enzyme of microglial cells in response to various inflammatory and 
degenerative stimuli.  NADPH oxidase is a multimeric protein composed of two membrane-
bound subunits, gp91phox and p22phox, three cytosolic subunits, p47phox, p40phox, 
p67phox and a small GTPase rac2.  It generates superoxide (O2
-
) from molecular oxygen.  
During its activation, its cytosolic subunits translocate to membrane and form the functional 
enzyme to generate (O2
-
) (Bokoch and Knaus, 2003).  Neurons located very close to activated 
microglial cells may thus have their cell membrane proteins and lipids vulnerable to NADPH 
oxidase mediated superoxide and other oxidants such as hydrogen peroxide (H2O2).  
Additionally, NADPH oxidase not only mediates superoxide production, but also controls the 
levels of other pro-inflammatory neurotoxic factors such as TNFα and IL-1β (Qin et al., 
2004).  In our study, we demonstrate that diapocynin attenuated MPTP induced expression of 
microglial gp91phox in substantia nigra and thereby reduced the production of reactive 
oxygen species (Fig. 3).    
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Besides having direct toxic effect on nigral dopaminergic neurons, nitric oxide (NO) 
and superoxide (O2
-
) derived from astrocytes and microglia can react to form highly reactive 
nitrogen species peroxynitrite (ONOO
-
).  Peroxynitrite causes nitration of tyrosine residues in 
various proteins including  tyrosine hydroxylase (TH) and α-synuclein (Ara et al., 1998; 
Blanchard-Fillion et al., 2001).  Peroxinitrite mediated nitration of TH is associated with 
reduced enzymatic activity.  3-nitrotyrosine (3-NT) is widely used as a marker of 
peroxynitrite in cells.  Here, we found increased expression of 3-NT in dopaminergic neurons 
in SN of MPTP treated mice and was found to be  predominantly  co-localized with TH 
positive dopaminergic neurons (Fig. 4A-C).  However, diapocynin significantly decreased 
MPTP-induced increased amount of 3-NT in dopaminergic neurons in the SN.  Along with 
peroxynitrite,  levels of 4-hydroxynonenol (4-HNE), an unsaturated aldehyde generated 
during lipid peroxidation was also significantly increased in the SN of PD brains compared to 
control (Yoritaka et al., 1996).  The 4-HNE has been demonstrated to block mitochondria 
respiration and induce caspase dependent apoptosis (Picklo et al., 1999; Liu et al., 2000).  In 
our study, we showed increased expression of 4-HNE, a marker of oxidative damage in the 
SN of MPTP-treated mice and it was colocalized in the cytosol of TH positive dopaminergic 
neurons (Fig 4D-F).  Whereas, diapocynin significantly decreased the amount of 4-HNE in 
the MPTP-treated SN, indicating that diapocynin acted by attenuating primary production of 
superoxide (OH
.
).   
At present, no useful therapy of PD is available.  Administration of a dopamine 
agonist or levodopa has been the widely used treatment for PD symptoms, but does not affect 
the disease pathogenesis.  Dopaminergic neuroprotection in animal models of PD have been 
181 
 
demonstrated with various substances including glial cell line derived neurotrophic factor 
(GDNF), brain derived neurotrophic factor (BDNF), TGF-β (Date et al., 1993; Kordower et 
al., 2000).  Additionally, various anti-inflammatory agents such as NSAIDs, COX inhibitors, 
statins, pioglitazone, minocycline have been used in different animal models of PD (Chen et 
al., 2003; Teismann et al., 2003; Ghosh et al., 2009; Kim and Suh, 2009).  However, most of 
these compounds failed in either preclinical trials or in human phase I trials due to their 
ineffectiveness to cross the blood-brain barrier or due to limited bioavailability.  Moreover, 
they also cause side effects and toxicity to the animals.  Hence, understanding the mechanism 
of the disease process and development of successful neuroprotective therapeutic approach to 
halt the disease progression are of principal importance in the PD research field.  MPTP  
causes glial activation and inflammation within 48h of its administration and initiates a self-
perpetuating dopaminergic neurodegenerative process beginning 72h (Ghosh et al., 2009).   
In this study, we demonstrate diapocynin inhibits the glial cells mediated production of 
proinflammatory molecules, oxidative stress and protects against MPTP-induced 
dopaminergic degeneration in animal models of PD.  Our conclusion is based on the 
following: (1) MPTP intoxication led to the stimulation of activation of various 
proinflammatory molecules within the activated glial cells in the nigra of MPTP-intoxicated 
mice.  However, cotreatment with diapocynin resulted in attenuation of expression of 
proinflammatory molecules.  (2) diapocynin was capable of suppressing oxidative stress in 
vivo in the SN of MPTP-treated mice.  (3) cotreatment with diapocynin improved MPTP 
induced behavioral imparities.  (4) diapocynin protected TH-positive dopaminergic neurons 
from MPTP toxicity and restored the level of dopamine and its metabolites.  (5) oral 
administration of  diapocynin on day 4, after the disease has been initiated by MPTP also 
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restored the levels of striatal dopamine neurotransmitters in MPTP treated mice, suggesting 
that diapocynin could attenuate disease progression.  There are several advantages of 
diapocynin compared to existing anti-PD therapies including its parent compound apocynin.  
First, diapocynin is fairly nontoxic, mice treated with diapocynin alone (300mg/kg/day) for 
12 days didn’t show any sign of behavioral imparities (data not shown), as well as their 
neurotransmitter levels were as per with saline treated control mice (Fig. 6F-H).  Second, 
diapocynin can be administered by gavage-orally, the least painful route.  Here we have 
shown that oral administration of diapocynin protects the nigrostriatum in subacute MPTP 
models of PD.  Third, being a lipophilic molecule, diapocynin easily crosses the blood-brain 
barrier and enters into substantia nigra (> 1.5µg/mg tissue) and striatum (> 0.9µg/mg tissue) 
regions of brain as detected by LC-MS/MS (Fig. SI 7).  
 In summary, we have demonstrated that diapocynin (a metabolite of apocynin) 
attenuates nigral activation of microglial and astroglial cells, inhibits proinflammatory 
molecule (iNOS) and production of NADPH oxidase mediated superoxide formation, 
decreases oxidative stress, improves behavioral functions and protects nigrostriatum in 
MPTP-treated mice.  Together, these results strongly suggest that diapocynin may be used as 
an effective anti-inflammatory, anti-oxidative stress and neuroprotective agent in therapeutic 
intervention of PD.   
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Figure 1  
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Figure 1. Diapocynin inhibits activation of microglia and astrocytes in substantia nigra 
(SN) of MPTP treated mice.  (A)  Treatment schedule of MPTP-injected mice with 
diapocynin.  Mice were administered diapocynin (300mg/kg/day) by oral gavage 24 h before 
MPTP treatment and continued for 4 -5 days of co-treatment with 25mg/kg/day MPTP 
administered via i.p. Control mice received 10% ethanol in saline.  Twenty-four h to 7days 
after the last dose of MPTP, mice were sacrificed.  (B) Representative western blots 
illustrating the expression of IBA-1(marker of microglia) in SN.  (C) Bar graph showing 
means Western blot IBA-1/β-actin ratios ± SEM in SN of 6 mice per group.  (D) DAB 
immunostaining of IBA-1 in SN.  (E) Representative western blots illustrating the expression 
of GFAP (marker of astrocytes) in SN.  (F) Bar graph showing mean Western blot GFAP/β-
actin ratios ± SEM in SN of 6 mice per group.  (G) DAB immunostaining of GFAP in SN 
region of ventral midbrain. Images were captured at 30X magnification. **, p < 0.01 vs. the 
control group; *, p < 0.05 vs. the MPTP group.  
 
 
 
 
 
 
 
 
 
 
192 
 
Figure 2  
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Figure 2. Diapocynin attenuates iNOS expression in substantia nigra (SN) of MPTP 
treated mice.  Mice were administered diapocynin (300mg/kg/day) by oral gavage 24 h 
before MPTP treatment and continued for 4 days of co-treatment with MPTP at a dose of 
25mg/kg/day.  Control mice received 10% ethanol in saline.  Twenty-four h after the last 
dose of MPTP, mice were sacrificed.  (A) Representative western blots illustrating the 
expression of iNOS in SN. (B) Bar graph showing means Western blot iNOS/β-actin ratios ± 
SEM in SN of 6 mice per group.  (C) Double labeling of GFAP and iNOS and (D) IBA-1 and 
iNOS in SN region of ventral midbrain.  Images were captured at 30X magnification. ***, p 
< 0.001 vs. the control group; *, p < 0.05 vs. the MPTP group.  
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Figure 3 
 
Figure 3. Diapocynin attenuates NADPH oxidase mediated inflammatory responses in 
SN of MPTP-treated mice.  Mice were administered diapocynin (300mg/kg/day) by oral 
gavage 24 h prior MPTP treatment and continued for 4 days of co-treatment with 
25mg/kg/day MPTP.  Control mice received 10% ethanol in saline.  Twenty-four h after the 
last dose of MPTP, mice were sacrificed.  (A) Representative western blots illustrating the 
expression of gp91phox (membrane bound subunit of NADPH oxidase) in SN.  (B) Bar 
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graph showing means Western blot gp91phox/β-actin ratios ± SEM in SN of 6 mice per 
group.  (C) Substantia nigra tissue sections were double labeled for gp91phox and IBA-1.  
Images were captured at 20X and 60X (inserts) magnification.  The substantia nigra zone is 
outlined in white dots.  Inset pictures demonstrated colocalization of IBA-1 and gp91phox. 
***, p < 0.001 vs. the control group; *, p < 0.05 vs. the MPTP group.  
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Figure 4  
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Figure 4. Diapocynin inhibits the formation of 3-nitrotyrosine (3-NT) and 4-
hydroxynonenol (4-HNE) in SN of MPTP treated mice.  Mice were administered 
diapocynin (300mg/kg/day) by oral gavage 24 h before MPTP treatment and continued for 4 
days of co-treatment with 25mg/kg/day MPTP via i.p. Control mice received 10% ethanol in 
saline.  Twenty-four h after the last dose of MPTP, mice were sacrificed.  (A) Representative 
western blots illustrating the expression of 3-NT in SN.  (B) Bar graph showing means 
Western blot 3-NT/β-actin ratios ± SEM in SN of 6 mice per group.  (C) Double labeling of 
TH (marker of dopaminergic neurons) and 3-NT in SN region of ventral midbrain.  (D) 
Representative western blots illustrating the expression of 4-HNE in SN. (B) Bar graph 
showing means Western blot 4-HNE/β-actin ratios ± SEM in SN of 6 mice per group.  (C) 
Double labeling of TH and 4-HNE in SN region of ventral midbrain.  Images were captured 
at 60X magnifications.  The substantia nigra zone is outlined in white dots.  Inset pictures 
demonstrated colocalization of TH and 3-NT/4-HNE. ***, p < 0.001 vs. the control group; 
**, p < 0.01 vs. the control group; *, p < 0.05 vs. the MPTP group; #, p < 0.001 vs. the 
MPTP group.    
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Figure 5 
 
Figure 5. Diapocynin improves motor function in MPTP injected mice.  Mice were 
administered diapocynin (300mg/kg/day) by oral gavage 24 h before MPTP treatment and 
continued for 5 days of co-treatment with MPTP (25mg/kg/day) and 4 days of post-treatment 
with MPTP (25mg/kg/day).  Control mice received 10% ethanol in saline. 4 days after the 
last dose of MPTP, mice were tested for motor activities.  (A) VersaPlot map showing 
moving track of mice.  VersaMax data showing (B) horizontal activity; (C) vertical activity; 
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(D) distance travelled (cm.); (E) movement time (sec.); (F) rest time (sec.); (G) no. of 
stereotypy ; (H) no. of rearing and (I) time spent on rotarod (second) at 20 rpm rod speed.  
Data are means ± SEM of eight to ten mice per group.  ***, p < 0.001 vs. the control group; 
**, p < 0.01 vs. the MPTP group; *, p < 0.05 vs. the MPTP group; #, p < 0.01 vs. the control 
group.   
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Figure 6 
 
201 
 
Figure 6. Diapocynin protects nigrostriatum in MPTP treated mice.  Mice were 
administered diapocynin (300mg/kg/day) by oral gavage 24 h before MPTP treatment and 
continued for 5 days of co-treatment with MPTP (25mg/kg/day) and 6 days of post-treatment 
of MPTP (25mg/kg/day).  Control mice received 10% ethanol in saline.  (A) 7 days after the 
last MPTP injection, mice were sacrificed and Tyrosine hydroxylase (TH)-DAB 
immunostaining in striatum and substantia nigra regions were performed (2X 
magnifications).  (B) Representative western blots illustrating the expression of TH in SN 
and striatum.  (C & D) Bar graphs showing mean Western blot TH/β-actin ratios ± SEM in 
SN and striatum of 6 mice per group.  (E) Stereological counts of TH-positive dopaminergic 
neurons in the SN of ventral midbrain.  7 days after the last MPTP treatment, striatal (F) 
dopamine, (G) DOPAC and (H) HVA were measured by HPLC. Data are means ± SEM of 
eight to ten mice per group. Images were captured at 2X magnification.  ***, p < 0.001 vs. 
control; **, p < 0.01 vs. MPTP; *, p < 0.05 vs MPTP; a, p < 0.01 vs. MPTP; #, p < 0.001 vs. 
MPTP.  
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Manuscript Supplementary Figures 
Figure 1.  
 
Figure 1. Quantification of diapocynin in SN and striatum of mice.  Mice were 
administered diapocynin (300mg/kg/day) by oral gavage 24 h before MPTP treatment and 
continued for 5 days of co-treatment with MPTP (25mg/kg/day) and 6 days of post-treatment 
of MPTP (25mg/kg/day).  Seven days after last injection of MPTP, SN and ST were 
dissected out and quantified for diapocynin.  (A) HPLC peak of diapocynin at Retention time 
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1.9 min.  (B) LC-MS peak of diapocynin at retention time 1.9 min coinciding with HPLC 
peak.  (C) The mass spectral peak m/z 313.9 negative ion produced by diapocynin, eluting at 
1.9 min.  (D) Standard curve of diapocynin standards ranging from 0.3µg to 30µg.  (E) 
Quantification of diapocynin in SN and ST. N=6.    
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Figure 2 
 
Figure 2. Diapocynin protects dopaminergic neurons in MPTP model of PD.  Mice were 
administered diapocynin (300mg/kg/day) by oral gavage 24 h before MPTP treatment and 
continued for 5 days of co-treatment with MPTP (25mg/kg/day) and 6 days of post-treatment 
of MPTP (25mg/kg/day).  Control mice received 10% ethanol in saline.  Seven days after the 
last MPTP injection, mice were sacrificed and substantia nigra sections were processed for 
TH (A). Double labeling of TH and FluoroJade –b in substantia nigra sections (B).  TH-DAB 
pictures were captured at 10X magnification and TH and Fluorojade-b double labeled 
pictures were captured at 20X magnification.  
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Figure 3 
 
SI figure 9. Diapocynin suppresses disease progression in the MPTP mouse model.  Mice 
were treated with MPTP (25mg/kg/day) for 5 days. Diapocynin (300mg/kg/day) treatment 
started on 4
th
 day of MPTP injection and continued for another 7 days.  Mice were sacrificed 
1 day after the last dose of diapocynin and striatal (A) dopamine, (B) DOPAC and (C) HVA 
were measured by HPLC.  Data are means ± SEM of six to eight mice per group. ***, p < 
0.001 vs. the control group; **, p < 0.01 vs. the MPTP group; *, p < 0.05 vs. the MPTP 
group;    
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Abstract: 
Parkinson’s disease (PD) is one of the most common neurodegenerative disorders 
marked by progressive increase in non-motor and motor deficits. Recent evidences indicate 
that glial cell activation and its inflammatory response may contribute to the progressive 
degeneration of dopaminergic neurons in PD. Despite intense investigation, no 
neuroprotective therapy that successfully intervenes in the progression of the disease is 
currently available. Apocynin has been shown to possess anti-inflammatory and antioxidant 
properties but the clinical utility of apocynin as a neuroprotective agent is still controversial. 
In this present study, we investigated whether mitoapocynin, a mitochondria targeted novel 
derivative of apocynin, promotes the survival of dopaminergic neurons in the 1-methyl-4-
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phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD. MPTP induced degeneration 
of dopaminergic neurons and loss of dopamine in the nigrostriatal region of midbrain. 
Additionally, MPTP led to activation of glial cells visualized by IBA-1 and GFAP 
immunostaining. Westernblotting and immunoreactivity also demonstrated increased 
expression of proinflammatory cytokines and molecules along with microglial NADPH 
oxidase which led to ROS/RNS production and formation of unsaturated aldehyde in the 
substantia nigra. However, oral administration with mito-apocynin improved mice behavioral 
activities, prevented nigrostriatal dopaminergic neurodegeneration, increased striatal 
dopamine. This neuroprotection afforded by mito-apocynin was associated with the 
attenuation of gliosis, proinflammatory molecules and cytokines, NADPH oxidase and iNOS 
derived RNS production and lipid peroxidation. Collectively, our results demonstrate that 
mitoapocynin produces distinct anti-inflammatory and antioxidant effects in a well-
established neurotoxicity animal model of PD.  These data strongly suggest that additional 
preclinical development of mitoapocynin may yield an effective neuroprotective drug 
capable of intervening in the progression of Parkinson’s disease. 
Introduction 
Parkinson’s disease (PD) is a common neurodegenerative movement disorder 
characterized by motor symptoms such as reting tremor, rigidity, bradykinesia and postural 
instability along with several non-motor symptoms (Dauer and Przedborski, 2003; Vila and 
Przedborski, 2004). The pathological hallmark of PD is the loss of dopaminergic neurons in 
the substantia nigra pars compacta (SNpc) of the midbrain that project to the striatum. 
Parkinsonian symptoms appear when majority (60 or 70%) of SNpc dopaminergic neurons 
208 
 
are lost, resulting in depletion of nigrostraital dopamine. The disease mechanism that causes 
the disease is not completely known, but recent evidences suggest that glial cells mediated 
inflammation and oxidative stress increase the risk of developing PD (Dauer and 
Przedborski, 2003). Sustained microglial and astroglial activation in close proximity of dying 
dopaminergic neurons in the SNpc is evident in PD patients and animal models of the disease 
(McGeer et al., 1988; Hirsch and Hunot, 2009). Different in vitro and in vivo animal models 
have demonstrated elevation of the key enzymes involved in the production of reactive 
oxygen species (ROS) or reactive nitrogen species (RNS), such as microglial NADPH 
oxidase and inducible nitric oxide synthase (iNOS) and astroglial myeloperoxidase (MPO) in 
dopaminergic neurodegenerating areas of substantia nigra (SN) (Gao et al., 2003; Wu et al., 
2003). In addition to that, variety of pro-inflammatory cytokines including tumor necrosis 
factor alpha (TNF-α), interleukin (IL) -1beta (β) , IL-6, interferon gamma (IFN-γ) and other 
immune neurotoxins are found either in CSF or affected regions of PD brain (Nagatsu et al., 
2000). However, the mechanism behind glial cells activation in the diseased state is not 
completely known. A recent study has shown that the activation of NF-κB  in microglial and 
astroglial cells play critical neurotoxic role by mediating proinflammatory cytokine levels in 
the SN (Ghosh et al., 2007). Nurr1, a nuclear orphan receptor suppresses glial activation by 
docking to NF-κB -p65 on target inflammatory gene promoters and protects against 
dopaminergic neurodegeneration in SN (Saijo et al., 2009). Collectively, these findings 
suggest controlling inflammation and oxidative stress could be a key neuroprotective strategy 
in PD and its animal model. 
 Along with inflammation and oxidative stress, PD is also associated with 
mitochondrial dysfunction leading to energy failure (Betarbet et al., 2000). Defects in 
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complexes I, II, and IV of the mitochondrial respiratory chain have been detected in 
neurodegenerative disorders such as Alzheimer's, Parkinson's, and Huntington's diseases. 
Various anti-oxidants and chelators have been tested in different animal models of PD with 
little success (Kaur et al., 2003; Golden and Patel, 2009). In our study we synthesized a novel 
mitochondria targeted anti-oxidant mito-apocynin which is also a derivative of apocynin and 
checked its anti-oxidant and anti-inflammatory roles in MPTP mouse model of PD. Here in, 
we demonstrate that in primary culture, mito-apocynin blocks MPP
+
-induced dopaminergic 
neurodegeneration by attenuating inflammatory reactions and oral administration of mito-
apocynin in mice protects the dopaminergic neurons and terminals from MPTP toxicity by 
reducing glial activation and glial cells mediated inflammatory reactions and oxidative stress. 
Collectively, these results strongly suggest that additional preclinical development of mito-
apocynin may yield an effective neuroprotective drug for treating PD patients.  
Materials and methods: 
Chemicals and biological reagents. 1-Methyl-4-phenyltetrahydropteridine (MPP
+
 iodide) 
and MPTP-HCl were purchased from Sigma (St. Louis, MO, USA). RPMI, neurobasal 
medium, B27 supplement, fetal bovine serum, L-glutamine, Sytox assay dye, IR-dye tagged 
secondary antibodies, penicillin, and streptomycin and other cell culture reagents were 
purchased from Invitrogen (Gaithersburg, MD). Recombinant murine TNF, LPS (E. coli 
0111:B4) and cytosine arabinoside were purchased from Sigma-Aldrich (St. Louis, MO).   
Mesencephalic Primary Neuron Cultures and Treatment. Primary mesencephalic culture 
was prepared from the ventral mesencephalon of gestational 14- to 15-day-old mice embryos 
as described previously. Briefly, mesencephalic tissues from E14 to 15 mouse embryos were 
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dissected and maintained in ice-cold calcium-free Hanks’ balanced salt solution and then 
dissociated in Hanks’ balanced salt solution containing trypsin-0.25% EDTA for 20 min at 
37°C. The dissociated cells were then plated at equal density of 0.6 million cells per well on 
12-mm coverslips precoated with 0.1 mg/ml poly-D-lysine. Cultures were maintained in 
neurobasal medium fortified with B-27 supplement, 500 mM L-glutamine, 100 IU/ml 
penicillin, and 100 g/ml streptomycin (Invitrogen, Carlsbad, CA). The cells were 
maintained in a humidified CO2 incubator (5% CO2 and 37°C) for 24 h. Half of the culture 
medium was replaced every 2 days. Approximately 6- to7-day-old cultures were used for 
experiments. Primary mesencephalic and striatal dopaminergic neuronal cells were exposed 
to 10 µM MPP
+
 in the presence or absence of mito-apocynin (10 µM) for 24 h. 
Primary microglial cultures and treatments. Primary microglial and astroglial cultures 
were prepared from C57BL/6 postnatal day 1 (P1) mouse pups. The mouse brains were 
harvested, meninges removed, and then placed in  Dulbecco’s modified Eagle’s medium/F-
12 nutrient media (DMEM-F12,GIBCO Cat # 11320) supplemented with 10% heat-
inactivated fetal bovine serum (FBS), 50 U/mL penicillin, 50 μg/mL streptomycin, 2 mM L-
glutamine, 100 μM non-essential amino acids, and 2 mM sodium pyruvate (Invitrogen). The 
brain tissue was then incubated in 0.25% trypsin for 30 min with gentle agitation. The trypsin 
reaction was stopped by adding an equal volume of DMEM/F12 complete medium and the 
brain tissue was washed 3 times. The tissue was then triturated gently to prepare a single cell 
suspension and then passed through a 70 μm nylon mesh cell strainer to remove tissue debris 
and aggregates. The cell suspension then was made up in DMEM/F12 complete medium and 
seeded into T-75 flasks. The cells were placed in humidified CO2 incubator at 37°C, the 
medium was changed after 4 to 5 days and the mixed glial cells were grown to confluence. 
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Microglial cells were separated from confluent mixed glial cultures by differential adherence 
and magnetic separation to >97% purity as described in our recent publication (Ghosh et al., 
2010). Both microglia and astrocytes were allowed to recover for at least 48 hours after 
plating. Primary microglia and astrocytes were treated in DMEM/F12 complete medium 
containing 2% FBS. 
Microglial nitric oxide detection. Nitric oxide production by primary microglia culture was 
measured indirectly by quantification of nitrite in the supernatant using the Griess reagent 
(Sigma Aldrich). BV2 microglial cells were plated in poly-D-lysine coated 96-well plates at 
50,000 cells per well. Cells were treated with either 1µg/ml LPS for 24 h in presence or 
absence of different doses of mito-apocynin and 100 μL of supernatant was collected from 
each well and an equal volume of the Griess reagent was added. The samples were incubated 
on a plate shaker at room temperature for 15 min until a stable color was obtained. The 
absorbance at 540 nm was measured using a Synergy 2 multi-mode microplate reader 
(BioTek Instruments) and the nitrite concentration determined from a sodium nitrite standard 
curve. 
Multiplex cytokine and chemokine Luminex immunoassays. Primary microglia from time 
pregnant pups from C57BL/6 mice were obtained and seeded in poly-D-lysine coated 96-
well plates respectively. The cells were treated for 24 h with 100 ng/mL LPS in the presence 
or absence of different doses of mito-apocynin. After treatment, 50 µL of supernatant from 
each well was collected and frozen at -80°C. The levels of cytokines and chemokines in the 
supernatants were determined using the Luminex bead-based immunoassay platform 
(Vignali, 2000) using pre-validated multiplex kits (Milliplex mouse cytokine and chemokine 
panels – Millipore Corporation) according to the manufacturer’s instructions. 
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Intracellular reactive oxygen species (iROS) detection. Intracellular reactive oxygen 
species (iROS) were determined using the fluorescent probe 2’,7’-dichlorodi-
hydrofluorescein diacetate (DCFH-DA) (Calbiochem), according to previously published 
reports (Zhang et al., 2005; Qian et al., 2007). Magnetically separated microglia from C57 
black mice were plated at 10
5
 cells per well in 96-well plates and allowed to attach overnight. 
Before treatment, cells were washed in HBSS and incubated with 40 µM DCFH-DA in 
HBSS containing 2% FBS for 30 min. Cells were then treated with 100 ng/mL LPS for 24h 
in the presence or absence of different doses of mito-apocynin. The fluorescence intensity 
was determined using a Synergy-2 multi-mode microplate reader at an excitation of 485/20 
nm and an emission of 530/25 nm. The fluorescence value from the control cultures was 
subtracted as background and the increase in fluorescence with treatments was expressed as 
increased iROS as previously described (Zhang et al., 2005; Qian et al., 2007). 
Immunocytochemistry. The primary mesencephalic and astroglial cultures were fixed with 
4% paraformaldehyde in phosphate buffered saline (PBS) for 20 minutes and processed for 
immunocytochemical staining as described previously (Ghosh et al., 2010). First, nonspecific 
sites were blocked with 2% bovine serum albumin, 0.5 % Triton X-100 and 0.05% Tween-20 
in PBS for 45 min at room temperature. Cells were then incubated with different primary 
antibodies such as TH (1:1600, mouse monoclonal; Millipore, Billerica, MA), GFAP 
(1:1000, mouse monoclonal; Chamicon), p65 (1:500, rabbit polyclonal; Santa Cruz) at 4°C 
overnight. Appropriate secondary antibodies (Alexa Fluor 488 or 594 or 555; Invitrogen) 
were used followed by incubation with 10µg/ml Hoechst 33342 (Invitrogen) for 5 min at 
room temperature to stain the nucleus. The coverslip containing stained cells were washed 
twice with PBS and mounted on poly-D lysine coated slides (Sigma, St Louis). Cells were 
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viewed under a NIKON inverted fluorescence microscope (model TE-2000U; NIKON, 
Tokyo, Japan) and images were captured with a SPOT digital camera (Diagnostic 
Instruments, Inc., Sterling Heights, MI). 
Animals and treatment.  Eight-week-old male C57BL/6 mice weighing 24 to 28 g were 
housed in standard conditions: constant temperature (22 ± 1°C), humidity (relative, 30%), 
and a 12-h light/dark cycle.  Use of the animals and protocol procedures were approved and 
supervised by the Committee on Animal Care at Iowa State University (Ames, IA).  Mice 
received mito-apocynin (3mg /kg / day) in 10% ethanol by oral gavage either 1 day before or 
after 3 days of the MPTP insult. For MPTP treatment, mice received 25mg/kg/day MPTP-
HCl in saline intraperitoneally for consecutive 5 days.  Control mice received equivolume 
injection of 1XPBS. 
HPLC analysis of striatal dopamine and its metabolites levels.    Samples were prepared 
and quantified as described previously (Ghosh et al., 2010).  In brief, 7 days after MPTP 
injection mice were sacrificed and striata were collected and stored at -80C.  On the day of 
analysis, neurotransmitters from striatal tissues were extracted using an antioxidant 
extraction solution (0.1 M perchloric acid containing 0.05% Na2EDTA and 0.1% Na2S2O5) 
and isoproterenol (as internal standard).  DA, DOPAC and HVA were separated isocratically 
by a reversed-phase column with a flow rate of 0.6 ml/min.  An HPLC system (ESA Inc., 
Bedford, MA) with an automatic sampler equipped with refrigerated temperature control 
(model 542; ESA Inc.) was used for these experiments.  The electrochemical detection 
system consisted of a Coulochem model 5100A with a microanalysis cell (model 5014A) and 
a guard cell (model 5020) (ESA Inc.).  The data acquisition and analysis were performed 
using the EZStart HPLC Software (ESA Inc.).  
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qRT-PCR. After treatment, total RNA were extracted from the mice brain SN using 
Absolutely RNA Miniprep Kit (Agilent Technologies, Santa Clara, CA) following the 
manufacturer’s protocol. Total RNA was treated with DNase I to remove DNA 
contamination and then reversibly transcribed into first-strand cDNA using the SuperScript 
III first-strand synthesis system (Invitrogen, Carlsbad, CA) as described in the kit 
instructions. SYBR-green Quantitative PCR was performed with validated primers of TNF-α 
, IL-1β, iNOS, IL-6 and control 18S primers (Qiagen, Valencia, CA) using RT2 SYBR®  
Green qPCR Master Mix (SABiosciences, Fredrick, MD) for the mice tissue. 
Western blotting.  Mice were sacrificed 3 days after MPTP treatment and substantia nigra 
tissue was dissected out.  Brain lysates containing equal amounts of protein were loaded in 
each lane and separated in a 10 to 15% SDS-polyacrylamidegel electrophoresis gel as 
described previously (Jin et al., 2011). Poteins were transferred to a nitrocellulose membrane 
and nonspecific binding sites were blocked by treating with Licor odyssey blocking buffer.  
The membranes were then incubated with different primary antibodies such as anti-IBA-1 
(Abcam), anti-GFAP (Chemicon), anti-iNOS (Santa Cruz), anti-gp91phox (Abcam), anti-
3NT (Chemicon) and anti-4HNE (R&D).  Next, membranes were incubated with Alexa Fluor 
680 goat anti-mouse or Alexa Fluor 680 donkey anti-goat (Invitrogen) or IR dye 800 donkey 
anti-rabbit (Rockland) secondary antibodies.  To confirm equal protein loading, blots were 
reprobed with a β-actin antibody (Sigma; 1:10000 dilution).  Western blot images were 
captured with a Licor Odyssey machine (Licor, NE).  The western blot bands were quantified 
using NIH Image J software.   
Immunohistochemistry. Three days after last MPTP treatment, mice were perfused with 4% 
paraformaldehyde and post fixed with PFA and 30% sucrose respectively.  Next, fixed brains 
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were cut into 30µm sections and were incubated with different primary antibodies such as 
anti-IBA-1antibody (Abcam), anti-GFAP (Chemicon), anti-iNOS (Santa Cruz), anti-3NT 
(Chemicon), anti-gp91phox (Abcam) and anti-4HNE (R & D) for overnight at 4C.  
Appropriate secondary antibodies (Alexa Fluor 488 or 594 or 555 from Invitrogen) were 
used followed by incubation with 10µg/ml Hoechst 33342 for 5 min at room temperature to 
stain the nucleus.  Sections were viewed under a Nikon inverted fluorescence microscope 
(model TE-2000U; Nikon, Tokyo, Japan); images were captured with a SPOT digital camera 
(Diagnostic Instruments, Inc., Sterlings Heights, MI). 
DAB immunostaining and stereological counting.  DAB immunostaining was performed 
in striatal and substantia nigral sections as described previously (Ghosh et al., 2009; Ghosh et 
al.).  In brief, 30 µm sections were incubsated with either anti-TH antibody (Calbiochem, 
rabbit anti-mouse, 1:1800) or anti-IBA-1(Abcam, goat anti-mouse, 1:1000) or anti-GFAP 
(Chemicon, mouse anti-mouse, 1:1000) antibody for overnight at 4C.  Next, sections were 
incubated in biotinylated anti- rabbit or goat or mouse secondary antibody followed by 
incubation with avidin peroxidase (Vectastatin ABC Elite kit, Vector laboratories). 
Immunolabeling was observed using diaminobenzidine (DAB), which yielded a brown stain.  
Total numbers of TH positive neurons in SN were counted stereologically with Stereo 
Investigator software (MBF Bioscience, Williston, VT, USA), using an optical fractionators 
(Ghosh et al., 2010).   
Behavioral measurements.  An automated device (AccuScan, model RXYZCM-16, 
Columbus, OH) was used to measure the spontaneous activity of mice.  The activity chamber 
was 40×40×30.5 cm, made of clear Plexiglas and covered with a Plexiglas lid with holes for 
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ventilation.  Data were collected and analyzed by a VersaMax Analyzer (AccuScan, model 
CDA-8, Columbus, OH).  Before any treatment, mice were placed inside the infrared monitor 
for 10 min daily and 5 min daily for 3 consecutive days to train them. After 5 days of last 
MPTP injection, openfield and rotarod experiments were conducted as described previously 
(Ghosh et al., 2010).  Locomotor activities (horizontal activities, vertical activities, total 
distance travelled, total rest time and rearing activities) were presented for 10 min test 
session. For rotarod experiment 20 rpm speed was used.  Mice were given a 5-7 min rest 
interval to eliminate stress and fatigue.    
Data analysis.  Data analysis was performed using Prism 4.0 software (GraphPad Software 
Inc., San Diego, CA).  Raw data were first analyzed using one-way analysis of variance and 
then Tukey’s post-test was performed to compare all treatment groups.  Differences with p < 
0.05 were considered significant.    
Results:   
Mito-apocynin protects dopaminergic neurons against MPP
+
- induced toxicity in 
primary mesencephalic cultures 
 We first examined whether mito-apocynin (Fig. 1) can rescue TH-positive neurons 
from MPP
+
-induced toxicity in primary mesencephalic cultures. Primary mesencephalic 
cultures were isolated from E15 C57 BL/6 mice embryos, and neurons were treated with 
10µM MPP
+
 in the presence or absence of 5µM mito-apocynin. After 24h of treatment, 
primary neurons were processed for TH immunochemistry. As shown in Fig. 1, MPP
+
 
treatment induced an approximately 75% loss of TH cell count (Fig. 1C) and 85% loss of 
neurite processes (Fig. 1B). However, 5µM mito-apocynin treatment significantly protected 
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against MPP
+
 neurotoxicity. Mean lengths of TH+ve neuronal processes in MPP
+ 
plus mito-
apocynin treated primary neurons were significantly longer (p < 0.01) than the MPP
+
 -treated 
processes. Similarly, mito-apocynin significantly (p < 0.05) rescued dopaminergic neurons 
against MPP
+
 toxicity. These results suggest that the mito-apocynin possesses 
neuroprotective properties in the MPP
+
-induced dopaminergic degenerative model. 
Mito-apocynin inhibits MPP+ induced activation of NF-κB in primary culture  
 Microglial activation plays an important role in the pathogenesis of PD as well as 
other neurodegenerative disorders (Dauer and Przedborski, 2003; Gao et al., 2003; Ghosh et 
al., 2007). Neurotoxin MPTP mimics some features of PD in rodents and primates. The 
neurotoxic effect of MPTP depends on its conversion into MPP
+ 
which then activates glial 
cells (Dauer and Przedborski, 2003). Recently, it has been demonstrated that MPP
+
 induces 
the activation of NF-κB  in glial cells and promoter region of proinflammatory molecules 
contain the DNA binding site for NF-κB  (Hayden and Ghosh, 2004; Ghosh et al., 2007). 
Similarly, we also observed increased NF-κB -p65 expression in primary dopaminergic 
neurons (Fig. 2A) and primary astrocytes (Fig. 2B) in MPP
+
 treated cultures and this p65 was 
present in both nucleus and cytoplasm because part of it did not colocalize with hoechst (Fig. 
2A-B).   However, as seen in Fig. 2A and B, mito-apocynin inhibited the expression of p65 in 
dopaminergic neurons and astrocytes.  It also blocked the entry of p65 into the nucleus.  
Mito-apocynin inhibits LPS-induced inflammatory processes in primary microglial 
cells. 
After establishing inhibitory role of mito-apocynin in p65 activation, we were 
interested to see whether mito-apocynin could attenuate LPS-induced inflammatory 
processes. First, we measured the levels of pro-inflammatory cytokines from supernatant of 
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LPS plus mito-apocynin treated culture. Primary microglial culture from day-1-old pups were 
treated with 100ng/ml LPS in presence or absence of two different doses (20µM and 40µM) 
of mito-apocynin. 24 h after treatment, the levels of various pro-inflammatory cytokines in 
the supernatant were determined using a multiplesx bead-based Luminex assay system 
(Milipore Bioplex). As evident in Fig. 3A-C, LPS triggered significant (p < 0.001) induction 
of TNF-α , IL-6 and IL-12 release in the supernatant, whereas, mito-apocynin treatment 
significantly attenuated the cytokine release.  
Nitric oxide production and intracellular ROS (iROS) generation are important 
aspects of the microglial activation response and are particularly relevant in PD models 
where deregulation of microglial activation is believed to trigger dopaminergic 
neurodegeneration via oxidative stress. We checked whether mito-apocynin could attenuate 
LPS-induced nitric oxide generation in primary microglia culture. Nitric oxide production 
was measured indirectly using Griess assay in primary microglia (Fig. 3D). Cells were 
treated with LPS (100ng/ml) in the presence or absence of mito-apocynin (20 µM or 40 µM) 
for 24 h. A sharp increase in nitrite levels (2 µM; p < 0.001) of LPS-treated culture in 
comparison to control was observed, however, mito-apocynin dose dependently attenuated 
LPS-induced nitrite levels (Fig 3D). Next, we wanted to test whether mito-apocynin inhibited 
intracellular superoxide release in primary microglial culture.  As evident in Fig. 3E, LPS 
treatment induced intracellular ROS levels in primary microglia at 12 h, whereas LPS plus 
mito-apocynin had significantly lower levels of intracellular ROS.  Together, these results 
provide anti-inflammatory role of mito-apocynin in the regulation of different aspects of the 
microglial proinflammatory responses.  
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Mito-apocynin improves motor behavior in MPTP mice 
After establishing efficacy of mito-apocynin in attenuation of inflammatory reactions 
and protection of dopaminergic neurons against MPP
+
 toxicity in primary culture, we 
examined the neuroprotective effect of mito-apocynin in a preclinical model of PD. We first 
evaluated whether mito-apocynin improves MPTP-induced motor deficits by testing 
behavioral performances in openfield and rotarod instrument as described recently (Ghosh et 
al., 2010). Animals receiving mito-apocynin (3mg/kg/day) were evaluated 4 days after MPTP 
treatment in Versamax infrared computerized activity monitoring system and rotarod 
instrument (Accuscan, OH). Representative motor activity maps of movement of saline 
treated control, MPTP and MPTP plus mito-apocynin treated mice are shown in Fig. 4A. As 
observed in the Versa Plot (Fig. 4A), we found decreased movement of MPTP treated mice 
and improvement of locomotion in MPTP plus mito-aocynin treated group. MPTP treatment 
decreased horizontal activity (Fig. 4B), vertical activity (Fig. 4C), total distance travelled 
(Fig. 4D), movement time (Fig. 4E), no. of stereotypy (Fig. 4G), no. of rearing (Fig. 4H) and 
time spent on rod at 20 rpm speed (Fig. 4I) consistent with our previous observations (Ghosh 
et al., 2010).  Additionally, rest time was increased in the MPTP treated mice (Fig. 4F).  
However, the behavioral dysfunctions in MPTP-treated mice were recovered significantly by 
mito-apocynin (Fig. 4B-I).          
Mito-apocynin protects nigrostriatal dopaminergic neurons and its fibers from MPTP-
induced neurotoxicity in vivo 
After doing behavioral experiments mice were sacrificed 7 days post MPTP treatment 
and brains were removed and sections were immunostained for tyrosine hydroxylase (TH) 
immunostaining to detect dopaminergic neurons and fibers. As observed earlier (Ghosh et al., 
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2010), there was a significant loss of TH positive cell bodies and terminals in SN and 
striatum respectively (Fig. 5A and B) in MPTP treated mice compared with those in PBS-
treated control mice (Fig. 5A and B). Higher magnified 10X pictures (Fig. 5B- lower panel) 
clearly demonstrated loss of neurons in substantia nigra pars compacta (SNpc), substantia 
nigra lateralis (SNl) and substantia nigra reticularis (SNr) regions of nigral tract of MPTP-
treated mice. To investigate whether mito-apocynin altered MPTP-induced 
neurodegeneration in nigrostriatum, we started gavage administration of mito-apocynin 
(3mg/kg/day) 1 day before MPTP injection and continued for 12 days. The results of TH 
immunostaining showed that mito-apocynin significantly reduced MPTP-induced death of 
dopaminergic neurons in SN and their terminals in striatum (Fig. 5A-B). Next, to determine 
whether mito-apocynin protects against neurotransmitter loss induced by MPTP, we 
sacrificed another batch of mice 7 days after MPTP treatment and striatal dopamine, DOPAC 
and HVA were measured by HPLC (Fig. 5C). In parallel with dopaminergic neuronal loss 
evidenced by immunohistochemistry, HPLC analysis revealed 75% loss of striatal dopamine 
compared with the PBS treated control mice. By contrast, treatement of MPTP-treated mice 
with mito-apocynin (3 mg / kg / day) increased dopamine levels by 66% compared with 
MPTP mice (p < 0.001; Fig. 2C). In addition to dopamine, MPTP treatment also led to 76% 
and 70% loss of DOPAC and HVA in striatum respectively, whereas mito-apocynin 
treatment restored those metabolite levels significantly (Fig. 5C).                        
Mito-apocynin inhibits microglial and astroglial activation in the SN in vivo 
Various evidences suggest that activated glial cells in SN play an important role in 
dopaminergic neurodegeneration in the human PD patients and in the MPTP model (Dauer 
and Przedborski, 2003; Block and Hong, 2007; Ghosh et al., 2007). Thus, we next evaluated 
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whether the neuroprotective effect of mito-apocynin resulted from attenuation of gliosis in 
the SN. At 3 day after MPTP treatment, mice were sacrificed and nigral tissue sections were 
processed for IBA-1 (marker of microglia) and GFAP (marker of astrocytes) immunostaining 
(Fig. 6A-B). We observed increased expression of activated microglial cells (characterized 
by amoeboid shape with thick processes) and astrocytes (characterized by bigger cell bodies 
with thick processes) in SN of MPTP treated mice compared with those in PBS treated 
control mice (Fig. 6A-B). However, mito-apocynin treatment reduced the number of IBA-1 
positive microglial cells and GFAP positive astroglial cells in the MPTP-treated SN (Fig. 6A-
B). To further confirm these findings, we also did western blotting of IBA-1 and GFAP in 
SN tissue. In MPTP-treated SN tissues, IBA-1 and GFAP expression increased significantly 
compared with PBS treated control samples (Fig. 6C-F). By contrast, gavage treatment with 
mito-apocynin significantly attenuated the expression of IBA-1 and GFAP in MPTP treated 
mice (Fig. 6C-F). Collectively, these results demonstrate anti-gliosis role of mito-apocynin 
(Fig. 6A-B). 
Mito-apocynin inhibits the expression of inducible nitric oxide synthase (iNOS) in the 
SN of MPTP treated mice 
Previous reports demonstrated increased level of inducible nitric oxide synthase in 
SN of MPTP-treated mice (Liberatore et al., 1999; Ghosh et al., 2009). Thus, we also 
examined whether mito-apocynin might modulate dopamine neuronal survival by affecting 
MPTP-induced expression of iNOS in the SN. Three days after MPTP treatment, mice were 
sacrificed and SN tissues were dissected out and immunoblotted for iNOS (Fig. 7A). We 
found marked increase in expression of iNOS in the SN of MPTP-treated mice when 
compared to PBS-treated control mice. However, mito-apocynin attenuated MPTP-induced 
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expression of iNOS protein in the SN (p < 0.05; Fig. 7A). Additionally, immunofluorescence 
analysis for iNOS in SN sections shows that MPTP treatment led to marked increase in nigral 
iNOS protein expression and that iNOS colocalized with IBA-1-positive microglia and 
GFAP-positive astroglial (Fig. 7B and C). However, consistent to their inhibitory effect on 
the activation of glial cells, mito-apocynin attenuated MPTP-induced expression of iNOS in 
the glial cells (Fig. 7B and C). 
Mito-apocynin inhibits the expression of proinflammatory molecules in vivo in the 
midbrain of MPTP-treated mice 
Glial cells when get activated release proinflammatory cytokines along with iNOS. 
Similarly, we also found marked increase in mRNA expression of iNOS, TNF-α, IL-1β and 
IL-6 in the ventral midbrain region of brain 3 days after MPTP administration (Fig. 8). 
However, 3mg/kg/day mito-apocynin treatment strongly inhibited MPTP-induced expression 
of these proinflammatory cytokines in vivo in the ventral midbrain (Fig. 8). These results 
strongly suggest that mito-apocynin can suppress the expression of proinflammatory 
molecules in vivo in the ventral midbrain of MPTP-treated mice.   
Mito-apocynin attenuates activation of NADPH oxidase in activated microglia of 
MPTP-treated mice 
Recent reports demonstrated that NADPH oxidase-induced oxidative stress played 
pivotal role in neurodegeneration of dopaminergic neurons in PD and in MPTP mouse model 
(Vejrazka et al., 2005). Thus, we also checked the protein expression of gp91phox, a major 
component of NADPH oxidase in SN region of mouse brain three days after MPTP 
treatment. The western blot analysis showed an increased expression of gp91phox in MPTP-
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treated mice compared to weak expression in saline treated mice (Fig. 9A-B). However, 
mito-apocynin attenuated MPTP-induced expression of gp91phox protein in the SN (p < 
0.05; Fig. 9B). Additionally, robust gp91phox immunoreactivity was seen specifically in 
larger cells with thick, shorter ramifications in the SN of MPTP treated mice (Fig. 9C).  
Double immunolabeling studies confirmed that gp91phox immunoreactivity appeared to 
colocalize with IBA-1 positive microglia (Fig. 9C, middle panel). Previous study suggested 
that in the MPTP model of PD, gp91phox does not colocalize either with astrocytes or 
dopaminergic neurons (Wu et al., 2003). However, mito-aocynin treatment attenuated MPTP 
induced gp91phox protein expression in the IBA-1 positive microglial cells in the SN (Fig. 
9C).  These results suggest that mito-apocynin effectively blocks the MPTP-induced 
microglial NADPH oxidase. 
Mito-apocynin attenuates nitrosative damages in the SN in vivo 
Nitration of protein tyrosine residues is believed to be a well known marker of 
oxidative stress in PD patients and its animal model (Dawson and Dawson, 2003). In 
oxidative stress condition, iNOS derived oxidants selectively nitrates the tyrosine residues 
and generates 3-nitrotyrosine (3-NT) (Ara et al., 1998). To observe the levels of iNOS-
mediated oxidative damage to tyrosine residues, we checked the expression of 3-NT 3 days 
after MPTP treatment in presence or absence of mito-apocynin. The western blot analysis 
showed robust increase in expression of 3-NT protein in SN compared with those in the PBS 
treated control mice (Fig 10A-B). However, mito-apocynin significantly attenuated (p < 0.05; 
Fig 10B) MPTP-induced 3-NT expression. Consistent with this western blotting result, 
immunohistochemistry analysis also demonstrated increased levels of 3-NT expression in TH 
positive dopaminergic neurons in SN of MPTP-treated mice (yellow color cells showing 
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colocalization of TH and 3-NT) compared with the PBS treated SN of control mice (Fig. 
10C). But, this robust increase of nitrotyrosine levels in MPTP-treated mice was dramatically 
inhibited by mito-apocynin, as very few TH positive cells express nitrotyrosine protein in 
their cytosol (Fig. 10C). Collectively, these results demonstrate that mito-apocynin is capable 
of reducing iNOS derived oxidative stress.  
Mito-apocynin reduces the formation of lipid peroxidation in the nigral dopaminergic 
neurons in vivo 
Along with peroxinitrite, lipid peroxidatin also induces neuronal apoptosis in the 
presence of oxidative stress (Awasthi et al., 2008). 4-hydroxynonenol (4-HNE) is widely 
used as a marker of membrane lipid peroxidation induced by cytotoxic radicals such as 
hydroxyl (·OH) (Stadler et al., 2008). Previous reports demonstrated increased levels of 4-
HNE in PD brain and MPTP mouse model (Selley, 1998; Fujita et al., 2009). In our study, 
we also observed robust increase in 4-HNE expression in SN of MPTP-treated mouse 3 days 
after MPTP administration compared to PBS treated control mice (Fig. 11A-B). However, 
mito-apocynin (3mg /kg /day) treatment significantly reduced the MPTP-induced expression 
of 4-HNE in SN (p < 0.01; Fig. 11B). Consistent with western blotting, we also observed 
increased expression of 4-HNE in SN of MPTP-treated mice and 70-80% TH-positive 
dopaminergic neurons express 4-HNE in their cytosol (Fig. 11C). In contrast, treatment of 
MPTP-treated mice with mito-apocynin resulted in reduction of 4-HNE expression in the 
dopaminergic neurons in the SN (Fig. 11C). Collectively, these results demonstrated that 
mito-apocynin is capable of reducing oxidative stress in nigral neurons in MPTP mouse 
model of PD.  
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Discussion: 
In this study, we demonstrated that mito-apocynin protects against MPP+ induced 
loss of dopaminergic neurons in primary culture and nigrostraiatal dopaminergic neurons 
from MPTP-induced neurotoxicity in vivo by attenuating glial cells mediated inflammatory 
reactions. We presented evidence that novel compound mito-apocynin blocked MPP
+
-
induced activation of NF-κB , resulting in attenuation of cytokine release and oxidative and 
nitrative stress in primary culture. In parallel to that, MPTP-induced ROS/RNS generation, 
pro-inflammatory cytokine production and NADPH oxidase activation in glial cells and 
oxidative damage to the dopaminergic neurons were also inhibited by mito-apocynin in vivo. 
Depletion of these inflammatory and oxidative stress processes led to reversal of motor 
imparities, survival of nigrostarial dopaminergic neurons and terminals and restoration of 
striatal neurotransmitter levels.    
In laboratory, different neurotoxins have been widely used as a compound that could 
induce neurochemical changes and symptoms in animals mimicking those of human PD 
patients (Gerlach, 1991; Vila and Przedborski, 2003). Substantial decrease in complex I to IV 
enzymes have been reported in PD patients (Dauer and Przedborski, 2003). Similarly, 
neurotoxin MPTP mimics major biochemical and pathophysiological properties of idiopathic 
PD by inhibiting complex I enzyme of mitochondria (Przedborski et al., 2004). Although, the 
MPTP animal model is the best and only available drug-induced preclinical model, its 
relevance to idiopathic PD is still questionable as MPTP does not mimic the progressive loss 
of dopaminergic neurons. Along with that, formation of lewy bodies and non motor 
symptoms which are very common in PD patients are also absent in this model.  But, among 
all neurotoxins, only MPTP replicates clinical symptoms indistinguishable from idiopathic 
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PD. So, the MPTP model of PD is an alternate, reliable, effective rodent model for testing the 
effectiveness of mitochondria targeted neuroprotective agent. Many conventional anti-
oxidant compounds (vitamin E, tempol, ubiquinone) failed to attenuate ROS/RNS in 
preclinical models due to their inability to accumulate in mitochondria (Murphy, 1997; Smith 
et al., 1999). In our study, we chemically synthesized mito-apocynin, a mitochondria targeted 
antioxidant with potential anti-oxidative and anti-inflammatory properties. Mito-apocynin is 
also a derivative of apocynin, a known NADPH oxidase inhibitor. Apocynin had been shown 
to attenuate superoxide formation and oxidative stress in vivo in spinal cord (Bedard and 
Krause, 2007). Additionally, apocynin administered at a dose of 300mg/kg/day protects 
against oxidative damage induced by ALS (Harraz et al., 2008). In vitro studies in 
dopaminergic neuronal cell lines and primary cultures also demonstrated protective role of 
apocynin in 1-methyl-4phenyl-pyridinium ion (MPP
+
) or MPTP induced NADPH oxidase 
mediated apoptotic cell death (Anantharam et al., 2007). In contrast, apocynin increased ROS 
production significantly, showing its pro-oxidative nature (Vejrazka et al., 2005). Apocynin 
was also unable to improve behavioral and neuropathological deficits in a transgenic mouse 
model of AD (Gao et al., 2003). In our study we established two functions of mito-apocynin. 
In one hand, it attenuates glial cells mediated formation of pro-inflammatory molecules and 
NADPH oxidase in vitro and in vivo, suggesting its anti-inflammatory role. On the other, it 
inhibits formation of peroxynitrite and lipid peroxidation in dopaminergic neurons, 
suggesting its anti-oxidant activities. Moreover, mito-apocynin also protects against MPTP-
induced motor abnormalities, striatal dopamine depletion and nigrostriatal dopaminergic 
degeneration. 
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In resting phase, microglia and astrocytes play an important role in supporting 
neurons in the brain and spinal cord. But, in the presence of adverse chemical or 
environmental stimuli they become activated and cause neuronal cell death. Activated 
microglia and astrocytes produce ROS/RNS and proinflammatory molecules. In our study, 
we also observed marked increase in glial activation in primary culture and nigrostriatum of 
MPTP treated mice. However, mito-apocynin reduces MPP
+
/MPTP induced glial activation 
(Fig. 2 & 3). Previous reports have shown that iNOS and proinflammatory cytokine such as 
β, IL-6 and TNF-α  increased in the PD brain and in MPTP model of PD (Nagatsu et al., 
2000). Moreover, nitric oxide (NO) generated by iNOS and derived from activated glial cells 
is believed to contribute to neurodegenerative diseases such as AD, PD, HIV associated 
dementia, HD and ALS (Galea et al., 1992; Ghosh et al., 2009). Proinflammatory cytokines 
such as TNF-α , IL-6 and IL-1β secreted from activated microglial cells may facilitates 
intracellular death-related signaling pathways or participate in activation of iNOS expression 
in the MPTP mouse model (Teismann et al., 2003). In addition to that, promoter region of 
iNOS and pro-inflammatory cytokines contains the DNA binding site for NF-κB , a 
transcription factor which regulates glial cells mediated inflammatory reactions (Hayden and 
Ghosh, 2004). In vitro data in our experiment clearly demonstrated attenuation of LPS-
induced production of reactive nitrative species and reactive oxygen species in mito-
apocynin treatment. Moreover, in vivo studies show increased expression of iNOS and 
proinflammatory cytokines in ventral midbrain regions of MPTP treated mice. However, oral 
gavage treatment of mito-apocynin inhibited MPTP-induced expression of these 
proinflammatory molecules in glial cells. These results strongly suggest that mito-apocynin 
has anti-inflammatory properties that contribute to its neuroprotective effects.   
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Along with iNOS mediated RNS, microglia-derived NADPH oxidase can also 
produce ROS and cause oxidative stress in PD patients and MPTP model of PD (Oyagi et al., 
2008). NADPH oxidase is a five-subunit protein that generates superoxide from molecular 
oxygen and is composed of three cytosolic subunits p47phox, p40phox and p67phox and two 
membranes bound subunits, gp91phox and p22phox. During its activation cytosolic subunits 
moves to membrane subunit and forms the active NADPH enzyme complex (Bokoch and 
Knaus, 2003). Different reports have demonstrated the  activation of NADPH oxidase 
causing dopaminergic neurodegeneration in vitro and in vivo (Gao et al., 2003; Wu et al., 
2003). Here, we demonstrated that MPTP induced activation of microglial gp91phox in SN 
and orally administered mito-apocynin inhibited the NADPH oxidase activation (Fig. 9). 
These results clearly suggest that mito-apocynin inhibited MPTP-induced activation of 
NADPH oxidase and oxidative damages, thereby resulting in neuroprotection in the MPTP 
model. 
Reactive glial cells mediated NO and NADPH oxidase mediated (O2.) reacts together 
and forms peroxynitrite (ONOO-), which induces oxidative stress to proteins by doing 
selective nitration to the tyrosine residues of dopaminergic neurons (Ara et al., 1998; Dawson 
and Dawson, 2003). In SN regions of PD patients, presence of activated glial cells that 
express iNOS and increased levels of nitrotyrosine are reported (Hunot et al., 1996). Previous 
studies have shown that in MPTP mouse model of PD, iNOS facilitates dopaminergic 
neurodegeneration via MPTP induced production of RNS and increase in nitrotyrosine levels 
(Liberatore et al., 1999; Dehmer et al., 2000). In our study, we found increased expression of 
3-NT in dopaminergic neurons in MPTP-treated mice, but oral administration of mito-
apocynin decreased the levels of TH nitrotyrosine in the SN of MPTP-treated mice (Fig. 10). 
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Consistent with peroxynitrite, 4-HNE is also a well-known marker for oxidative insult 
mainly caused by hydroxyl radical (·OH). The 4-HNE is an unsaturated aldehyde which is 
generated during lipid peroxidation in SN of PD brain compared to control (Yoritaka et al., 
1996). Previous studies also demonstrated that 4-HNE blocked mitochondrial respiration and 
induced caspase dependent apoptosis in neurons (Picklo et al., 1999). We showed that a 
significant increase in 4-HNE expression 3 days after MPTP aministration (Fig. 11). 
However, mito-apocynin significantly decreased the amount of 4-HNE in the SN of MPTP 
treated mice. Collectively, these results suggest that mito-apocynin decreases MPTP-induced 
oxidative stress, leading to dopaminergic neuronal survival.  
The loss of dopamine and its metabolites is the most prominent biochemical change 
observed in PD patients and MPTP mouse model of PD (Jackson-Lewis and Przedborski, 
2007). In our study, we also observed significant reduction of striatal neurotransmitters as 
well as behavioral imparities. However, mito-apocynin was able to restore the 
neurotransmitter levels and behavioral imparities in MPTP-treated mice nearly to the control 
level (Fig. 4 & 5). Consistently, mito-apocynin was found to protect the dopaminergic 
neurons and its terminals in nigrostritum of MPTP-injected mice (Fig. 5). Neuroprotection 
afforded by mito-apocynin could be attributed either to partial restoration or prevention of 
further decreases in dopaminergic neurons in the nigrostritum.  
In conclusion, we have demonstrated that mito-apocynin improves behavioral 
imparities and protects nigrostriatal axis from MPTP toxicity by attenuating nigral activation 
of microglial and astroglial cells, reducing iNOS and pro-inflammatory cytokines, inhibiting 
the formation of active NADPH oxidase enzyme and decreasing oxidative stress in MPTP-
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treated mice. Together, we propose that mito-apocynin may have therapeutic value in the 
treatment of PD and other disorders associated with inflammation and oxidative stress.  
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Figure 1  
Figure 1. Mito-apocynin protects dopaminergic neurons against MPP
+
-induced toxicity 
in primary neuronal culture. Mesencephalic tissues from E15 mouse embryos were 
cultured and grown on laminin-coated coverslips. The neuronal cultures were treated with 
10M MPP+ for 24 h in the presence or absence of 10M mito-apocynin. After treatment, 
primary neurons were fixed with 4% paraformaldehyde and incubated with anti-TH antibody 
and viewed under a NIKON TE2000 fluorescence microscope. A. Tyrosine hydroxylase 
(TH) immunolabeling in primary mesencephalic culture from substantia nigra. B. TH-
positive dopaminergic neuronal process length were quantified using MetaMorph image 
analysis software, as mentioned in Materials and Methods. C. Quantification of TH-positive 
dopaminergic neurons using MetaMorph software, as mentioned in Materials and Methods. 
Data represent the mean ± SEM of three to four experiments. ***, p < 0.001 vs. Control; @, 
p < 0.05 vs. MPP
+
; **, p < 0.01 vs MPP
+
.      
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Figure 2  
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Figure 2. Effects of mito-apocynin on the translocation of NF-κB -p65 into nucleus of 
primary culture. Mesencephalic tissues from E15 mouse embryos and day 1 old pups were 
cultured and grown on laminin-coated coverslips separately. The neuronal cultures from E15 
mouse embryos were treated with 10M MPP+ for 24 h in the presence or absence of 10M 
mito-apocynin. The glial cultures from day 1 old pups were also treated with 10M MPP+ for 
24 h in the presence or absence of 10M mito-apocynin. After treatment, cells were fixed 
with 4% paraformaldehyde and incubated with different antibodies and viewed under a 
NIKON TE2000 fluorescence microscope. A. Double labeling of TH and p65 in primary 
mesencephalic culture from substantia nigra (60X). Inset, higher magnified picture shows 
translocation of p65 into nucleus in MPP
+
-treated dopaminerculture. White arrowheads show 
expression of the markers. B. Double labeling of GFAP and p65 in primary glial culture from 
substantia nigra (60X). Inset, higher magnified picture shows translocation of p65 into 
nucleus in MPP
+
-treated astrocytes. White arrowheads show expression of the markers.  
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Figure 3  
 
Figure 3. Mito-apocynin inhibits LPS-induced inflammatory processes in primary 
microglial cells. Primary microglial cells were isolated from C57BL/6 one day old pup and 
seeded in equal numbers on poly-d-lysine coated plates. Cells were treated with LPS 
(100ng/ml) in presence or absence of different doses of mito-apocynin (20µM or 40µM). A-
C. After treatment, supernatants were collected and TNF-α, IL-6 and IL-12 proinflammatory 
cytokine levels were quantified using the luminex immunoassay system. D. Primary 
microglial cells from C57BL/6 one day old pups were treated with LPS (100ng/ml) in 
presence or absence of 20µM or 40µM of mito-apocynin. After 24 h of treatment, nitric 
oxide production was determined indirectly by quantifying the nitrite levels in the 
supernatant using the Griess reagent and a sodium nitrite standard curve. E. Primary 
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microglia from day 1 old pups of C57 BL/6 mice were treated with LPS (100 ng/ml) in 
presence or absence of miti-apocynin for 12 h and intracellular ROS generation was 
quantified using the fluorescent DCFDA dye. Data represent the mean ± SEM of three to 
four experiments. ***, p < 0.001 vs. Control; @, p < 0.01 vs. LPS; #, p < 0.001 vs LPS.       
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Figure 4 
 
Figure 4. Mito-aocynin blocked MPTP-induced behavioral and locomotor deficits. Mice 
were administered mito-apocynin (3mg/kg/day) by oral gavage 24 h before MPTP treatment 
and continued for 5 days of co-treatment with MPTP (25mg/kg/day) and 4 days of post-
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treatment with MPTP (25mg/kg/day). Control mice received 10% ethanol in saline. Mice 
were tested for motor activities 4 days after the last dose of MPTP. A. VersaPlot movement 
track of mice collected over 10minutes was plotted. VersaMax data showing B. horizontal 
activity; C. vertical activity; D. distance travelled (cm.); E. movement time (sec.); F rest time 
(sec.); G. no. of stereotypy ; H. no. of rearing and I. time spent on rotarod (second) at 20 rpm 
rod speed.  Data represent the mean ± SEM of six to eight mice per group.  ***, p < 0.001 vs. 
the control group; **, p < 0.01 vs. the control group; *, p < 0.05 vs. the MPTP group; @, p < 
0.001 vs. the MPTP group; #, p < 0.01 vs. the MPTP group.   
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Figure 5 
 
Figure 5. Mito-apocynin prevents MPTP-induced neurotoxicity in the nigrostriatum of 
the mouse brain. Mice were administered mito-apocynin (3mg/kg/day) by oral gavage 24 h 
before MPTP treatment and continued for 5 days of co-treatment with MPTP (25mg/kg/day) 
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and 6 days of post-treatment of MPTP (25mg/kg/day).  Control mice received 10% ethanol in 
saline.  Seven days after the last MPTP injection, mice were sacrificed and Tyrosine 
hydroxylase (TH)-DAB immunostaining in striatum (A) and substantia nigra regions (B, 
upper panel 2X magnification; lower panel 10X magnification) were performed. 7 days after 
the last MPTP treatment, striatal (C) dopamine, (D) DOPAC and (E) HVA were measured by 
HPLC. Data represent the mean ± SEM of six to eight mice per group.  ***, p < 0.001 vs. 
control; @, p < 0.01 vs. MPTP; #, p < 0.05 vs MPTP. 
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Figure 6 
 
Figure 6. Mito-apocynin blocks activation of microglia and astrocytes in substantia 
nigra (SN) of MPTP treated mice.  Mice receiving PBS as a control, MPTP (25mg/kg/day) 
or MPTP and mito-apocynin (3mg/kg/day) were sacrificed 3 days after the last dose of 
MPTP administration. Mouse SN tissues were immunostained with antibodies against IBA-
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1(marker of microglia) (A) and GFAP (marker of astrocytes) (B). Insets, four fold higher 
magnification of A-B. Dotted lines indicate the SNpc. Representative western blots 
illustrating the expression of IBA-1(C) and GFAP (E) in SN.  D. Bar graph showing means 
Western blot IBA-1/β-actin ratios ± SEM in SN of 6 mice per group.  F. Bar graph showing 
mean Western blot GFAP/β-actin ratios ± SEM in SN of 6 mice per group.  ***, p < 0.001 
vs. the control group; *, p < 0.05 vs. the MPTP group. 
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Figure 7  
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Figure 7. Mito-apocynin decreases MPTP-induced nitric oxide damage in substantia 
nigra (SN) of MPTP treated mice.  Mice were administered mito-apocynin (3mg/kg/day) 
by oral gavage 24 h before MPTP treatment and continued for 4 days of co-treatment with 
MPTP at a dose of 25mg/kg/day.  Control mice received 10% ethanol in saline.  Twenty-four 
h after the last dose of MPTP, mice were sacrificed.  A. SN tissue lysates were analyzed by 
western blotting using antibody against iNOS. B. Bar graph showing means Western blot 
iNOS/β-actin ratios ± SEM in SN of 6 mice per group. C. Double labeling of GFAP and 
iNOS and (D) IBA-1 and iNOS in SN region of ventral midbrain.  Images were captured at 
20X and 60X (insets) magnification. Dotted lines indicate the SNpc.  ***, p < 0.001 vs. the 
control group; *, p < 0.05 vs. the MPTP group. 
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Figure 8 
 
Figure 8. Mito-apocynin inhibits the expression of iNOS and proinflammatory 
cytokines in ventral midbrain of MPTP-treated mice. Mice receiving PBS as a control, 
MPTP (25mg/kg/day) or MPTP and mito-apocynin (3mg/kg/day) were sacrificed 3 days after 
the last dose of MPTP administration. The mRNA expression of iNOS (A), TNF-α  (B), IL-
1β (C) and IL-6 (D) was analyzed by quantitative real-time PCR. Data represent the mean ± 
SEM of six mice per group.  **, p < 0.01 vs. control; *, p < 0.05 vs. control; @, p < 0.05 vs 
MPTP. 
 
250 
 
Figure 9 
 
Figure 9. Mito-apocynin attenuates activation of NADPH oxidase in SN of MPTP-
treated mice.  Mice were administered mito-apocynin (3mg/kg/day) by oral gavage 24 h 
prior MPTP treatment and continued for 4 days of co-treatment with 25mg/kg/day MPTP.  
Control mice received 10% ethanol in saline.  Twenty-four h after the last dose of MPTP, 
mice were sacrificed.  A. Representative western blots illustrating the expression of 
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gp91phox (membrane bound subunit of NADPH oxidase) in SN.  B. Bar graph showing 
means Western blot gp91phox/β-actin ratios ± SEM in SN of 6 mice per group. C. Substantia 
nigra tissue sections were double labeled for gp91phox and IBA-1.  Images were captured at 
20X and 60X (insets) magnification.  The SNpc zone is outlined in white dots.  Inset pictures 
demonstrated colocalization of IBA-1 and gp91phox. **, p < 0.01 vs. the control group; *, p 
< 0.05 vs. the MPTP group.  
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Figure 10.  
 
Figure 10. Mito-apocynin decreases the formation of 3-nitrotyrosine (3-NT) in SN of 
MPTP treated mice.  Mice were administered mito-apocynin (3mg/kg/day) by oral gavage 
24 h before MPTP treatment and continued for 4 days of co-treatment with 25mg/kg/day 
MPTP via i.p. Control mice received 10% ethanol in saline.  Twenty-four h after the last dose 
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of MPTP, mice were sacrificed.  A. Representative western blots illustrating the expression 
of 3-NT in SN. B. Bar graph showing means Western blot 3-NT/β-actin ratios ± SEM in SN 
of 6 mice per group. C. Double labeling of TH (marker of dopaminergic neurons) and 3-NT 
in SN region of ventral midbrain.  Images were captured at 20X and 60X (insets) 
magnifications.  The SNpc zone is outlined in white dots.  Inset pictures demonstrated 
colocalization of TH and 3-NT. ***, p < 0.001 vs. the control group; *, p < 0.05 vs. the 
MPTP group. 
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Figure 11 
 
Figure 11. Mito-apocynin inhibits MPTP induced formation of 4-hydroxynonenol (4-
HNE) in SN in vivo.   Mice were administered mito-apocynin (3mg/kg/day) by oral gavage 
24 h before MPTP treatment and continued for 4 days of co-treatment with 25mg/kg/day 
MPTP via i.p. Control mice received 10% ethanol in saline.  Twenty-four h after the last dose 
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of MPTP, mice were sacrificed. A. Representative western blots illustrating the expression of 
4-HNE in SN. B. Bar graph showing means Western blot 4-HNE/β-actin ratios ± SEM in SN 
of 6 mice per group.  C. Double labeling of TH (marker of dopaminergic neurons) and 4-
HNE in SN region of ventral midbrain.  Images were captured at 20X and 60X (insets) 
magnifications.  The SNpc zone is outlined in white dots.  Inset pictures demonstrated 
colocalization of TH and 4-HNE. ***, p < 0.001 vs. the control group; **, p < 0.01 vs. the 
MPTP group. 
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CHAPTER VI 
GENERAL CONCLUSIONS 
 
This section presents a general overview of the results and findings described in this 
dissertation, with a special emphasis on the future directions and overall implications of these 
findings on the pathogenesis of Parkinson’s disease.  The major findings pertaining to each 
research chapter and their specific implications are covered in the discussion section of the 
relevant chapters.  
Pin1, a peptidyl-prolyl isomerase, is differentially activated in neuronal and glial 
cells of the substantia nigra 
Reversible phosphorylation on Ser/Thr – Pro (S/T-P) motifs regulated by Pro-directed 
protein kinases and phosphatases is an important molecular switch in controlling various 
cellular processes (Gothel and Marahiel, 1999). Since the discovery of protein interacting 
with never in mitosis – A (Pin1), a lot has become known about the conformational 
importance of Pro-directed kinases in cellular signaling (Uchida et al., 1999). Pin1 is unique 
among the peptidyl-prolyl  isomerases in that it specifically recognizes phosphorylated serine 
or threonine residues immediately preceding proline (pSer/Thr-Pro) in a subset of proteins 
and isomerizes the cis/trans conformation of peptide bond (Joseph et al., 2003; Lu, 2004). 
Recently, Ryo et al., reported that Pin1 overexpression facilitates formation of -synuclein 
inclusions in a cellular model of -synuclein aggregation and Pin1 also localizes in Lewy 
bodies in PD patients (Ryo et al., 2006). But the level, activity and the role of Pin1 in the 
inflammatory responses in the pathogenesis of PD are completely unknown. Results from 
chapter II and chapter III clearly demonstrate that dopaminergic neurons and glial cells (both 
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microglia and astrocytes) express Pin1 in the cytosol, and the level of Pin1 upregulates 
during disease states. Deregulation of Pin1 activity has been proposed in different diseases. 
We identified that Pin1 is highly expressed in the pigmented dopaminergic neurons of PD 
patients in comparison to age-matched controls. Human PD cases are associated with loss of 
pigmented dopaminergic neurons in SN, and our findings of elevated Pin1 expression only in 
pigmented dopaminergic neurons suggest a possible role of Pin1 in the pathogenesis of PD. 
We show in this study for the first time that Pin1 may also be a possible therapeutic target for 
PD. Additionally, Pin1 levels increases significantly in response to different toxic stimuli in 
cell culture and animal models of PD. Recent findings have demonstrated that Pin1 inhibition 
has anti-cancer effects in experimental studies (Dourlen et al., 2007). Among various Pin1 
inhibitors, Juglone (5-hydroxy-1,4-napthalenedione, C10H6O3) has been widely used in 
research fields. It is an aromatic organic napthoquinone, naturally found in the leaves, roots 
and bark of black walnut plants (Esnault et al., 2008; Jeong et al., 2009). In our experiment, 
Juglone not only inhibits Pin1 expression, but also shows anti-inflammatory and 
neuroprotective effects in cell and animal models of PD, suggesting the potential of Pin1 as a 
therapeutic target in the progression of PD.  
The precise signaling mechanism and downstream targets of Pin1 during 
dopaminergic neurodegeneration are not known yet. However, potential downstream targets 
for regulation by Pin1 can be inferred based on the known substrates and functions of Pin1 in 
cancerous and innate immune cells.  Previous reports indicated Pin1’s role in controlling 
several transcription factors that mediate induction of iNOS, a key inflammatory molecule 
involved in the pathogenesis of PD (Gothel and Marahiel, 1999; Shen et al., 2005). In 
cancerous cells, Pin1 has been shown to bind to the phosphorylated Thr254-Pro residue of 
258 
 
transcription factor NF-κB p65. Through this interaction, Pin1 helps stabilize p65 in the 
nucleus, maintaining activation of NF-κB  (Ryo et al., 2003). NF-κB  activation is a key 
inflammatory mediator and Ghosh et 
al. (2007) previously reported 
induction of NF-κB  in SN of PD 
patients and MPTP-treated mice.  In 
our study, different types of stimulus 
mediated activation of Pin1 in glial 
cells and its association with p65 
strongly suggest that Pin1 controls the 
NF-κB-mediated inflammatory 
processes in PD. Additionally, 
depletion of Pin1 by small interfering 
RNA reduces oxidative stress in 
microglial cells. Overall, this study 
demonstrates that Pin1 is a key upstream signaling molecule of inflammation and oxidative 
stress, and inhibition of Pin1 activation rescues the dopaminergic neurons from 
neurotoxicity.   
Antinflammatory and neuroprotective properties of novel compounds diapocynin and 
mito-apocynin 
The findings in chapter IV and V demonstrate that by attenuating inflammation and 
oxidative stress, the novel compounds diapocynin and mitoapocynin protect dopaminergic 
neurons in nigrostriatum. Parkinson’s disease is a multifactorial disease, with glial activation, 
Figure 12. Schematic presentation of Pin1 and NF-
kB mediated inflammatory reactions in Parkinson's 
disease 
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inflammation, oxidative stress and mitochondrial dysfunction playing a central role in 
dopaminergic neurodegeneration, specifically in the nigrostriatum. For the last few years, 
there have been increased efforts to search for neuroprotective agents to protect against the 
irreversible loss of neurons. Administration of a dopamine agonist or levodopa has been the 
widely used treatment for PD symptoms, but this treatment does not affect the disease 
pathogenesis.  Dopaminergic neuroprotection in animal models of PD has been demonstrated 
with various substances, including glial cell line derived neurotrophic factor (GDNF), brain 
derived neurotrophic factor (BDNF) and TGF-β (Kordower et al., 2000).  Additionally, 
various anti-inflammatory agents such as NSAIDs, COX inhibitors, statins, pioglitazone, 
minocycline have been used in different animal models of PD (Chen et al., 2003; Ghosh et 
al., 2009). However, most of these compounds failed in either preclinical trials or in human 
phase I trials due to their inability to cross the blood-brain barrier or due to limited 
bioavailability. Moreover, these agents also cause side effects and toxicity. Hence, 
understanding the mechanism of the disease process and development of a successful 
neuroprotective therapeutic approach to halt the disease progression are of principal 
importance in the PD research field.  MPTP causes glial activation and inflammation within 
24 h of its administration and initiates a self-perpetuating dopaminergic neurodegenerative 
process beginning at 72 h (Ghosh et al., 2009). Here, we clearly demonstrate that diapocynin 
(a metabolite of apocynin) crosses the blood brain barrier, attenuates nigral activation of 
microglial and astroglial cells, and inhibits proinflammatory molecule (iNOS) and production 
of NADPH oxidase mediated superoxide formation. Additionally, it also decreases oxidative 
stress, improves behavioral functions and protects the nigrostriatum in MPTP-treated mice.  
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These results suggest its potential as a therapeutic candidate in clinical trials of human PD 
patients.   
Mitochondrial dysfunction due to oxidative stress, mitochondrial DNA deletions, 
altered mitochondrial morphology, and interaction of pathogenic proteins with mitochondria 
results in dopaminergic neurodegeneration. Consequently, therapeutic approaches targeting 
mitochondrial dysfunction and related oxidative stress have great promise in the cure of PD.  
MPTP and other complex-I inhibitors such as rotenone, maneb, paraquat, fenzaquin and 
trichloroethylene result in loss of nigral dopaminergic neurons in a mouse model of PD, 
implicating mitochondrial dysfunction in the disease pathogenesis (Betarbet et al., 2000; 
Gash et al., 2008).  
Moreover, reduced complex-I 
activity and an increased susceptibility 
to MPP
+
, the toxic metabolite of MPTP, 
were also observed in mitochondrial 
DNA from PD patients, clearly 
demonstrating the mtDNA encoded 
defects in PD (Swerdlow et al., 1996; 
Gu et al., 1998). Based on these 
observations, intervening one of these 
processes should alleviate harmful 
effects of mitochondrial dysfunction. 
Numerous bioenergetics agents that 
Figure 13. Schematic presentation of 
neuroprotection by diapocynin and mito-apocynin 
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improve mitochondrial function, including creatine and CoQ10 are in clinical trial for PD. 
Recently, we (Ghosh et al., 2010) demonstrated that mitochondria targeted antioxidant Mito-
Q10, which is a chemical modification of Co-Q -, could protects dopaminergic neurons from 
MPTP-induced toxicity in mice (Ghosh et al., 2010). Similarly, we synthesized a novel 
mitochondria targeted anti-oxidant, mito-apocynin, which is also a derivative of apocynin 
and tested its efficacy in cell culture and animal models of PD. Herein, we demonstrate that 
mito-apocynin protects against MPP
+
-induced loss of dopaminergic neurons in primary 
mesencephalic culture by reducing glial cell mediated inflammatory reactions. Mioreover, 
administration of mito-apocynin in mice protects the dopaminergic neurons and terminals 
from MPTP toxicity by reducing inflammatory reactions and oxidative stress. Collectively, 
these results strongly suggest that additional preclinical development of mito-apocynin may 
yield an effective nmeuroprotective drug for treatment of ing PD.  
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